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ABSTRACT 
 Novel liposome-nanoparticle assemblies (LNAs) provide a biologically 
inspired route for designing multifunctional bionanotheranostics. LNAs combine the 
benefits of lipids and liposomes to encapsulate, transport, and protect hydrophilic and 
hydrophobic therapeutics with functional nanoparticles. Functional nanoparticles 
endow LNAs with additional capabilities, including the ability to target diseases, 
triggered drug release, controlled therapeutic output, and diagnostic capabilities to 
produce a drug delivery system that can effectively and efficiently deliver therapeutics 
while reducing side effects. Not only could LNAs make existing drugs better, they 
could also provide an avenue to allow once promising non-approved drugs (rejected 
due to harmful side effects, inadequate pharmacokinetics, and poor efficacy) to be 
safely used through targeted and controlled delivery directly to the diseased site. 
LNAs have the potential to be stimuli responsive, delivering drugs on command by 
external (ultrasound, RF heating, etc.) or internal (pH, blood sugar, heart rate, etc.) 
stimuli. Individually, lipids and nanoparticles have been clinically approved for 
therapy, such as Doxil (a liposomal doxorubicin for cancer treatment), and diagnosis, 
such as Feridex (an iron oxide nanoparticle an MRI contrast enhancement agent for 
liver tumors).  
 In order to engineer these multifunctional LNAs for theranostic applications, 
the interactions between nanoparticles and lipids must be better understood. This 
research sought to explore the formation, design, structures, characteristics, and 
functions of LNAs. To achieve this goal, different types of LNAs were formed, 
  
specifically magnetoliposomes, bilayer decorated LNAs (DLNAs), and lipid-coated 
magnetic nanoparticles (LMNPs).  
 A fluorescent probe was embedded in the lipid bilayer of magnetoliposomes 
allowing the local temperature and membrane fluidity to be observed. When subjected 
to an electromagnetic field that heated the encapsulated iron oxide nanoparticles 
encapsulated in the lipid bilayer, the local temperature and membrane fluidity could be 
observed. 
 DLNAs were encapsulated with different sized nanoparticles and 
concentrations in order to observe the effect of the bilayer nanoparticles on the lipid 
bilayer’s phase behavior and leakage. Two different sized nanoparticles were used, a 2 
nm gold nanoparticle (GNP) much smaller than the thickness of the bilayer and a 4 nm 
GNP near the thickness of the lipid bilayer. The 2 nm GNPs were shown to affect the 
lipid bilayer differently than the 4 nm GNP. Specifically, the two nanoparticles altered 
the phase behavior and leakage differently in a temperature dependent fashion, 
demonstrating that embedded nanoparticle size can be used induce or inhibit bilayer 
leakage. 
 A dual solvent exchange method was used to control the lipid surface 
composition of an iron oxide nanoparticle with a cationic lipid and a polyethylene 
glycol (PEG) lipid to produce lipid coated magnetic nanoparticles (LMNPs). PEG is 
well known for its ability to enhance the pharmacokinetics of nanostructures by 
preventing uptake by the immune system. By controlling the lipid surface 
composition, the surface charge and PEG conformation can be controlled which 
  
allowed the LMNPs to be used as an MRI contrast agent and a delivery system for 
siRNA that could be triggered with temperature. 
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PREFACE 
 This dissertation was prepared in manuscript format. Chapter 1 is an overview 
into the various different lipid-nanoparticle assemblies (LNAs) structures that can be 
formed combining lipids and nanoparticles for therapeutic and diagnostic (theranostic) 
applications. Chapter 2 investigates LNAs responsive to stimuli, such as magnetic, 
temperature, pH, light, ultrasound, etc., which can allow them to be used for triggered 
and controlled release of therapeutics. Chapters 1 and 2 provide a summary of the 
current status of LNA research and development. Chapter 3 is a manuscript related to 
measuring the fluidity of the lipid bilayer of a magnetoliposomes (liposomes with iron 
oxide encapsulated in its aqueous core) when the nanoparticles are heated with an 
electromagnetic field at radio frequency. Chapter 4 is a manuscript that investigated 
the effect nanoparticle size and concentration on the phase behavior and permeability 
of bilayer decorated LNAs (DLNAs). Chapter 5 is a manuscript that examines how 
lipid surface concentration of an iron oxide nanoparticle effects the MRI relaxivity and 
siRNA binding and release. 
 The first chapter, entitled “Liposome-Nanoparticle Assemblies”, is Chapter 11 
(pg. 273-307) in the book Bionanotechnology: Biological Self-Assembly and its 
Applications published by Caister Academic Press (Norfolk, UK) in 2013. This 
chapter was invited submission by the editor, Bernd H.A. Rehm. Also, flatteringly, the 
front cover of the book (displayed on the Chapter 1 title page) was selected from 
Figure 1-2 that we submitted.   
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 The second chapter, entitled “Stimuli-Responsive Liposome-Nanoparticle 
Assemblies”, was an invited article published in Expert Opinion on Drug Delivery in 
2011 (Expert Opinion on Drug Delivery 8(8) 1025-1040 (2011)). 
 The third chapter, entitled “Local Heating in Magnetite Nanoparticle-
Liposome Dispersions via Fluorescence Anisotropy”, was published in the Journal of 
Colloid and Interface Science in 2011 (Journal of Colloid and Interface Science 
357(1) 70-74 (2011)). 
 The fourth chapter, entitled “Hydrophobic Nanoparticles Embedded in 
Liposomes Modify the Thermal Release Behavior of Encapsulated 
Carboxyfluorescein”, is a manuscript currently in preparation for submission to ACS 
Nano. 
 The fifth chapter, entitled “MRI Relaxivity and siRNA Binding Capacity of 
Lipid-Coated Magnetic Nanoparticles Controlled by PEG Confirmation”, is a 
manuscript currently in preparation for submission to Nano Letters. 
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 Abstract 
 Liposome-nanoparticle assemblies (LNAs) combine the demonstrated potential 
of clinically approved nanoparticles and liposomes to achieve multiple therapeutic and 
diagnostic objectives. Efficient and effective biomedical application requires 
assemblies to be stable, biocompatible, and bioavailable, while enhancing the 
properties of encapsulates. LNAs have been demonstrated to be very effective for in 
vivo and in vitro providing targeting and stimuli-responsive delivery of therapeutic and 
imaging agents. The ability to design LNAs with nanoparticle encapsulation, bilayer-
decoration, and surface coupling provides a variety of different structures and 
functions. While the potential of LNAs has been demonstrated, future investigation 
into the interaction between the lipid bilayer and nanoparticles is necessary to 
understand and develop LNAs for clinical applications. This section will discuss the 
current state of liposome-nanoparticle assembly design, characterization, and 
applications of liposome-nanoparticle assemblies.  
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 Introduction 
 Only about 11% of new promising therapeutic compounds in clinical 
development are eventually approved. Nearly 70% of drug failures are attributed to 
poor pharmacokinetics, efficacy, toxicology, clinical safety, and formulation (Kola 
and Landis, 2004; Leeson and Davis, 2004). High drug attrition rates are the major 
cause of the recent decline in breakthrough drugs and the rise in costs of new drug 
therapies. Developments in nanotechnology have demonstrated potential for 
overcoming the issues related to drug pharmacokinetics and pharmacodynamics. 
Targeted and controlled delivery of therapeutic agents directly to targeted tissues can 
be achieved, improving efficacy, lowering the necessary dose, and reducing adverse 
effects. Nobel Laureate Paul Ehrlich’s dream of a “magic bullet” to fight disease may 
be realized through controlled and targeted nanoscale therapeutics (Koo et al., 2005).  
 In 2004, the National Cancer Institute launched the Alliance for 
Nanotechnology in Cancer (Alliance). The Alliance’s goal is development of 
nanotechnology-based cancer treatments and imaging. Specifically, the Alliance is 
emphasizing the development of drug delivery that targets tumor cells, tumor’s 
microenvironment, and metastatic, recurrent, and drug resistant cancers with 
nanotherapeutic delivery systems, theranostics, contrast agents, and complexes 
capable of providing multiple therapies (National Cancer Institute). The design of such 
multifunctional constructs is inherently complex as it requires combining different 
molecular, colloidal, and/or particulate agents. Furthermore, the construct must be 
stable, resistant to protein and immune system absorption, and capable of targeting.  
 4 
 
 Novel liposome-nanoparticle assemblies (LNAs) provide a biologically 
inspired route for designing multifunctional targeted therapeutics and imaging. The 
LNA structure is inspired by the early development of magnetoliposomes (liposomes 
with magnetic nanoparticles encapsulated in the aqueous core). Recent literature has 
referred to LNAs as “liposome-nanoparticle hybrids” (Al-Jamal and Kostarelos, 
2007). LNAs are liposome structures in which nanoparticles (NPs) are encapsulated in 
the aqueous core, embedded in the lipid bilayer, or coupled to the bilayer surface. 
Liposomes are a well-established vehicle for the administration of therapeutic and 
diagnostic agents (Bangham and Horne, 1964; Bangham et al., 1965; Gregoriadis, 
1973; Papahadjopoulos and Ohki, 1969). As a biocompatible carrier, liposomes 
provide a stable means for the transportation and protection of hydrophilic and/or 
hydrophobic molecules. Nanoparticles are nanoscale moieties that have been 
demonstrated to be effective transportation vehicles, contrast agents, and agents 
responsive to external stimuli (such as electromagnetic fields and light). LNAs 
combine the advantageous properties of liposomes with functional nanoparticles to 
create a multifunctional therapeutic and diagnostic construct (Zhang et al., 2008).  
 LNAs have several advantages when utilized for drug delivery, hyperthermia, 
imaging, and diagnostic applications. LNAs are able to delivery hydrophobic and/or 
hydrophilic molecules and NPs (Zhang et al., 2009). The liposome can be modified to 
protect encapsulated agents from biomolecule absorption and functionalized for 
targeting. LNAs can also be used to concentrate encapsulates, increasing the efficiency 
of delivery. Also, the strategies for processing, stabilizing, and targeting liposomes are 
 5 
 
well established (Immordino et al., 2006). NPs can be magnetically guided for in vivo 
targeting and provide a mechanism for stimuli-responsive triggering. Surface-bound 
NPs also enhance the colloidal stability of LNAs and bilayer-embedded NPs can 
reduce spontaneous leakage (Chen et al., 2010; Paasonen et al., 2007b; Yu et al., 2007; 
Zhang and Granick, 2006). LNAs harness the intrinsic advantages of a liposomal 
carrier, enhancing stability, bioavailability, and biocompatibility, and adds the imaging 
and/or responsive functionality of a NP (Zhang et al., 2008). 
 Drug delivering liposomes and nanoparticles have both been approved 
separately for clinical use by the U.S. Food and Drug Administration (FDA), see 
Table 1-1 and Table 1-2, respectively. These approved therapies represent the first-
generation of development for nano-scale therapeutics and diagnostics. Combining 
liposomes and nanoparticles, to form multimodal LNAs, is the natural evolution for 
these technologies. This section will focus on a review of LNA design and structure, 
characterization techniques, and biomedical applications, such as controlled drug 
release, imaging, and hyperthermia, expanding on our group’s review on stimuli-
responsive LNAs (Preiss and Bothun, 2011). Recent reviews focusing on the 
therapeutic and diagnostic applications of liposomes are provided in references (Goyal 
et al., 2005; Immordino et al., 2006; Kshirsagar et al., 2005; Maurer et al., 2001; 
Mulder et al., 2006; Puri et al., 2009; Samad et al., 2007; Torchilin, 2005) and NPs are 
provided in references (Corchero and Villaverde, 2009; Emerich and Thanos, 2006; 
Fukumori and Ichikawa, 2006; Groneberg et al., 2006; Jin and Ye, 2007; Laurent et 
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al., 2008; McCarthy and Weissleder, 2008; Michalet et al., 2005; Polyak and 
Friedman, 2009; Rotomskis et al., 2006; Wang et al., 2008). 
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Table 1-1. FDA-approved liposomal formulations. 
Drug Trade Name Manufacturer Nano Component Treatment 
Route of 
Administration
FDA 
Approval 
Amphotericin B  Abelcet Sigma-Tau Lipid complex Fungal infections Injectable 1995 
Amphotericin B  AmBisome Astellas Liposome Fungal and protozoal infections Injectable 1997 
Amphotericin B  Amphotec Aldopharma USA 
Lipid colloidal 
dispersion Fungal infections Injectable 1996 
Daunorubicin  DaunoXome Galen Liposome Advanced HIV Kaposi’s sarcoma; Ovarian cancer Injectable 1996 
Cytarabine  DepoCyt Pacira Pharms Liposome Malignant lymphomatous meningitis Injectable 1999 
Morphine DepoDur EKR Theraputics Liposome Postsurgical analgesia Epidural 2004 
Doxorubicin Doxil Janssen PEGylated liposomes 
Metastatic ovarian cancer; 
AIDS-related Kaposi’s 
sarcoma 
Injectable 1995 
Verteporfin  Visudyne QLT Liposome 
Age-related macular 
degeneration, pathologic 
myopia, ocular 
histoplasmosis 
Injectable 2000 
Propofol Diprivan APP Pharms Liposome Anesthetic Injectable 1989 
Bupivacaine Exparel Pacira Pharmaceuticals Liposome Analgesic Injectable 2011 
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Table 1-2. FDA-approved therapeutic nanoparticles. 
Drug Trade Name Manufacturer 
Nano 
Component Treatment 
Route of 
Administration
FDA 
Approval 
Superparamagnetic 
Iron Oxide Feridex AMAG Pharms Nanoparticle Liver tumor imaging Injectable 1996 
Superparamagnetic 
Iron Oxide Gastromark AMAG Pharms Nanoparticle 
Gastrointestinal 
imaging Oral 1996 
Superparamagnetic 
Iron Oxide Feraheme AMAG Pharms Nanoparticle Iron deficiency anemia IV 2009 
Gold Verigene Nanosphere Nanoparticle Nucleic Acid Detection Medical Device 2007 
Silver Acticoat Smith & Nephew Nanoparticle 
Anti-microbial 
Dressing Medical Device 1996 
Silver Allevyn Ag Smith & Nephew Nanoparticle 
Anti-microbial 
Dressing Medical Device 2007 
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 Liposome 
 Since the early work by Bangham, Papahadjopoulos, and Gregoriadis in the 
1960-1970s, liposomes have become one of the most highly investigated nano-
structures. Today, liposomes are used as model biological membranes and for 
therapeutic and diagnostic agent delivery (Bangham and Horne, 1964; Bangham et al., 
1965; Gregoriadis, 1973; Papahadjopoulos and Ohki, 1969). Liposomes are reliable 
systemic drug delivery systems because they are non-toxic, biocompatible, capable of 
prolonging bioavailability of encapsulated agents by reducing or preventing drug 
degradation and enhancing solubility and stability (Al-Jamal and Kostarelos, 2007). 
 Liposomes, as depicted in Figure 1-1(A), are composed of self-assembled 
spherical vesicles consisting of one or multiple lipid bilayers surrounding an internal 
aqueous core. Bilayer thickness (lb) is ~5 nm thick (lb), composed of a hydrophobic 
acyl lipid tail region (~3 nm) and a hydrophilic headgroup. Liposomes can be prepared 
with zwitterionic, anionic, or cationic lipids, and the net liposome surface charge can 
be adjusted by mixing different ratios of these components. From a morphological 
aspect, liposomes are distinguished according to their diameter, small (<100 nm), 
large (100-1000 nm, or giant (>1000 nm), and number of bilayers, single (unilamellar) 
or multiple (multilamellar) (Sivashankar, 2011). Figure 1-1(B) is a cryogenic 
transmission electron microscope (cryo-TEM) image of liposomes depicting the 
structures that can be formed. For drug delivery and diagnostics, liposomes are 
attractive because of their ability to encapsulate both hydrophilic (in the aqueous core 
or bound to the liposome surface) and hydrophobic (in the lipid bilayer) molecules. 
 10 
 
Liposomes also open the therapeutic window, reducing adverse effects, by altering the 
pharmacokinetic and pharmacodynamic characteristics of the encapsulated agent (Al-
Jamal and Kostarelos, 2007).  
 
 
Figure 1-1. Schematic and cryogenic transmission electron micrograph of 
dipalmitoylphosphatidylcholine liposomes (DPPC). 
(A) Liposome schematic depicting the aqueous core, hydrophilic headgroup, and 
hydrophobic tail regions and (B) a cryogenic transmission electron micrograph of 
dipalmitoylphosphatidylcholine liposomes (DPPC, 10 mM) prepared in phosphate 
buffered saline.  
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 FDA-approved liposomal amphotericin B formulations (Abelcet®, 
AmBisome®, and Amphotec®) are good examples of the effectiveness of liposomes 
for drug delivery. Amphotericin B is considered the “gold standard” for systemic 
treatment of fungal infections. However, amphotericin B is hydrophobic and 
nephrotoxic, limiting its stability and administered dosage. Encapsulation of 
amphotericin B in the lipid bilayer reduced the concentration of amphotericin B in the 
kidneys, providing similar efficacy as conventional amphotericin B while significantly 
reducing adverse side-effects (Gibaldi et al., 2007; Moen et al., 2009).  
 Release of encapsulated molecules from liposomes is controlled by the 
permeability through the lipid bilayer, which can be achieved by transbilayer diffusion 
or transient pore formation triggered by bilayer disruption or phase separation. Phase 
separation can be induced by ‘melting’ the liposomal bilayers – i.e. heating to a 
temperature greater than the characteristic main phase transition or melting 
temperature of the lipids (Tm). Below Tm the lipids are in the solid or gel phase in 
which the lipids are rigid and highly organized. Above Tm the lipids are disordered in a 
liquid crystalline or fluid phase. Permeability is high at the interface between gel and 
fluid phases. Phase separation and bilayer permeability can be manipulated by 
adjusting the lipid bilayer composition. A simple example illustrating this principle 
can be made with dipalmitoylphosphatidylcholine (DPPC, Tm = 42 oC) and 
dimyristoylphosphatidylcholine (DMPC, Tm = 23 oC). At a DPPC/DMPC molar ratio 
of 74:26 the melting temperature occurs at physiological temperature (37 oC). 
Furthermore, cholesterol is commonly incorporated into the bilayer to reduce 
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membrane fluidity above the melting temperature. Membrane fluidity has been shown 
to be affected by pH, ion concentration, and the presence of molecules (such as 
nanoparticles) absorbed into the bilayer (Al-Jamal and Kostarelos, 2007; Bothun, 
2008; Chen et al., 2010).  
 A major limitation to liposomal drug delivery is the short half-life (Zhang et 
al., 2008). Within minutes, the reticuloendothelial system (RES) will eliminate the 
liposomes from the blood, limiting the drug’s efficacy and ability to accumulate at 
target sites (Moghimi and Szebeni, 2003). Proteins, called opsonins, recognize and 
target foreign agents (such as untargeted liposomes) for elimination by the 
mononuclear phagocyte system (MPS) or by hepatocyte uptake. Other proteins are 
capable of lysing liposomes directly by compromising the stability of the lipid bilayer 
(Ishida et al., 2002; Maurer et al., 2001; Yan et al., 2005). Liposome residence time is 
dependent on liposome size, surface charge, lipid packing, bilayer composition, and 
surface modifiers (Maurer et al., 2001; Samad et al., 2007). Attaching polyethylene 
glycol (PEG) to the liposome, forming “stealth liposomes”, can increasing half-life to 
2-24 hours and increase liposome stability (Medina et al., 2004; Moghimi and 
Szebeni, 2003; Zhang et al., 2008). The first FDA approved liposomal drug 
formulation (and FDA approved “nanodrug”) was Doxil® in 1995. Doxil® is 
doxorubicin, the most commonly used anthracycline anticancer drug, encapsulated 
within a PEGylated liposome. The elimination half-life for Doxil® is 55 hours and an 
area under the plasma concentration time curve of 900μg h mL-1, compared to 0.2 
hours and 4μg h mL-1 for free doxorubicin (Barenholz, 2012; Chang and Yeh, 2012).    
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 Drug delivery from liposomes can also be accomplished by cellular uptake, 
which can occur by adsorption, endocytosis, fusion, and/or lipid transfer (Pagano and 
Weinstein, 1978; Samad et al., 2007; Torchilin, 2005). Adsorption is the association of 
liposome bilayer with cell bilayer without destroying the liposome bilayer or being 
internalized by the cell. Adsorption can be specific (assisted by targeting ligands such 
as antibodies) or nonspecific (controlled by intermolecular and surface forces). 
Endocytosis involves the uptake of liposomes into the cell by encapsulation within 
endosomes. Release of drugs to the cytoplasm can occur by membrane destabilization 
of the encapsulating endosome or by delivery to lysosomes. Lysosomes have an acidic 
pH and contain lysing enzymes. Drug release is accomplished when lysosome 
enzymes hydrolyze the lipid bilayer releasing the drug. Lysosome drug release is only 
effective when the encapsulated drugs are not susceptible to lysosome enzymes and 
pH. Fusion involves the adsorption and incorporation of the liposome bilayer with the 
cell membrane, releasing the payload into the cytoplasm. Finally, lipid transfer 
involves the exchange of lipids between the liposome bilayer and the cell membrane 
without enveloping the liposome (Samad et al., 2007; Torchilin, 2005). 
 
 Nanoparticles 
 Nanoparticles are nanoscale moieties having magnetic and optical properties 
for use in therapeutic and imaging applications. The high surface area-to-volume ratio, 
stability, functionalization, and size (1-100nm, on the order of biological 
macromolecules) of nanoparticles make them particularly attractive for biomedical 
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applications. Nanoparticles have shown to be particularly effective as a contrast agent, 
a heat source, and as a targeting agent. Clinical application of nanoparticles can be 
hindered by poor colloidal stability, hydrophobicity, protein absorption, immune 
system uptake, and cytotoxicity. LNAs provide a carrier to take advantage of the 
properties of nanoparticles for controlled release, targeted therapies, hyperthermia, 
diagnostics, and imaging applications (Al-Jamal and Kostarelos, 2007; Huang et al., 
2011). A number of different inorganic nanoparticles have been used in LNAs, such as 
quantum dots (Al-Jamal et al., 2008b; Bothun et al., 2009; Gopalakrishnan et al., 
2006), fullerenes (fullerenosomes) (Babincova et al., 2003, 2004; Chen and Bothun, 
2009; Doi et al., 2008; Hwang and Mauzerall, 1993; Ikeda and Kikuchi, 2008; Ikeda et 
al., 2009; Ikeda et al., 2005; Jeng et al., 2005; Niu and Manzerall, 1996), silver 
(Bothun, 2008; Park et al., 2005), superparamagnetic iron oxide (SPIO) (Bothun and 
Priess, 2011; Chen et al., 2010), and gold (Park et al., 2006). This section will discuss 
several nanoparticles that have been utilized in LNA applications. 
 Despite their applications in drug and gene delivery and cosmetics, 
cytotoxicity remains a major concern. Understanding the interactions between 
nanoparticles and cell membranes is crucial to NP biomedical applications and 
provides insight into their toxicity. NPs can be designed to bind on the cell surface, 
adsorb within the membrane, and translocate across the cell membrane. NPs can be 
exploited for novel applications by controlling the interaction between the NP and 
bilayer. A common way to achieve this interaction is by modifying the surface of the 
NP, specifically by adding positive or negative charges onto NP surface (N. Li, 2006; 
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S. Legrand, 2008). Binding interaction between superparamagnetic iron oxide 
particles and stem cells are being used in cell selection process (L.F. Pavon, 2008). 
NPs used in drug delivery applications can be modified to avoid drug degradation by 
increasing the circulation period which in turn results in cell uptake efficiency (S. Jin, 
2007).  
 
 
4.1 Quantum Dots 
 Quantum dots (QDs), 2-10nm florescent semiconductor nanocrystals, have 
been demonstrated as effective imaging and diagnostics agents. QDs can provide a 
highly sensitive contrast agent capable of exhibiting fluorescence that is 10-20 times 
greater than conventional imaging agents, such as organic dyes and florescent 
proteins. QDs are also 100 times more stable against photobleaching than organic dyes 
(Chan, 1998). The optical properties of QDs can be tuned by adjusting their size and 
composition. Commonly used quantum dots for biomedical applications include 
cadmium selenide (CdSe), cadmium telluride (CdTe), indium phosphide (InP), and 
indium arsenide (InAs) (Bharali and Mousa, 2010). Clinical application of quantum 
dots is limited due to their inherent hydrophobicity and potential cytotoxicity. 
Conjugation of quantum dots with liposomes have shown to be effective to overcome 
these limitations (Al-Jamal and Kostarelos, 2007; Bothun et al., 2009; Dudu et al., 
2008; Smith et al., 2006; Walling et al., 2009; Weng et al., 2008).   
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4.2 Gold Nanoparticles 
 Imaging and photothermal effects of gold NPs stem from their enhanced 
surface plasmon resonance (SPR), where visible or near-infrared light is absorbed 
causing oscillation of surface electrons (Huang et al., 2010). SPR absorbance and the 
wavelength range are dependent upon nanoparticle size, core/shell configuration (e.g. 
silica core/gold shell (Oldenburg et al., 1999)), and geometry. Shifts in these 
properties are indicative of the degree of NP aggregation and/or molecular adsorption 
on the NP surface (Li and Gu, 2010). For photothermal therapy, absorbed light energy 
is converted into local heat that thermally diffuses into the surrounding medium. 
Varying NP size and core/shell configuration provides a means of tuning the 
frequency window for photothermal therapy. It is generally accepted that gold NP-
mediated phototherapy is attributed to heat or resulting bubble nucleation depending 
on the light intensity and mode of exposure (Li and Gu, 2010). However, recent work 
by Krpetic et al. at low light energies suggests that photochemical effects – the 
formation of free radicals during NP irradiation – may play an important role. In 
addition to photothermal heating, electromagnetic fields operating at RF can be used 
to heat gold NPs (Krpetic et al., 2010). For example, Gannon et al. examined the effect 
of NP concentration and RF field strength on the heating rates of 5 nm Au NPs in 
water. A rate of ~74 oC min-1 was measured using an 800 W RF field at a NP 
concentration of 67 μM (Gannon et al., 2008). 
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4.3 Superparamagnetic Iron Oxide Nanoparticles 
 Superparamagnetic iron oxide (SPIO) NPs are 4-20nm nanoparticles typically 
composed of magnetite (Fe3O4) or maghemite (γ-Fe2O3). SPIO NPs demonstrate 
physical and magnetic properties, such as low toxicity and paramagnetism, making 
them advantageous for in vitro and in vivo applications. Due to the nanoscale crystal 
size of iron oxide, a single magnetic domain forms making the particle 
superparamagnetic. The atomic magnetic dipoles of paramagnetic materials are 
randomly oriented due to Brownian fluctuation in the absence of a magnetic field. 
Presence of a magnetic field causes the crystals to align in the direction of the field. 
After removal of the magnetic field, Brownian fluctuation will cause the random 
orientation, leaving no magnetic reminisce (Thorek et al., 2006). The 
superparamagnetic characteristics of SPIO NPs allow them to be used as contrast 
agents for magnetic resonance imaging (MRI), targeted therapeutic agents capable of 
being directed under a static magnetic field, and a heat source from when exposed to 
alternating current electromagnetic fields (AC EMF) (Brezovich, 1988; Teja and Koh, 
2009). SPIO NPs also have low toxicity because the iron oxide is broken down 
naturally by the liver and spleen (Laurent et al., 2008; Mornet et al., 2004; Pankhurst 
et al., 2003; Rivera Gil et al., 2010). The characteristics of SPIO NPs allow for the 
development of multifunctional LNAs capable of simultaneous targeting, imaging, 
hyperthermia and/or drug delivery.  
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 Formation, Structure, and Design Strategies 
 The functionality of a LNA is determined by the liposome composition, 
liposome and NP surface modifiers, NPs employed, intermolecular and surface 
interactions, and colloidal stability. LNA design strategies include the encapsulation of 
individual or multiple NPs within the aqueous core of the liposome, embedding 
hydrophobic NPs in the lipid bilayer, and binding or conjugating NPs to the liposome 
surface (Figure 1-2). Table 1-3 contains a list of Au, iron oxide, and γ-iron oxide 
LNAs reported in the literature since 2008. LNAs can be used to protect NPs and 
encapsulated agents from the adsorption of exogenous molecules, enhancing 
bioavailability and reducing the need for complex surface chemistries. Concentration 
of NPs and therapeutic agents within the liposome can increase intracellular delivery, 
providing greater contrast for imaging, more efficient drug delivery, and enhanced 
heating capability for hyperthermia applications. Functionality can also be added by 
modifying the LNA bilayer with functional lipids or surface coatings for improved 
stability and providing targeting capability. 
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Figure 1-2. Schematics and cryogenic transmission electron micrograph of 
liposome-nanoparticle assemblies.  
Schematic and representative transmission electron micrographs of LNAs formed by 
encapsulating hydrophilic nanoparticles (E-LNAs; A, A-1; Wijaya and Hamad-
Schifferli, 2007), bilayer decorating hydrophobic nanoparticles (D-LNAs; B, B-1; 
Rasch et al., 2010b), or surface coupling hydrophilic nanoparticles (S-LNAs; C C-1; 
Wu et al., 2008). Surface coupling (C) can also be used to create controlled aggregates 
or complexes (D1, D2; D1-1, D2-1; Volodkin et al., 2009). Structures and proportions 
are not to scale. Reprinted from Rasch et al., 2010b; Volodkin et al., 2009; Wijaya and 
Hamad-Schifferli, 2007; Wu et al., 2008 
 
 LNA functionality extends beyond that of a traditional liposome. Liposome 
delivery requires not just creating a stable system capable of retaining cargo during 
both storage and circulation, but also the ability to release encapsulates at a target site. 
Efficient release can be achieved by using environmental responsive liposomes that 
melt near physiological temperature or through chemical mechanisms, such as pH-
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sensitive lipids. Controlled and triggered-release from LNAs can be achieved by 
taking advantage of these liposomal responsive properties and NP RF and 
photothermal heating capability. Multifunctional LNAs capable of targeting, imaging, 
hyperthermia, and/or controlled release can be constructed by combining the 
advantageous properties of the nanoparticles and lipids used. 
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    Table 1-3. Review of LNAs formed with gold (Au) nanoparticles. 
Lipids (ratio)a Charge 
NP 
diameter 
(nm) 
NP surface coating Lipid:NPa LNA Ref 
DOPC 
DOPC:DOPC+ (90:10) 
DOPC:DOPP (9:1) 
Zwitterionic 
Cationic 
Anionic 
n.r. Ascorbic acid n.r. S-LNA Sau et al., 2009 
DOPC:DOTAP (8:2) Cationic 80 Citrate n.r.f E-LNA Anderson et al., 2010 
DPPC:Chol (55:40) Zwitterionic 1.4 n.r. 500:1-2000:1 (DPPE-AuNP:Liposome) S-LNA 
Chithrani et 
al., 2010 
DPPC:DPTAP:Chol (6:3:1 
w/w) Cationic 20 n.r.  C-LNA 
Volodkin et 
al., 2009 
DPPC:DSPC (9:1) Zwitterionic 2.5 Hexanethiol 17.2:1 (w/w) D-LNA Paasonen et al., 2010b 
DPPC:DSPC (9:1) Zwitterionic 4 Mercaptosuccinic acid 10:1 (w/w) E-LNA Paasonen et al., 2010b 
DPPC:DSPC (9:1) Zwitterionic 1.4 DPPE-Nanogold™ n.r. E-LNA, D-LNA 
Paasonen et 
al., 2007a 
Egg PC Cationic 10 Chitosan n.r. S-LNA 
Pornpattanan
angkul et al., 
2011 
EggPC Zwitterionic 2 Dodecanethiol 100:1-1500:1 D-LNA Rasch et al., 2010a 
EggPC:DOTAP (9:1 w/w) Cationic 4 Mercaptopropionic acid ≥3.6x10-3:1 (mol/mol) S-LNA 
Pornpattanan
angkul et al., 
2010 
EYPC 
EYPC:DDAB (9:1) 
EYPC:PEG-DSPE (95:5) 
Zwitterionic 
Cationic 
Zwitterionic 
13 Citrate 10:1, 1:1 (mol/mol) S-LNA Kojima et al., 2008b 
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    Table 1-4. Review of LNAs formed with iron oxide nanoparticles. 
Iron oxide (Fe3O4) 
[maleimide]PEG-
DSPE:FAM-DOPE (10:1 
w/w) 
 10-14 Heptanioc acid, acetic acid 1:1.8 (w/w) E-LNA 
Larsen et 
al., 2008 
DMPC:Chol:XLe 
(47.5:47.5:5) 
DPPC:DMPC:XLe 
(9.5:85.5:5) 
Zwitterionic 10 Catechol ≥8.3:1 (mol/w) C-LNA Mart et al., 2009 
DMPC:DMTAP:Chol:DMP
E-PEG (35:50:10:5) Cationic n.r n.r. n.r E-LNA 
Dandamudi 
et al., 2009 
DPPC:Chol:PEG-
DMPE:Fol-PEG-DSPE 
(80:20:4.2:0.5) 
Zwitterionic 10 Lauric acid n.r. E-LNA Pradhan et al., 2010 
PC Zwitterionic 12.5 n.r.  E-LNA Sabate et al., 2008 
PC:PE (2:1) Zwitterionic 10 n.r. n.r. E-LNA Kikumori et al., 2008 
Iron oxide (γ-Fe2O3) 
DOPC:DPTAP:Chol:DPPE:
PEG-DMPE:Fol-PEG-
DSPE 
(47.5:18.9:28.5:1:4:0.1 
w/w) 
Cationic 16 Oleic acid n.r E-LNA Bothun et al., 2011 
DOPE:Chol Cationic 20 Tartaric acid 0.75-3 mg/ml E:LNAs Zheng et al., 2009 
DOTAP:DOPE Cationic 10 (3-Aminopropyl) triethoxysilane n.r E-LNA 
Yang et al., 
2008 
  
 
23 
DPPC Zwitterionic 5 Oleic acid 1000:1-10000:1 D-LNA Chen et al., 2010 
DPPC:Chol (5:1, 15:3 w/w) 
DPPC:DSPC:Chol (10:5:3 
w/w) 
Zwitterionic 43 Dextran n.r. E-LNA Tai et al., 2009 
DPPC:Chol (67:33) Zwitterionic 10 Glutamic acid n.r. E-LNA Zhu et al., 2009 
DPPC:DPTAP Cationic 16, 30 Oleic acid  S-LNA 
Chen and 
Bothun, 
2011 
aMolar ratios provided unless noted otherwise, n.r. stands for not reported. 
bCationic peptide lipid (Murakami et al., 1984). 
cContained within a cyclodextran cavity and embedded via fullerene exchange method (Ikeda et al., 2005). 
dCerasome (ceramic coated liposome). 
eCross-linking molecule (adhesive lipid). 
fEstimated at 4 liposomes per NP. 
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5.1 Encapsulated Liposome-Nanoparticle Assembly 
 
 Encapsulated liposome-nanoparticle assemblies (E-LNAs) are formed by 
encapsulating NPs within the aqueous core of liposomes (Figure 1-2(A)). The first 
investigation of LNAs was inspired by the use of liposomes as a carrier for 
hydrophilic drugs. E-LNAs, by encapsulating NPs in the liposome core, force NPs to 
cluster together at a high density. High density nanoparticle loading is advantageous to 
hyperthermia and drug delivery because heating and drug release can be localized 
preventing damage to adjacent tissues. Also, high density loading provides a strong 
contrast agent for biomedical imaging (Wijaya and Hamad-Schifferli, 2007).  
 Magnetoliposomes (MLs), liposomes encapsulating superparamagnetic NPs, 
are one of the simplest and first developed LNA configurations (De Cuyper and 
Joniau, 1988; Shinkai et al., 1996). They can be prepared by encapsulating preformed 
NPs in solution or by forming NPs within the liposome core, as first shown by 
Papahadjopoulos in 1983 (Hong et al., 1983). E-LNAs can be prepared by thin film 
hydration (TFH), double emulsion (DE) (Zheng et al., 1994), or reverse phase 
evaporation (REV) (Szoka and Papahadjopoulos, 1978). Extrusion or sonication of 
post-formation liposomes can be employed to control the size of E-LNAs. Supported 
lipid bilayers (SLBs), NPs coated with a lipid bilayer, are formed when dcore = dNP. E-
LNA formation requires the use of colloidal stable nanoparticles with a diameter (d) 
that is smaller than the inner diameter of the aqueous liposome core, dcore > dNP 
(Figure 1-3(A)). The maximum theoretical number of encapsulated NPs is n ≈ 
0.74(Vcore/VNP; V represents the volume of the core or NP), due to the close packing of 
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spheres and dcore >> dNP. Wijaya and Hamad-Schifferli demonstrated that it is possible 
to approach this limit, demonstrating high-density encapsulation of Fe3O4 NPs (dNP = 
12.5 nm) within DPPC liposomes (Figure 1-2(A-1)). With this design the available 
core volume for co-encapsulating aqueous drug molecules decreases within increasing 
NP concentration (Wijaya and Hamad-Schifferli, 2007). However, the ability for 
embedding hydrophobic molecules within the bilayer is unaffected by NP 
concentration. 
 The osmotic pressure differential across the lipid bilayer and the attractive or 
repulsive forces between the bilayer and the NPs determine the structure of E-LNAs. 
The elasticity of the bilayer determines how the LNA will deform in response to these 
forces. Attractive forces can include van der Waals, hydrophobic, and electrostatic 
interactions; and repulsive forces can include electrostatic, depletion, hydration, and 
steric interactions. The physical stability of a liposome-NP system can be determined 
by the Deryaguin-Landau-Verwey-Overbreek (DLVO) theory. The DLVO theory 
balances the opposing forces to provide a total energy of interaction between the 
particles. Liposome-NP systems are characterized by three types of interactions that 
take place, repulsion between liposome-liposome and NP-NP and attractive forces 
between liposome and NP. Electrostatic repulsion becomes significant when 
nanoparticles and liposomes approach each other and their double layers begin to 
interfere. Electrostatic energy curve represents the energy required to overcome the 
repulsion. The maximum energy corresponds to the situation when the surfaces are 
touching each other and is zero outside the double layer (Leckband, 2001). 
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The adhering and non-adhering characteristics of nanoparticles can lead to changes in 
bilayer curvature, which can impact liposome size, shape, and phase homogeneity 
(Lipowsky and Dobereiner, 1998). Generally, this will occur when encapsulates are 
different from molecules present outside (e.g. sugars or proteins) liposomes.  
 LNAs are generally formed with small non-adhering NPs because NP adhesion 
to bilayers can significantly alter LNA structure and morphology. The exception to 
this is LNAs formed by coating a single large NP with an adsorbed or supported lipid 
bilayer. For non-adhering encapsulated particles, the bilayer can curve towards the 
larger particles. As an example of a non-adhesive system, Pradhan et al. (Pradhan et 
al., 2007) compared the encapsulation efficiency of 10 nm MnFe2O4 NPs coated with 
lauric acid composed of egg-PC:cholesterol (at molar ratios of 1:0, 2:1, 3:2, 1:1, and 
1:2) and formed by TFH and DE. In general, TFH resulted in higher encapsulation 
efficiency with smaller ML diameter compared to DE due to stripping of lauric acid 
during the DE process. In both cases, the observation that an Egg PC:cholesterol ratio 
of 2:1 yielded the best encapsulation efficiency (70% via TFH) was attributed to 
cholesterol inducing a single liquid ordered bilayer phase.  
 In contrast, for small adhering encapsulated particles (attractive) where dcore >> 
dNP and dNP < 2lb the bilayer can curve away from the particles. For large adhering 
particles, where dNP >> 2lb, the bilayer can curve around or engulf the particles. For 
example, Sabate et al. examined the effect of Fe3O4 NP concentration coated with 
tetramethylammonium hydroxide (58 nm hydrodynamic dNP) on the encapsulation 
efficiency of extruded soybean PC MLs. The encapsulation efficiency decreased from 
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96.6% at 1.22 g Fe3O4/mol PC to 18.5% at 119.95 g Fe3O4/mol PC. This was 
attributed to electrostatic interactions (attraction) between the cationic NPs and the PC 
bilayers. The size of the MLs increased from 140 to 197 nm, consistent with lower 
curvature due to NP adhesion at the inner bilayer surface (Sabate et al., 2008). 
 Electrolytes can also effect the curvature of lipid bilayers (Lipowsky and 
Dobereiner, 1998). Gomes et al. (Gomes et al., 2009) prepared polyelectrolyte-coated 
MLs by encapsulating 8 nm anionic γ-Fe2O3 NPs within egg PC liposomes and then 
coating with alternating poly(allylamine hydrochloride) and poly(sodium 4-
styrenesulfonate) layers. The final coating determined the surface charge (anionic PSS 
or cationic PAH). The size ranged from 200-400 nm and two or more polyelectrolyte 
coatings sufficiently protected the lipid bilayer from detergent-induced disruption.
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Lipids (ratio)a Charge DNP 
(nm) 
NP surface 
coating 
Lipid:NPa LNA Ref 
Gold 
DOPC:DOTAP (8:2) Cationic 80 Citrate n.r.f E-LNA (Anderson et al., 
2010) 
DPPC:DSPC (9:1) Zwitterionic 2.5 Hexanethiol 17.2:1 (w/w) D-LNA (Paasonen et al., 
2010) 
EggPC Zwitterionic 2 Dodecanethiol 100:1-1500:1 D-LNA (Rasch et al., 
2010) 
DPPC:DSPC (9:1) Zwitterionic 4 Mercaptosuccinic 
acid 
10:1 (w/w) E-LNA (Paasonen et al., 
2010) 
DPPC:DSPC (9:1) Zwitterionic 1.4 DPPE-Nanogold™ n.r. E-LNA 
D-LNA 
(Paasonen et al., 
2007) 
DOPC 
DOPC:DOPC+ (90:10) 
DOPC:DOPP (9:1) 
Zwitterionic 
Cationic 
Anionic 
n.r. Ascorbic acid n.r S-LNA (Sau et al., 2009) 
EYPC 
EYPC:DDAB (9:1) 
EYPC:PEG-DSPE (95:5) 
Zwitterionic 
Cationic 
Zwitterionic 
13 Citrate 10:1, 1:1 
(mol/mol) 
S-LNA (Kojima et al., 
2008) 
EggPC:DOTAP  
(9:1 w/w) 
Cationic 4 Mercaptopropionic 
acid 
≥3.6x10-3:1 
(mol/mol) 
S-LNA (Pornpattananangk
ul et al., 2010) 
DPPC:DPTAP:Chol  
(6:3:1 w/w) 
Cationic 20 n.r.  C-LNA (Volodkin et al., 
2009) 
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DPPC:Chol (55:40) Zwitterionic 1.4 n.r. 500:1-2000:1 
(DPPE-
AuNP:Liposome)
S-LNA (Chithrani et al., 
2010) 
Egg PC Cationic 10 Chitosan n.r. S-LNA (Pornpattananangk
ul et al., 2011) 
Iron oxide (Fe3O4) 
[maleimide]PEG-
DSPE:FAM-DOPE  
(10:1 w/w) 
 10-14 Heptanioc acid, 
Acetic acid 
1:1.8 (w/w) E-LNA (Larsen et al., 
2008) 
DMPC:Chol:XLe 
(47.5:47.5:5) 
DPPC:DMPC:XLe 
(9.5:85.5:5) 
Zwitterionic 10 Catechol ≥8.3:1 (mol/w) C-LNA (Mart et al., 2009) 
PC Zwitterionic 12.5 n.r.  E-LNA (Sabate et al., 
2008) 
DMPC:DMTAP:Chol:DM
PE-PEG (35:50:10:5) 
cationic n.r n.r. n.r E-LNA (Dandamudi et al., 
2009) 
PC:PE (2:1) zwitterionic 10 n.r. n.r. E-LNA (Kikumori et al., 
2008) 
DPPC:Chol:PEG-
DMPE:Fol-PEG-DSPE 
(80:20:4.2:0.5) 
zwitterionic 10 Lauric acid n.r. E-LNA (Pradhan et al., 
2010) 
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Iron oxide (γ-Fe2O3) 
DPPC:Chol (67:33) zwitterionic 10 Glutamic acid n.r. E-LNA (Zhu et al., 2009) 
DPPC:Chol  
(5:1, 15:3 w/w) 
DPPC:DSPC:Chol  
(10:5:3 w/w) 
zwitterionic 43 Dextran n.r. E-LNA (Tai et al., 2009) 
DPPC zwitterionic 5 Oleic acid 1000:1-10000:1 D-LNA (Chen et al., 2010) 
DOPC:DPTAP:Chol:DPP
E:PEG-DMPE:Fol-PEG-
DSPE 
(47.5:18.9:28.5:1:4:0.1 
w/w) 
cationic 16 Oleic acid  E-LNA (Bothun et al., 
2011) 
DPPC:DPTAP cationic 16, 30 Oleic acid  S-LNA (Chen and Bothun, 
2011) 
DOTAP:DOPE cationic 10 (3-
Aminopropyl)trieth
oxysilane 
 E-LNA (Yang et al., 2008) 
DOPE:Chol catonic 20 Tartaric acid 0.75-3 mg/ml E:LNAs (Zheng et al., 
2009) 
amolar ratios provided unless noted otherwise. 
bcationic peptide lipid (Murakami et al., 1984). 
ccontained within a cyclodextran cavity and embedded via fullerene exchange method (Ikeda et al., 2005). 
dcerasome (ceramic coated liposome). 
ecross-linking molecule (adhesive lipid). 
festimated at 4 liposomes per NP. 
 31 
 
 
5.2 Bilayer-Decorated Liposome-Nanoparticle Assembly 
 
 Bilayer decorated liposome-nanoparticle assemblies (D-LNA) are liposomes 
with hydrophobic nanoparticles embedded in the lipid bilayer (Figure 1-2(B)). Similar 
to the ability of cells to accommodate membrane proteins, liposomes can distort to 
accommodate hydrophobic NPs that exceed the thickness of hydrophobic acyl region 
of the bilayer (~3 nm) (Al-Jamal et al., 2008b; Bothun, 2008; Chen et al., 2010; Jang 
et al., 2003). Embedded NPs can affect lipid packing, lipid phase behavior, 
transbilayer permeability, and LNA structure and morphology (Binder et al., 2007; 
Bothun, 2008; Bothun et al., 2009; Chen et al., 2010; Chen and Bothun, 2009; Jeng et 
al., 2005; Park et al., 2005, 2006; Rasch et al., 2010b). Cryo-TEM can be used to 
observe the structure and morphology of these nano-scale systems in solution (Chen 
and Bothun, 2011). Atomic force microscopy has also been used to observe phase-
separated domains and monitor membrane remodeling and alteration due to the 
presence and distribution of nanoparticles within the bilayer (Kirat, 2010). The 
diameter of embedded nanoparticles (core and surface coating) is similar to the 
thickness of the lipid bilayer (~5 nm). Theoretically, the diameter of embedded 
nanoparticle must be less than 6.5 nm in order for the lipid bilayer to maintain its 
structure. Hydrophobic nanoparticles with diameters greater than 6.5 nm form 
micelles because they are more energetically favorable due to the high local curvature 
strain on the bilayer, as described in Figure 1-4 (Ginzburg and Balijepalli, 2007; Wi et 
al., 2008).  
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Figure 1-3. Changes in bilayer decoration mechanism of D-LNAs with increasing 
nanoparticle diameter.  
Nanoparticle diameter, dNP, is equal to the diameter of the particle core plus two times 
the surface coating. (A) Small nanoparticles (defined herein as dNP < 2 nm) can cluster 
together to minimize bilayer bending energy (Rasch et al., 2010b). (B) Larger 
nanoparticles (defined herein as dNP = 2-6.5 nm) can create ‘pockets’ within the 
bilayer or (C) bridge adjoining liposomes (Al-Jamal et al., 2008b; Chen et al., 2010). 
(D) D-LNA assembly is governed in part by the bilayer deformation energy, which 
can be evaluated based on the energy penalty associated with lipid stretching (related 
to the compressibility modulus) and monolayer curvature (related to bending 
modulus). 
  
 The characteristics of LNAs are directly affected by embedded nanoparticles. 
Embedded NPs interact with the lipid acyl tails changing the fluidity of the membrane 
bilayer. Physical obstruction of the movement of lipid tails reduces the lipid bilayer 
ordering. The melting temperature of LNAs with embedded silver (Bothun, 2008), 
gold (Mady et al., 2011), and SPIO NPs (Chen et al., 2010) have shown to reduce the 
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transition temperature of the bilayer with increased loading by fluorescence anisotropy 
and differential scanning calorimetry. Recent FTIR measurements of embedded gold 
NPs have validated the interaction of NPs and the acyl tail groups. Changes in the 
frequency of CH2 stretching indicated conformational change in acyl tails of bilayers 
with embedded NPs. Also, dynamic light scattering of citrate-stabilized gold NPs 
embedded in DPPC liposomes demonstrated an increase in the negative charge. 
Surface charge can hinder aggregation of LNAs affecting the overall stability of LNAs 
(Mady et al., 2011). Therefore, changes to the membrane alter LNA properties for 
delivery of therapeutic and diagnostic agents. The interactions between NPs and 
liposomes still remains misunderstood. Further investigation into the effect of 
nanoparticles is necessary to develop more efficient multimodal LNAs   
  Clustering of embedded NPs has been observed by Rasch et al. in LNAs with 
dodecanethiol-coated Au (dNP = 1.6-1.8 nm) (Figure 1-4(A)) (Rasch et al., 2010b). 
They showed that high NP loading with uniform distribution can be achieved in PC 
liposomes via thin film hydration (with sonication and extrusion). Janus particles can 
be prepared with embedded NPs clustered in approximately one half of the liposomes 
via detergent loading followed by dialysis. Clustering occurs as the liposomes 
minimize the energy penalty for bilayer deformation – i.e. for a given concentration of 
embedded NPs the periodic bilayer bending energy needed to accommodate individual 
particles is greater than that needed to accommodate nanoparticle clusters. Park et al. 
(Park et al., 2006) and Chen et al. (Chen et al., 2010) have observed a similar 
clustering phenomenon with stearylamine-coated 3-4 nm Au and oleic acid-coated 5 
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nm γ-Fe2O3 NPs in DPPC liposomes (Figure 2(B-1)), respectively. This suggests that 
NP clustering is not restricted to dNP < 2 nm (Chen et al., 2010).  Increasing the 
loading of nanoparticles in the bilayer causes turbidity to change, which can be 
detected by higher shifts in absorption bands in UV-vis. The shifts are attributed to 
stronger interactions on dipole moments on aggregate nanoparticles (Marchenko, 
2010).  
 In addition to clustering, embedded NPs with dNP = 2-6.5 nm can reside in 
bilayer ‘pockets’ within individual (Figure 1-4(B)) or neighboring (Figure 1-4(C)) 
LNAs. -These cases arise when the lipid:NP ratio is high (~1000:1 or greater). This 
has been observed by Al Jamal et al. (Al-Jamal et al., 2008a) for 4 nm hydrophobic 
CdSe/ZnS core/shell quantum dots in DOPC bilayers. Embedded SPIO NPs clusters 
have also led to merging of adjacent liposomes. Chen et al. hypothesizes that optimal 
nanoparticle embedding for controlled release is a “trade-off between structural 
changes and aggregation, which reduce the effective liposome surface area, bilayer 
stabilization, which reduced bilayer permeability, and the localized heating in a EMF” 
(Chen et al., 2010).  
 
5.3 Surface-Coupled Liposome-Nanoparticle Assembly and Complexation  
 Surface coupled magnetoliposomes (S-LNAs) are formed when hydrophilic 
NPs are absorbed onto or coupled to the outer surface of the lipid bilayer (Figure 1-
2(C)). This is achieved through attractive surface interactions, notably long-range 
electrostatic attraction. An advantage of S-LNAs is the ease in which they can be 
prepared – adding NPs to pre-existing liposome dispersions. Similar to bilayer 
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embedment, decorated bilayers also provide direct heating to the bilayer in the 
presence of external stimuli. The design constraint for forming S-LNAs is dependent 
on bilayer NP adhesion and curvature. Recent investigations have shown that NPs 
with dNP > ~20 nm lead to the formation of SLBs due to liposome adsorption and 
rupture, followed by the bilayer curving around the particle (Figure 1-3(A)) (Chen and 
Bothun, 2011). The critical NP diameter under which S-LNAs can be formed is dNP < 
2(kb/w)1/2, where kb is the bilayer bending elasticity, which is dependent on lipid 
composition and phase state, and w is the adhesion energy (Roiter et al., 2008).  
 The Granick group has shown that stable S-LNA dispersions can be formed 
using zwitterionic liposomes with decorated cationic or anionic NPs (< 20 nm) with a 
NP surface coverage above ~25% (Yu et al., 2007; Zhang and Granick, 2006). This 
was achieved by electrostatic attraction. Lower surface coverage led to aggregation, 
which demonstrates the need to balance the lipid:NP ratio. It was shown with 
isothermal titration calorimetry that upon binding the nanoparticles could restructure 
the lipid bilayer, inducing gel phases in fluid liposomes and fluid phases in gel 
liposomes (Wang et al., 2008). This observation shows that, even without external 
stimuli, bound NPs can induce changes in lipid phase behavior and, presumably, 
permeability. 
 NP adhesion to the outer bilayer can affect the morphology and structure of S-
LNAs similar to E-LNAs. Cationic nanoparticle adhesion to the outer surface of 
GUVs has been shown to cause pearling. The head group area of zwitterionic lipids 
was increased due to the use of charged particles. Attraction of the head group and 
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electrostatic repulsion to the cationic nanoparticles caused a mismatch of the outer and 
inner curvature of liposomes. These interactions resulted in the pearling structure of 
the liposome (Yu and Granick, 2009).  
 Sau et al. have also used electrostatic binding to prepare S-LNAs with Au NPs. 
High NP surface coverage was achieved by using anionic Au NPs with physisorbed 
ascorbic acid and cationic liposomes (9:1 DOPC to ethyl-DOPC; Tm = -20 oC) (Sau et 
al., 2009). This high surface coverage was accompanied by NP aggregation due to the 
high local concentration and (likely) to charge screening via cationic lipids between 
bound particles (Kojima et al., 2008a). Binding was also achieved on zwitterionic and 
anionic liposomes with decreasing coverage (and NP aggregation), respectively. 
Pornpattananangkul et al. have taken this one step further and have shown that pH can 
be used to control carboxyl-modified (anionic) Au NP binding to cationic liposomes 
and, in turn, liposome stability. Above the pKa of the carboxyl groups the bound NPs 
stabilize the S-LNAs and prevent aggregation and fusion, while below the pKa the 
NPs detach and liposome fusion resumes (Pornpattananangkul et al., 2010).  
 Lastly, LNAs can be formed by complexation (C-LNAs) if the liposomes 
surround NP aggregates (Figure 1-2(D2)) or the NPs bind to multiple liposomes and 
act as “bridges” (Figure 1-2(D1)). Voldokin et al. have shown that either structure can 
be formed from the same anionic Au NP-cationic liposome by manipulating 
electrostatic interactions using via salt concentration. High NaCl concentration (75 
mM) enhanced NP aggregation (Figure 1-2(D2-1)) and low salt concentrations 
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inhibited it (Figure 1-2(D1-1)). In addition to non-specific physical interactions 
(electrostatic), cross-linking can be used to create C-LNAs (Volodkin et al., 2009). 
 Mart et al. used Fe3O4 NPs coated with histidine groups to bind to and 
complex zwitterionic/cholesterol liposomes containing Cu(iminodiacetate)-
functionalized lipid. The objective was to demonstrate a potential method using 
histidine-Cu(IDA) binding to form C-LNAs, thereby concentrating a therapeutic and 
an imaging agents at a target site. The resulting aggregates ranged from 20-100 μm in 
diameter. The C-LNAs demonstrated EMF heating and controlled release of model 
drugs (Mart et al., 2009). 
 
 Controlled Release 
 Controlled release of encapsulated payloads from LNAs can be induced by 
heating of nanoparticles raising temperature of the lipid bilayer. In vivo heating of 
magnetic nanoparticles has been demonstrated with external stimuli such as 
alternating current electromagnetic fields, microwaves, light irradiation, and lasers 
(Brazel, 2009). As discussed earlier, the bilayer permeability rises with temperature 
allowing release of encapsulates. Bothun and Preiss have demonstrated local bilayer 
heating due of Fe3O4 nanoparticles heated by RF causing phase transition. However, 
there was negligible difference between the bulk and local bilayer temperatures. 
Therefore, controlled release is likely due to both thermally-induced phase transition 
and mechanical rupture of the bilayer caused by NP heating. LNA controlled release 
with gold and iron oxide nanoparticle will be discussed herein (Bothun and Priess, 
2011).  
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6.1 Gold Nanoparticles and Photothermal Effects 
 
 Heating of Au NPs is caused by the SPR properties that convert absorbed light 
into heat. SPR heating makes Au NPs efficient heat sources for LNA controlled 
release (Sassaroli et al., 2009). Utilizing the photothermal heating of Au NPs, 
Paasonen et al. (Paasonen et al., 2007b) demonstrated the ability to control the release 
of calcein (622.6 MW) from Au LNAs composed of DPPC/DSPC at 9:1 (Tm = 44.9 
oC) with E-, D-, and S-LNAs (Figure 1-2(A-C)). Leakage was examined with and 
without UV light at a wavelength of 250 nm over 30 min at 37 oC. Without UV 
exposure, spontaneous calcein release was observed for E-LNAs with encapsulated 
mercaptosuccinic acid-coated NPs and D-LNAs with embedded hexanethiol-coated 
NPs. This was attributed to NP-lipid interactions at the bilayer/water interface and 
within the acyl tail region, respectively, which reduced bilayer integrity. With UV 
exposure, direct contact between NPs and the liposomes via bilayer-embedment led to 
the greatest release (~90% at 30 min). Intuitively, direct contact would improve the 
local heat transfer from the NPs to the liposomal bilayers relative to encapsulation. 
This led to a gel-fluid phase transition where calcein release was presumably enhanced 
by diffusion at the interface between coexisting gel and fluid domains. 
 Volodkin et al. demonstrated the release of 5(6)-carboxyfluorescein (CF; 376.3 
MW) from C-LNAs formed by the complexation of 128 nm cationic liposomes 
(DPPC/DPTAP/chol, Tm ~ 40-45 oC) and 20 nm anionic Au NPs. Low NaCl 
concentration (7.5 mM) yielded LNAs with NP-mediated liposome bridges (Figure 1-
 39 
 
2(D1-1)) and high NaCl concentration (75 mM) yielded LNAs with liposome-coated 
NP aggregates (Figure 1-2(D-1)). CF release from the C-LNAs was observed within 5 
s after near-IR irradiation (Figure 1-5) (Volodkin et al., 2009). 
 
 
Figure 1-4. Remote dye release triggered by near IR laser illumination from C-
LNAs.  
C-LNAs were prepared with gel-phase cationic liposomes and 20 nm hydrophilic gold 
nanoparticles. The scale bars represent 10 µm. These results show that near complete 
release can be achieved from the complexes after 5 s of illumination. Reprinted from 
(Volodkin et al., 2009) with permission. 
  
 
 Anderson et al. utilized the principle of plasmonic nanobubble (PNB) 
formation to control the release of 104 and 240 kDa proteins from cationic LNAs (~1 
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μm) containing encapsulated 80 nm anionic Au NPs (Figure 1-6). Irradiation was 
achieved using a single pump laser at 532 nm over 0.5 ns. Local vapor bubble 
formation led to mechanical disruption, as opposed to thermal, of the LNA bilayer and 
rapid protein release. The advantage of PNB formation is heating is isolated within the 
LNA triggering the immediate release of all encapsulated cargo (Anderson et al., 
2010). 
 
 
Figure 1-5. Proposed ‘plasmonic nanobubble’ release mechanism of encapsulated 
molecules from E-LNAs prepared with gold nanoparticles. 
Pulsed laser irradiation of the nanoparticles nucleates vapor bubbles that expand and 
mechanically disrupt the liposomal bilayer and trigger permeabilization. Reprinted 
from (Anderson et al., 2010) with permission. 
  
 Wu et al. used hollow gold nanoshells (HGNs) encapsulated within or 
decorating the surface of DPPC liposomes to trigger CF release by near-IR pulses (800 
nm) via microbubble formation and collapse (Figure 1-2(C-1)). LNA release was 
dependent on the proximity of the HGNs to the liposomes (decorated or tethered 
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HGNs yielded the greatest response) and the laser power. Their results strongly 
suggest that release was attributed to transient disruption or poration of the lipid 
bilayer via transient bubble cavitation (Wu et al., 2008). 
 
6.2 Iron Oxide Nanoparticles and Alternating Magnetic Fields 
 AC EMF operating at RF heating is due to magnetic losses being converted to 
heat, typically at low frequencies between 100-400 kHz. The magnetic losses for NPs 
< ~30 nm are due to Néel relaxation, arising from rapidly alternating magnetic dipole 
moments, and Brownian relaxation, arising from nanoparticle rotation and viscous 
losses (friction). RF heating is advantageous because it is non-invasive, easily 
penetrates the body, and is physiologically acceptable for up to 1 h if the product Hf, 
where H is the field amplitude (current  number of coils per length) and f is the 
frequency, is below 4.85105 kA/m/s (Brezovich, 1988). NP heating capability is 
based on the inherent specific absorbance rate (SAR, W/g) of the nanoparticles: 
 
  

SAR 
cp
mNP
T
t
 
 
where 
  

cp  is the average heat capacity of the sample,   

mNP  is the NP mass, and   

T / t  
is the initial heating rate of the sample. SAR values up to approximately 700 W/g can 
be obtained depending on the NP size, composition, and surface coating (Mornet et al., 
2004). 
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 Tai et al. examined CF release from thermosensitive zwitterionic liposomes 
containing encapsulated dextran-coated 43 nm γ-Fe2O3 NPs (Resovist™) using a high 
frequency generator (6.4 kW, 750-1150 kHz) operating for 5-25 min. CF release from 
DPPC:Chol (5:1) liposomes without encapsulated NPs was initiated between 35 oC 
and 37 oC. In contrast, the LNA analogs exhibited initial release at 34 oC and 32 oC 
with 7 and 14 mg Fe/ml, respectively. This initial release temperature was further 
tuned by increasing the cholesterol content (DPPC:Chol at 15:3) and incorporating a 
higher melting lipid (DSPC, Tm = 55 oC). Release was attributed to NP heating. Using 
a rat model, they demonstrated that release could also be achieved in vivo (Tai et al., 
2009). 
 Chen et al. have recently examined the release of CF from LNAs formed with 
DPPC and bilayer-embedded oleic acid-coated 5 nm γ-Fe2O3 NPs at lipid:NP ratios of 
10000:1, 5000:1, and 1000:1 as a function of RF energy (1 kW; 50-250 A, 281 kHz). 
Experiments were conducted at non-invasive RF energies up to 40 min and the 
greatest release rate was observed at 5000:1, indicating an optimal NP loading for 
triggering release. This optimum reflected a balance between NP loading and LNA 
structure – high loading is needed for triggering bilayer release, but can lead to NP 
aggregation and can compromise LNA structure and stability. A unique observation 
was the fact that increasing NP loading reduced or eliminated spontaneous leakage by 
increasing bilayer stability. CF release was attributed to bilayer disruption via local 
heating and/or LNA rupture, which produced transient voids or pores. Although, these 
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findings demonstrated that higher nanoparticle embedding does not strictly equate to 
greater release controlled release during EMF heating (Chen et al., 2010).  
 
 
 Targeted Therapy 
 Optimal drug delivery and biomedical imaging involves the distribution of 
drug and/or imaging agent to the diseased tissue while minimizing adverse side-effects 
to healthy tissues. Adverse side-effects limit the drug dosage that may be used during 
treatment, potentially requiring the dosage to be reduced, delayed, and/or 
discontinued. Targeting LNAs limit adverse side-effects to healthy tissues and 
enhance drug delivery and uptake by localizing drug delivery to specific target sites 
(Malam et al., 2009; Minko et al., 2006). 
 Effective therapeutic and diagnostic treatment requires sufficient 
bioavailability of LNAs to diseased cells. A major limitation of LNAs, and liposomal 
drug delivery in general, is that the residence time is not long enough to enable the 
non-modified liposome assemblies to accumulate at tumor sites (Zhang et al., 2008). 
LNA residence time is directly related to size and surface properties (discussed herein) 
(Maurer et al., 2001; Samad et al., 2007). 
 
7.1 Passive Targeting 
 Passive targeting of lipid-nanoparticle assemblies is facilitated by the enhanced 
permeability and retention (EPR) effect. Tumor growth requires a sufficient supply of 
oxygen and nutrients. Therefore, during angiogenesis, tumors will produce an 
increased amount of vascular endothelial growth factors routing new blood vessels 
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and/or existing blood vessels directly to growing tumors. These tumor-associated 
neovasculatures are typically disorganized and highly permeable allowing leakage of 
larger entities, such as lipid-nanoparticle assemblies, into the tumor. The entities are 
retained by the tumor because the defective lymphatic drainage prevents larger entities 
from returning to the circulatory system. LNAs accumulate in the tumor providing an 
effective targeting mechanism that can be utilized for drug delivery, imaging, and/or 
hyperthermia (Cho et al., 2008; Corchero and Villaverde, 2009; van Vlerken and 
Amiji, 2006).  
 In order for LNAs to accumulate within a tumor by the EPR effect, the 
residence time of LNAs in the blood must be sufficient to permeate into the tumor. 
Longer circulating assemblies provide a greater opportunity to reach the tumor 
vascular system and enter the tumor for drug delivery and/or imaging. Nanoparticle 
elimination is primarily based upon the reticuloendothelial system (RES) uptake. 
LNAs (as mentioned earlier) can increase their blood residence times by reducing 
clearance and absorption through PEGylation.  
 Passive targeting also exploits the unique environment created by tumors. As 
stated above, rapidly proliferating tumor cells require sufficient oxygen and nutrients. 
However, the supply of oxygen and nutrients is typically insufficient to maintain the 
rapid cell growth, forcing tumor cells to breakdown sugars through glycolysis (Cho et 
al., 2008; Corchero and Villaverde, 2009; Minko et al., 2006; van Vlerken and Amiji, 
2006). Glycolysis, under anaerobic conditions, leads to lactic acid build-up creating an 
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acidic environment (Pelicano et al., 2006). LNAs comprised of pH-responsive lipids 
facilitating drug release in the acidic tumor environment (Cho et al., 2008).   
 Passive targeting can also be utilized for antibacterial applications. 
Pornpattananangkul et al. (Pornpattananangkul et al., 2011) attached chitosan-coated 
gold to vancomycin encapsulated Egg PC liposomes. The attached gold nanoparticles 
prevented fusing and spontaneous leakage increasing stability and shelf-life. 
Antibiotic release was triggered by the presence of bacterial toxins that caused pore 
formation. After 24 hours of exposure, 100% of vancomycin was released from the 
liposome. Vancomycin is used as a “last resort” for MRSA infections (Crossley, 
2010). Such regulated LNA delivery systems reduce side effects and dosage by being 
capable of releasing encapsulates at the delivery site and in response to the severity of 
the infection.  
 Overall LNA size between 50-150 nm is optimal in order to avoid renal 
elimination (nanoparticles smaller than 6 nm) and prevent uptake by the 
reticuloendothelial system (nanoparticles larger than 200 nm) (Gullotti and Yeo, 2009; 
Veiseh et al., 2010). LNA residence time is also dependent on surface charge. Cationic 
LNAs demonstrate a much higher affinity to bind to the vasculature of tumors than to 
normal healthy tissues. Tumor vessel area targeted by cationic LNAs was 
approximately 5 times greater than the vessels of normal healthy tissues (Campbell et 
al., 2002). Cationic LNA uptake has been shown to be almost10 times higher than 
similar anionic and neutral LNAs (Ito et al., 2005). The preferential binding can be 
exploited for targeted hyperthermia, drug delivery, and/or imaging.  
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 Anionic and neutral entities and bodies larger than 200 nm, upon entering the 
blood stream, tend to absorb antibodies, called opsonins, activating the 
reticuloendothelial system and inducing mononuclear phagocyte system (MPS) or by 
hepatocyte uptake and elimination (Ishida et al., 2002; Maurer et al., 2001; Yan et al., 
2005). Incorporation of polyethylene glycol (PEG), a neutral hydrophilic polyether, 
onto the surface of LNAs is very effective for preventing opsonization and increasing 
the residence time. PEG has proven to be one of the most effective surface 
modifications and is probably the most used for producing long-circulating entities. 
For example, Doxil and Myocet in Table 1-1 is a PEG-liposome encapsulated 
formulation of doxorubicin. Myocet and Doxin have an elimination half-life of 2.5 h 
and 55 h, respectively, whereas free doxorubicin has elimination half-life of 0.2 h 
(Danhier et al., 2010). Other surface modifiers and ligands, such as polysaccharides, 
dysopsonins, dextran, etc., have been incorporated into the bilayer to increase 
liposome stability, residence time, and enabling targeting capability (Zhang et al., 
2008). 
 The final passive targeting method is topical delivery. Topical delivery is 
localized drug administration directly to a tumor by injection or surgery. This 
approach bypasses drugs administration through the circulatory system. By avoiding 
the circulatory system, adverse side-effects can be limited to the administration site 
(Minko et al., 2006). 
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7.2 Active Targeting 
 
 Active targeting involves incorporating a targeting ligand, most often 
antibodies, antibody fragments, vitamins, glycolipids, or peptides (Jørgensen and 
Nielsen, 2009), onto the surface of LNAs. In order to be effective, the targeting ligand 
must specifically bind to a receptor that is exclusive to tumors or is overexpressed by 
tumors compared to normal healthy tissue. Active targeting can be split into two 
categories: cancer cell targeting and tumoral endothelium targeting. Cancer cell 
targeting promotes tumor internalization of LNAs and intracellular delivery of 
therapeutic agents. The most common receptors for cancer cell targeting are 
transferrin, folate receptor, cell surface glycoproteins, and the epidermal growth 
factor. Tumoral endothelium targeting restricts the blood supply available to tumor 
cells by attacking angiogenic blood vessels. The most common entities subject to 
tumoral endothelium targeting are vascular endothelial growth factors, vascular 
endothelial growth factors receptors (VEGFR-1 and VEGFR-1), αvβ3 integrin, 
vascular cell adhesion molecule-1, and matrix metalloproteinases (Danhier et al., 
2010).  
 Active targeting can also be accomplished with magnetic drug targeting 
(MDT). MDT utilizes a static magnetic field to concentration of LNAs at selected 
delivery sites. LNAs with encapsulated or embedded magnetic or superparamagnetic 
NPs can be forced to aggregate at sites with applied magnetic fields. MDT allows 
LNAs to be localized at an identified disease site for hyperthermia and drug delivery, 
minimizing the effect to adjacent tissues.  
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7.2.1 Ligand Targeting 
Active targeting of tumors by LNAs has been accomplished by targeting folate 
receptor (FR). Tumor cells express FRs almost 100 times normal cells. Also, the FR 
expression rate is proportional to the how advanced the cancer is. Therefore, FR 
targeting can be an effective method for identifying and treating tumors (Lu and Low, 
2002). FR targeting has been demonstrated both in vitro and in vivo. Folate targeted 
liposomes have been used with nanoparticles for tumor imaging, drug delivery, and 
hyperthermia (Kamaly et al., 2009; Pradhan et al., 2010).  
 FR targeted MLs have demonstrated selective drug delivery in vitro. 
PEGylated MLs incorporating FR targeting-lipids were constructed with co-
encapsulated doxorubicin and maghemite. Human cervical cancer cell (HeLa), which 
overexpress FR, bound to the cell surface and uptake from HeLa cells was observed, 
whereas the control showed no surface binding or uptake. FR targeting was combined 
with AC EMF at RF nanoparticle heating to induce doxorubicin release. Doxorubicin 
release under EMF treatment for 2 h was three times greater than without EMF 
(Bothun et al., 2011).  
 Pradhan et al. developed multifunctional thermosensitive PEGylated 
magnetoliposomes with a folic acid ligand capable of binding to FR. The 
magnetoliposomes were encapsulated with doxorubicin and iron oxide nanoparticles 
(Figure 1-7). Folate receptor mediated uptake of magnetoliposomes into tumor cells 
was demonstrated. In vitro hyperthermia and controlled release of encapsulated 
doxorubicin was achieved by subjecting cell lines to EMF (Pradhan et al., 2010). 
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Figure 1-6. A multifunctional E-LNA for cancer thermo-chemotherapy from 
Pradhan et al. 
In this example the LNA is a temperature sensitive magnetoliposome containing co-
encapsulated iron oxide nanoparticles and doxorubicin. Passive targeting can be 
achieved through the enhanced permeation and retention (EPR) effect of tumor 
vasculature, and active targeting can be achieved via folate receptor and by applying a 
permanent magnetic field. The application of an AC electromagnetic field can be used 
to release the drug and achieve hyperthermia treatment. Reprinted from (Pradhan et 
al., 2010) with permission. 
 
 
 Liposomes with incorporated antibodies or antibody fragments are referred to 
as immunoliposomes. A number of studies have utilized immunoliposomes and 
nanoparticles for biomedical applications. Antibody conjugated LNAs has been 
employed to target cells that overexpress epidermal growth factor receptor 2 (Her-2). 
Overexpression of Her-2 frequently occurs in cervical, colon, breast, prostate, brain, 
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bladder, and lung cancers because it allows cells to grow more rapidly. Current cancer 
treatments tend to lack specificity administered causing adjacent tissues to be 
damaged. Her-2 targeted treatment may encounter similar adverse effects to adjacent 
tissues because Her-2 is a naturally occurring protein. Kullberg et al. developed a two-
component drug delivery system to ensure that treatment would be concentrated to 
cells that overexpress Her-2. The two-component system requires more than one LNA 
to bind to a tumor cell in order to release the encapsulated drugs. The two-component 
system could also have two or more sets of LNAs that encapsulate different substances 
that are only effective when they are both present. The specificity of the two-
component system is equal to the difference of tumor and healthy tissue Her-2 
expression squared. Therefore, the two-component system could potentially deliver 
3600 times more drugs to glioblastomas (capable of a 60-fold overexpression) than 
normal cells. The two-fold system could hypothetically be expanded to three or more 
components increasing the specificity exponentially (Kullberg et al., 2005, 2009). Her-
2 antibodies have also been utilized to construct targeted magnetoliposomes for 
hyperthermia treatment. The magnetoliposomes demonstrated localized hyperthermia 
to Her-2 overexpressing tumors under AMF (Kikumori et al., 2008). 
 Cationic MLs incorporating transferrin receptor targeting antibodies (anti-
transferrin receptor single-chain antibody fragment or TfRscFv) have been developed 
by Yang et al.. SPIO NPs were encapsulated into DOTAP-DOPE liposomes with 
TfRscFv incorporated onto the bilayer surface. In vitro breast and pancreatic uptake of 
SPIO liposomes with TfRscFv antibodies was at least ~2.5 times and 11 times greater 
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than non-targeting SPIO liposomes and free SPIO NPs, respectively (Yang et al., 
2008).   
 
7.2.2 Magnetic Drug Targeting 
 Accumulation with MDT is dependent on the properties of the encapsulated 
magnetic nanoparticles, tumor depth, blood flow, vasculature, drug binding, and 
concentration. MDT is also highly dependent on the external magnetic field. 
Penetration depth of magnets has been shown to be on the millimeter scale making 
MDT only effective for superficial tissues. Although, neodymium iron boron magnets 
have demonstrated magnetic field depths of up to 15 cm on SPIOs (Neuberger et al., 
2005). Interest in MDT has declined in recent years due to lack of effectiveness and 
issues such as embolization (Sun et al., 2008).  
 The feasibility of magnetic targeting of with magnetoliposomes in vitro and in 
vivo with external magnet has been demonstrated (Fortin-Ripoche et al., 2006). MLs 
(E-LNAs) encapsulating 7.5 nm maghemite have been used as effective MRI contrast 
agents in vivo. MDT delivery of MLs had a MRI negative enhancement of -52% 
compared to -7% for without MDT. Enhancement was maximized after 3 hours and 
after 24 hours maghemite only remained in the targeted tumor (Fortin-Ripoche et al., 
2006). Rivière et al. also demonstrated that real-time in vivo imaging and drug 
delivery of LNAs with a neodymium magnet to the brain vasculature of mice was 
achievable (Riviere et al., 2007).   
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 Magnetic targeting has also been applied to gene delivery. Transfection of 
pDNA was shown to be greater under the influence of a static magnetic field. After 10 
min of magnetic induction, was 2.8 and 1.9 times greater for MLs (E-LNAs) with 3.0 
mg/ml and 1.5 mg/ml magnetite concentration, respectively. Also, transfection at 0.75 
mg/ml magnetite concentration was 2.6 fold greater with 30 min of magnetic induction 
than without (Zheng et al., 2009).   
 Dandamudi et al. utilized MDT to deliver vinblastine-loaded MLs. After 
application of an external magnet for 2 h, PEGylated cationic liposomes encapsulating 
magnetite showed enhanced delivery of vinblastine (a chemotherapeutic drug). Tumor 
uptake with the magnet was ~16% as compared to ~5% with no magnet. MDT of 
vinblastine showed a significant showed an antitumor effect versus the control, 
reducing tumor nodules and hindering the growth of the tumor vasculature 
(Dandamudi et al., 2009).   
 Some studies incorporated MDT with other targeting techniques. Pradhan et al. 
examined the effect of MDT on human epidermoid carcinoma (KB) and human 
cervical carcinoma (HeLa) cell uptake of doxorubicin encapsulated liposomes with 
and without folate receptor targeting (Figure 1-7). Uptake was 2-fold higher for KB 
and 4-fold higher for HeLa with MDT than without. Also, the combination of MDT 
and folate receptor targeting uptake was 8-fold greater in KB and 42-fold greater in 
HeLa than without either active targeting techniques (Pradhan et al., 2010). These 
results suggest that further research into MDT as for supplementary targeting may be 
beneficial.  
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 Diagnostics and Imaging 
 Magnetic resonance imaging is a noninvasive imaging technique that can be 
enhanced by the use of LNAs with superparamagnetic nanoparticles, such as iron 
oxide. These particles are capable of being manipulated by magnetic fields allowing 
them to be used as a contrast agent form magnetic resonance imaging (MRI). MRI is 
based upon the nuclear magnetic resonance of hydrogen protons of water in the body. 
A strong magnetic field (B0) is applied to the body causing these hydrogen protons 
align with the magnetic field. The body is then exposed to a radio frequency (RF) 
pulse, transverse to B0, perturbing proton alignment with B0. Relaxation, or the 
realignment of protons with B0 after the RF pulse, releases energy absorbed during the 
RF pulse.  Two separate relaxations are monitored; longitudinal relaxation, or T1-
recovery, and transverse relaxation, or T2-decay. T1-recovery (also referred to as 
“spin-lattice” relaxation) is the release of energy to adjacent tissue as hydrogen 
realigns with B0. T2-decay (also referred to as “spin-spin” relaxation) is the energy 
released from the exchange of energy between separate protons as nuclei goes from 
spinning in phase with each other (due to the RF pulse) to out of phase. 2D Fourier 
transform is applied to the relaxation data to generate an image.  Differences in density 
and physical properties of tissues are related to the relaxation time and therefore can 
be distinguished in MRI images. Magnetic nanoparticles and LNAs can shorten the 
relaxation times of surrounding tissue and therefore be used as a contrast agent. A 
compound’s effect on the relaxation of surrounding tissues, and therein its 
effectiveness on contrast agent, is called relaxivity. Relaxivity is defined as R1 = 1/T1 
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and R2=1/T2 (Mornet et al., 2004; Sun et al., 2008).  Enhancement of relaxivity by 
LNA contrast agents is based on the concentration and inherent relaxivity of 
nanoparticles delivered (Fattahi et al., 2011).  
 MRI has also provided to be a very useful tool for observing and understanding 
interstitial drug delivery. Ponce et al. measured doxorubicin concentration by 
measuring the change in T1 relaxation of the co-encapsulated contrast agent. Spatial 
and temporal distribution profiles of doxorubicin and manganese from temperature-
sensitive liposomes during hyperthermia is crucial to understanding tumor-drug 
interaction (Ponce et al., 2007). Similar real time observations will provide 
pharmacodynamic and pharmacokinetic information to optimize drug efficacy from 
LNAs.  
 QDs have also been utilized for to measure and observe the cellular delivery. 
Bothun et al. demonstrated the ability to deliver different types of QDs. Hydrophobic 
and hydrophilic QDs were co-encapsulated in the bilayer and aqueous core of a 
cationic liposome. Uptake by human hepatocellular carcinoma cells demonstrated 
multi-fluorescent imaging (Bothun et al., 2009). Subsequent work by Al-Jamal et al. 
demonstrated the release characteristics of D-LNAs containing QDs (for imaging) and 
encapsulated doxorubicin from gel (DSPC-QD) and fluid phase (EPC-QD) LNA 
bilayers. Their results showed that fluid phase D-LNAs were able to achieve 80% 
release over 6 h and that the cytotoxicity of doxorubicin was reduced through D-LNA 
encapsulation. The QD D-LNAs without doxorubicin exhibited minimal cytotoxicity 
(Figure 1-8) (Al-Jamal and Kostarelos, 2011; Tian et al., 2011). 
 55 
 
 
 
Figure 1-7. Combined imaging and doxorubicin release from D-LNAs prepared 
with hydrophobic quantum dots (green). 
QD embedment and D-LNA structure was verified by cryogenic transmission electron 
microscopy and atomic force microscopy. The results show that bilayer phase 
behavior is a key parameter in doxorubicin release; fluid-phase D-LNAs achieved 
sustained release while gel-phase D-LNAs did not. Reprinted from (Al-Jamal and 
Kostarelos, 2011) with permission. 
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 Hyperthermia 
 Hyperthermia therapy to treat cancer dates back to Ancient Egyptian medical 
texts from about 3000 BC (Bolomey et al., 1995). Hyperthermia involves heating the 
malignant tissues to temperatures between ~40-45°C. During hyperthermia, heat 
denatures intracellular proteins inducing death by necrosis or apoptosis. Hyperthermia 
has also demonstrated the ability to make tumor cells more vulnerable to therapies. 
Therefore, when hyperthermia is used, it is frequently used in conjunction with 
chemotherapy and radiotherapy. While the side-effects of hyperthermia are far less 
severe than chemotherapy and radiotherapy, there is a tendency to damage adjacent 
tissues. Use of hyperthermia has been tempered in recent years because of difficulty in 
applying heat to deeper tumors and delivering targeted heating (Hsu and Su, 2008; Ito 
et al., 2004; Pradhan et al., 2010). Development of new therapies may reenergize the 
field as an effective treatment for malignant tumors. Local hyperthermia has been 
demonstrated with NPs capable of photothermal and RF heating treatment of 
malignant tissues (Hildebrandt et al., 2002). Targeting LNAs potentially can provide a 
local heat source for both hyperthermia and drug release without adversely effecting 
adjacent tissue (Hsu and Su, 2008; Huang et al., 2011; Ito et al., 2004; Smith et al., 
2006).  
 NPs capable of RF or photothermal heating have been used for local 
hyperthermia treatment of malignant tissues, which involves heating the tissues to 
temperatures between ~40-45 °C (Hildebrandt et al., 2002). During hyperthermia, heat 
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denatures intracellular proteins inducing death by necrosis or apoptosis. Hyperthermia 
has also been shown to make tumor cells more vulnerable to therapies, such as 
chemotherapy and radiotherapy, therefore it can be used in conjunction with these 
therapies (Hsu and Su, 2008; Ito et al., 2004; Pradhan et al., 2010). The use of 
conventional hyperthermia (i.e. without NPs) has been tempered in recent years 
because of difficulty in applying heat to deeper tumors and delivering targeted heating. 
This difficulty may be addressed by targeting NPs to malignant cells and tissues. 
 Heat transfer within tissues via NP heating can be described by a modified 
Pennes’ bio-heat transfer model (Pennes, 1948) 
 
  

tcp, t
T
t
  (ktT ) bcp,b b(T Tb )Qm QNP  
 
where   

t  is the tissue density and   

cp, t  is the tissue heat capacity. The first term on the 
right hand side (RHS) of the equation describes the conductive heat transfer (  

k t  is the 
tissue thermal conductivity) and the second term describes the convective heat transfer 
(  

b is the blood density,   

cp,b  is the blood heat capacity,   

 b  is the blood perfusion rate, 
and   

Tb  is the blood temperature).   

Qm  is the rate of heat generated metabolically and 
  

QNP  is the rate of heat generated from the power dissipation by the NPs, which 
accounts for the concentration of NPs (e.g.   

QNP  represented as SAR). This equation 
represents the case where the temperature profile in a tissue mass (macro-scale) can be 
determined as a function of NP concentration and applied field strength (e.g. laser or 
RF). It has been shown theoretically that sufficient iron oxide NP heating can be 
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achieved (> 42 oC) at low blood perfusion rates to achieve tissue-level hyperthermia 
(Rast and Harrison, 2010). For cellular-level heating (nano- or micro-scale), 
convective heat transfer due to blood transfusion and   

Qm  are eliminated from the 
equation, yielding the expression reported by Keblinski et al. (Keblinski et al., 2006) 
for RF NP heating and Xu et al.(Xu et al., 2007) for Fe3O4 NP hyperthermia in vitro. 
 
 In vivo and in vitro Biomedical Applications 
10.1 Cellular Uptake and Drug Delivery 
 Chithrani et al. prepared anionic Au decorated liposomes with 105 nm dh by 
incorporating Au-conjugated DPPE (DPPE-Nanogold; 1.4 nm Au particles) into 
preformed DPPC/cholesterol liposomes. Incorporation of DPPE-Nanogold was 
confirmed by TEM and EDS. Liposome uptake by HeLa cells in vitro was 
independent of the DPPE-Nanogold concentration (2000:1, 1000:1, and 500:1 Au NPs 
per liposome). This key discovery suggests that the presence of DPPE-Nanogold does 
not influence cell uptake and that high nanoparticle loadings can be achieved in such 
LNAs without compromising internalization. Examining the intracellular fate revealed 
that the Au-liposomes were present in lysosomes and accumulated near the nuclear 
membrane after incubating for 45 min (Chithrani et al., 2010). 
 Paasonen et al. examined uptake and light-induced calcein release of b-LNAs 
prepared hexanethiol-coated Au NPs (extension of (Paasonen et al., 2007b)). The 
LNAs were composed of DSPC:DPPC (9:1 molar ratio) and were multilamellar with 
sizes ranging from 250-370 nm. In vitro studies with human retinal pigment epithelial 
cell line (ARPE-19) showed that the b-LNAs were internalized by endocytosis and 
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localized in endosomes. Exposure to UV light at 400 mW/cm2 for 300+ s led to 
calcien release from D -LNAs, but not from liposomes that did not contain embedded 
nanoparticles (Paasonen et al., 2010a). 
 
10.2 Drug Delivery and Hyperthermia 
 Pradhan et al. recently prepared folate (Fol) ligated magnetoliposomes (E-
LNAs) via thin film hydration that contained co-encapsulated 60 nm iron oxide NPs 
and doxorubicin in PBS (Figure 1-8). The lipid components included DPPC, Chol, 
PEG2000-DSPE, and Fol-PEG2000-DSPE and the liposomes exhibited a melting 
temperature near 41 oC. The liposomes were 361 nm in diameter and polydispersed 
(0.289), with a nanoparticle encapsulation efficiency of 24% (low, presumably 
attributed to the use of the thin film hydration method). The liposomes exhibited 
temperature-dependent doxorubicin release (>2-fold increase from 37 oC to 43 oC). 
Folate-receptor targeted uptake was demonstrated in HeLa and KB cell cultures, and 
reductions in cell viability were attributed to a synergistic effect of doxorubicin and 
hyperthermia treatment achieved in the presence of an EMF. While not mentioned 
specifically, we speculate that liposomal heating by the nanoparticles may have aided 
doxorubicin release (Pradhan et al., 2010). 
 Babincova et al. prepared DPPC/PEG2000-DSPE LNAs via REV that contained 
both dextran-coated Fe3O4 and C60 fullerene (referred to as magnetofullerenosomes) to 
achieve magnetic targeting and photodynamic therapy (PDT), respectively. Bis(di-
isobutyloctadecylsiloxy)-2,3-naphthalocyanato silicon (isoBO-SiNc), a 
photosensitizing agent, was also encapsulated. LNA performance for treating B16 
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pigmented melanoma was examined in vivo using a female mouse model. Without 
magnetic targeting, C60-mediated PDT followed by isoBO-SiNc-mediated PDT led to 
a significant reduction in tumor growth over 19 days relative to no treatment or 
isoBO-SiNc-mediated PDT alone. When magnetic targeting was applied (0.32 T 
magnet placed on the tumor surface for 24 h) there was negligible tumor growth over 
the same duration (Babinec et al., 2005).  
 
 Conclusion and Future Outlook 
 Liposomes and NPs are both well-established therapeutic and diagnostic 
agents. As both have been approved for clinical use, the next stage of development is 
to combine these two systems. LNAs combine the therapeutic advantages of these two 
nanotechnology systems creating a unique opportunity for achieving multi-functional 
therapeutic objectives. The liposomes can act to concentrate small NPs and shield 
them from the immune system. In turn, the NPs can be used to initiate and control 
drug release when exposed to external stimuli. Recent work demonstrates that there is 
a range of options for the design of LNAs to provide desired structures and functions. 
LNAs have been demonstrated to enhance the qualities of encapsulated payloads, by 
providing a system capable of targeting, responding to external stimuli, and 
concentrating encapsulates. Also, LNAs are capable of both therapeutic and diagnostic 
functions.     
 Nanotechnology is a burgeoning new field, providing solutions to problems 
that were once considered unsolvable. The multi-functional quality of LNAs makes 
them a very exciting development in the field of nanotheranostics. However, the 
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design and use of LNAs is still in its infancy. Further investigation of the interactions 
between nanoparticles and the lipid bilayer is necessary to fully understand the 
formation, structure, and stability of LNAs.  For biomedical applications, LNA 
bioavailability and toxicity need to be studied to grasp the full potential as multimodal 
nanotechnology therapeutics and diagnostics. 
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 Abstract 
1.1 Introduction:  
 Nanoscale assemblies are needed that achieve multiple therapeutic objectives 
including cellular targeting, imaging, diagnostics, and drug delivery. These must 
exhibit high stability, bioavailability, and biocompatibility, while maintaining or 
enhancing the inherent activity of the therapeutic cargo. Liposome-nanoparticle 
assemblies (LNAs) combine the demonstrated potential of liposome-based therapies 
with functional nanoparticles. Specifically, LNAs can be used to concentrate and 
shield the nanoparticles and, in turn, stimuli-responsive nanoparticles that respond to 
external fields can be used to control liposomal release. The ability to design LNAs 
via nanoparticle encapsulation, decoration, or bilayer-embedment offers a range of 
structures with different structures and functions.  
 
1.2 Areas Covered:  
 The current state of research and understanding of the design, characterization, 
and performance of LNAs. Brief reviews are provided for liposomes and nanoparticles 
for therapeutic application, followed by a discussion of the opportunities and 
challenges associated with combining the two in a single assembly to achieve 
controlled release via light or radiofrequency stimuli.  
 
1.3 Expert Opinion:  
 LNAs offer a unique opportunity to combine the therapeutic properties of 
liposomes and nanoparticles. Liposomes act to concentrate small nanoparticles and 
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shield nanoparticles from the immune system while, the nanoparticle can be used to 
initiate and control drug release when exposed to external stimuli. These properties 
provide a platform to achieve nanoparticle-controlled liposomal release. LNA design 
and application is still in its infancy. Research concentrating on the relationships 
between LNA structure, function, and performance is essential for future clinical use 
of LNAs.  
 
Keywords: liposome, nanoparticle, photothermal, electromagnetic, controlled release 
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Article Highlights. 
 Review of recently reported liposome-nanoparticle assemblies (LNAs) designed 
for stimuli-responsive controlled-release. Radio frequency-triggered 
magnetoliposomes are a classic example of a stimuli-responsive LNA. In recent 
years, there has been an increased interest in LNA designs utilizing light-
responsive nanoparticles, such as gold nanoparticles. 
 Three distinct strategies are used to design LNAs: nanoparticle encapsulation, 
bilayer-embedment, or surface decoration. With each design, nanoparticle-
liposome interactions must be considered as they play a role in LNA structure and 
stability. 
 Intuitively, LNA release in the presence of an electromagnetic field is enhanced 
when the nanoparticle is closely associated with the bilayer. Examples are 
presented from the literature for iron oxide and gold nanoparticles. 
 LNA release is commonly attributed to local nanoparticle heating; however, 
mechanically-induced release may be more plausible. 
This box summarizes key points contained in the article. 
 
  Introduction 
A significant challenge faced today in drug discovery is that many promising 
therapeutics have poor pharmacological properties, making them unsuitable for use in 
their native forms [1]. Some estimate that greater than 95% of new drug candidates 
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fail to have the pharmacokinetic properties needed to be an effective treatment [2]. 
Improving pharmacokinetics requires chemically modifying the drug, for instance to 
make it water soluble, or physically modifying it by mixing or encapsulating it within 
a suitable matrix. Disconnect between drug discovery and drug delivery is one of the 
biggest reasons for the decline in breakthrough drugs in recent years [1]. New 
nanotechnology-based drug delivery systems have shown great potential for 
overcoming obstacles related to poor pharmacokinetics by providing a mechanism for 
controlling the delivering of low drug dosages to specific tissues or cells [3, 4]. 
Targeted and controlled delivery can reduce the adverse effects of systemic delivery 
and off-target affects.  The dream of Nobel Laureate Paul Ehrlich’s “magic bullet” 
may be within reached through controlled and targeted nanoscale therapeutics. 
In 2005 the National Cancer Institute provided a vision for nanotechnology-
based cancer treatment that combines targeted delivery with imaging, diagnostics, and 
the ability to provide multiple therapies within a single nanoscale construct [5]. The 
design of such a multifunctional construct is inherently complex as it requires 
combining different molecular, colloidal, and/or particulate agents that, for example, 
may have different degrees of hydrophobicity or thermal instability. Furthermore, the 
construct must be colloidally stable, resist protein adsorption and immune system 
recognition, and achieve cellular targeting in its native form (i.e. without ‘losing’ 
components or cargo during circulation).  
Liposome-nanoparticle assemblies (LNAs) represent a promising route for 
designing multifunctional therapeutic constructs.  They draw inspiration from 
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magnetoliposomes (liposomes containing encapsulated magnetic nanoparticles [6-11]) 
and have also been referred to in recent literature as liposome-nanoparticle hybrids or 
liposome-nanoparticle complexes (Lip-NPs) [12, 13]. LNAs consist of liposomes that 
contain nanoparticles encapsulated in the aqueous core, embedded in the lipid bilayer, 
or bound (decorated) onto the surface (Figure 2-1).  While liposomes and 
nanoparticles have both been approved separately for clinical use, the research and 
development of LNAs is still relatively new.  Liposomes are attractive for drug 
delivery and biomedical imaging because they are biocompatible carriers capable of 
protecting and transporting hydrophobic and/or hydrophilic therapeutic molecules.  
Nanoparticles (NPs, up to 100 nm) have also been shown to be effective transporters, 
contrast agents, and agents capable of providing in vivo heating when subjected to 
external stimuli such as alternating current electromagnetic fields (EMFs; typically at 
radiofrequencies, RF) or light [14-19].  LNAs can incorporate the intrinsic properties 
of liposomes and NPs, providing novel multifunctional therapeutic and diagnostic 
vehicles. This concept was depicted by Pradhan et al. [20] for folate receptor and 
magnetically targeted magnetoliposomes capable of combined drug delivery and 
hyperthermia (Figure 2-2). Principle advantages of LNAs include the following: 
 
 Delivery of hydrophobic and hydrophilic molecules and NPs, including small 
NPs (< 25 nm) that are less prone to endocytic uptake due to the high curvature 
energy required for a membrane to ‘wrap’ around the particle [21]. 
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 Strategies for processing, stabilizing, and targeting liposomes are well 
established [22]. 
 NPs can be magnetically guided for targeting in vivo and provide a triggering 
mechanism for controlled release (not discussed in detail herein).  
 Surface-bound NPs can also enhance the colloidal stability of LNAs and 
bilayer-embedded NPs can reduce spontaneous leakage [23-26].  
 
 The objective of this article is to provide a detailed review of LNA design and 
structure with an emphasis on recent work that utilize photothermal (via gold NPs) or 
RF heating (via iron oxide NPs) to achieve hyperthermia treatment, controlled drug 
release, or combined hyperthermia and drug release. LNAs containing carbon 
fullerenes such as C60 of C70 (i.e. fullerenosomes, see references [27-36]) are 
promising therapeutic structures and provide insight into LNA design, but will not be 
discussed herein. Likewise, NPs containing supported lipid bilayer coatings are also 
quite promising, but will not be discussed (see, for example [7, 37-39]). A discussion 
of reported LNA performance in vitro and in vivo will be provided.  This compliments 
a review of “liposome-nanoparticle hybrids” by Al Jamal and Kostarelos in 2007 [12]. 
Recent reviews focusing on liposomes or NPs for therapeutic application, which are 
discussed only briefly herein, are provided in references [22, 40-43] and [4, 15-17, 44-
48], respectively. An expert opinion is provided that focuses on the need for more 
complete design principles, additional characterization of LNA structure and stability, 
and the validity of local heating. 
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Figure 2-1. Schematics and TEM micrographs of liposome-nanoparticle 
assemblies. 
Schematic and TEM micrographs of LNAs formed by encapsulated hydrophilic 
nanoparticles with an aqueous liposome core (A; A-1 [70]), embedding hydrophobic 
nanoparticles within a liposome bilayer (B; B-1 [82], B-2 [23]), or binding hydrophilic 
nanoparticles to a liposome surface (C; C-1 [92]). Surface decoration (C) can also be 
used to create controlled aggregates or complexes (D; D1-1, D2-1 [13]). Structures 
and proportions are not to scale. Reprinted from [13, 23, 70, 82, 92] with permission. 
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Figure 2-2. Conceptualization of a multifunctional liposome-nanoparticle 
assembly. 
The concept of a multifunctional LNA (a temperature sensitive magnetoliposome 
containing co-encapsulated iron oxide nanoparticles and doxorubicin) for cancer 
thermo-chemotherapy from Pradhan et al. [20]. Passive targeting can be achieved 
through the enhanced permeation and retention (EPR) effect of tumor vasculature, and 
active targeting can be achieved via folate receptor and by applying a permanent 
magnetic field. The application of an AC electromagnetic field can be used to release 
the drug and achieve hyperthermia treatment. Reprinted from [20] with permission. 
 
 
2.1 Liposomes 
 Since the pioneering work by Bangham and Papahadjopoulos in the 1960s [49-
51], liposomes have become a well-established platform for administering therapeutic 
and imaging agents. In 1973, Gregoriadis reported the potential of liposome-aided 
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drug delivery and started what would become a burgeoning new field of liposomes as 
nanoscale delivery vehicles [52]. Since then, liposomes have become one of the most 
reliable systemic drug delivery systems, particularly because of their biocompatibility 
and ability to reduce or prevent drug degradation and toxicity. 
 Liposomes are self-assembled spherical vesicles consisting of one 
(unilamellar) or multiple (multilamellar) lipid bilayers surrounding an internal aqueous 
core. Bilayer thickness (lb) is ~5 nm thick (lb), of which 3 nm is the acyl lipid tail 
region. Liposomes can be prepared with zwitterionic, anionic, or cationic lipids, and 
the net liposome surface charge can be adjusted by mixing different ratios of these 
components. Lipids with headgroup-conjugated polyethylene glycol (PEG) and 
ligands can be used to improve liposome stability, increase blood circulation times, 
and for cellular targeting is achieved using [22, 41]. For drug delivery and diagnostics, 
liposomes are attractive because of their ability to encapsulate both hydrophilic (in the 
aqueous core or bound to the liposome surface) and hydrophobic (in the lipid bilayer) 
molecules. This enhances the solubility and stability of these molecules and prolongs 
their bioavailability. 
 Release of encapsulated molecules from liposomes is controlled by the 
permeability through the lipid bilayer, which can be achieved by transbilayer diffusion 
or transient pore formation triggered by bilayer disruption or phase separation.  Phase 
separation can be induced by ‘melting’ the liposomal bilayers – i.e. heating to a 
temperature greater than the characteristic main phase transition or melting 
temperature of the lipids (Tm).  Below Tm the lipids are in the solid or gel phase in 
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which the lipids are rigid and highly organized.  Above Tm the lipids are disordered in 
a liquid crystalline or fluid phase.  Permeability is high at the interface between gel 
and fluid phases. Phase separation and bilayer permeability can be manipulated by 
adjusting the lipid bilayer composition.  A simple example illustrating this principle 
can be made with dipalmitoylphosphatidylcholine (DPPC, Tm = 42 oC) and 
dimyristoylphosphatidylcholine (DMPC, Tm = 23 oC). At a DPPC/DMPC molar ratio 
of 74:26 the melting temperature occurs at physiological temperature (37 oC). 
Furthermore, cholesterol is commonly incorporated into the bilayer to reduce 
membrane fluidity above the melting temperature.  Membrane fluidity is affected by, 
for example, pH, ion concentration, and the presence of molecules absorbed into the 
bilayer. 
 Drug delivery from liposomes is accomplished by cellular uptake, which can 
occur by adsorption, endocytosis, fusion, and/or lipid transfer [41, 42, 53]. Adsorption 
is the association of liposome bilayer with cell bilayer without destroying the liposome 
bilayer or being internalized by the cell.  Adsorption can be specific (assisted by 
targeting ligands such as antibodies) or nonspecific (controlled by intermolecular and 
surface forces). Endocytosis involves the uptake of liposomes into the cell by 
encapsulation within endosomes.  Release of drugs to the cytoplasm can occurs by 
membrane destabilization of the encapsulating endosome or by delivery to lysosomes.  
Lysosomes have an acidic pH and contain lysing enzymes.  Drug release is 
accomplished when lysosome enzymes hydrolyze the lipid bilayer releasing the drug.  
Lysosome drug release is only effective when the encapsulated drugs are not 
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susceptible to lysosome enzymes and pH. Fusion involves the adsorption and 
incorporation of the liposome bilayer with the cell membrane, releasing the payload 
into the cytoplasm.  Finally, lipid transfer involves the exchange of lipids between the 
liposome bilayer and the cell membrane without enveloping the liposome [41, 42]. 
 
2.2 Gold and iron oxide nanoparticles 
 Imaging and photothermal effects of gold NPs stem from their enhanced 
surface plasmon resonance (SPR), where visible or near-infrared light is absorbed 
causing oscillation of surface electrons [54]. SPR absorbance and the wavelength 
range are dependent upon nanoparticle size, core/shell configuration (e.g. silica 
core/gold shell [55]), and geometry. Shifts in these properties are indicative of the 
degree of NP aggregation and/or molecular adsorption on the NP surface [19]. For 
photothermal therapy, absorbed light energy is converted into local heat that thermally 
diffuses into the surrounding medium. Varying NP size and core/shell configuration 
provides a means of tuning the frequency window for photothermal therapy. It is 
generally accepted that gold NP-mediated phototherapy is attributed to heat or 
resulting bubble nucleation depending on the light intensity and mode of exposure 
[19]. However, recent work by Krpetic et al. [56] at low light energies suggests that 
photochemical effects – the formation of free radicals during NP irradiation – may 
play an important role. In addition to photothermal heating, electromagnetic fields 
operating at RF can also be used to heat gold NPs. For example, Gannon et al. [57] 
examined the effect of NP concentration and RF field strength on the heating rates of 5 
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nm Au NPs in water. A rate of ~74 oC min-1 was measured using an 800 W RF field at 
a NP concentration of 67 µM. 
 The magnetic properties of iron oxide NPs, notably single domain 
superparamagnetic magnetite (γ-Fe2O3) or maghemite (Fe3O4), can also be exploited 
for imaging and therapy. They act as contrast agents for MR imaging, can be directed 
by static magnetic fields (magnetic drug delivery), and can be heated by RF 
(hyperthermia) [16, 18, 58].  RF heating is due to magnetic losses being converted to 
heat, typically at low frequencies between 100-400 kHz. The magnetic losses for NPs 
< ~30 nm are due to Néel relaxation, arising from rapidly alternating magnetic dipole 
moments, and Brownian relaxation, arising from nanoparticle rotation and viscous 
losses (friction).  RF heating is advantageous because it is non-invasive, easily 
penetrates the body, and is physiologically acceptable for up to 1 h if the product Hf, 
where H is the field amplitude (current  number of coils per length) and f is the 
frequency, is below 4.85105 kA m-1 s-1 [59]. NP heating capability is based on the 
inherent specific absorbance rate (SAR, W g-1) of the nanoparticles 
  
  

SAR 
cp
mNP
T
t    (1) 
where 
  

cp is the average heat capacity of the sample,   

mNP  is the NP mass, and   

T /t  
is the initial heating rate of the sample. SAR values up to approximately 700 W g-1 can 
be obtained depending on the NP size, composition, and surface coating [18].
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2.3 Nanoparticle-mediated hyperthermia 
 NPs capable of RF or photothermal heating have been used for local 
hyperthermia treatment of malignant tissues, which involves heating the tissues to 
temperatures between ~40-45 °C [60]. During hyperthermia, heat denatures 
intracellular proteins inducing death by necrosis or apoptosis. Hyperthermia has also 
been shown to make tumor cells more vulnerable to therapies, such as chemotherapy 
and radiotherapy, therefore it can be used in conjunction with these therapies [20, 61, 
62]. The use of conventional hyperthermia (i.e. without NPs) has been tempered in 
recent years because of difficulty in applying heat to deeper tumors and delivering 
targeted heating. This difficulty may be addressed by targeting NPs to malignant cells 
and tissues. 
 Heat transfer within tissues via NP heating can be described by a modified 
Pennes’ bio-heat transfer model [63] 
 
  

tcp, t
T
t
 (ktT)bcp,bb(T Tb)Qm QNP  (2) 
where   

t  is the tissue density and   

cp, t  is the tissue heat capacity. The first term on the 
right hand side (RHS) of the equation describes the conductive heat transfer (  

kt  is the 
tissue thermal conductivity) and the second term describes the convective heat transfer 
(  

b is the blood density,   

cp,b  is the blood heat capacity,   

 b  is the blood perfusion rate, 
and   

Tb  is the blood temperature).   

Qm  is the rate of heat generated metabolically and 
  

QNP  is the rate of heat generated from the power dissipation by the NPs, which 
accounts for the concentration of NPs (e.g.   

QNP  represented as SAR). Equation 2 
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represents the case where the temperature profile in a tissue mass (macro-scale) can be 
determined as a function of NP concentration and applied field strength (e.g. laser or 
RF). It has been shown theoretically that sufficient iron oxide NP heating can be 
achieved (> 42 oC) at low blood perfusion rates to achieve tissue-level hyperthermia 
[64]. For cellular-level heating (nano- or micro-scale), convective heat transfer due to 
blood transfusion and   

Qm  are eliminated from equation 2, yielding the expression 
reported by Keblinski et al. [65] for RF NP heating and Xu et al. [66] for Fe3O4 NP 
hyperthermia in vitro. 
 
 LNA Formation and Structure 
 LNA design strategies include the encapsulation of individual or multiple NPs 
within the aqueous core of the liposome, embedding hydrophobic NPs in the lipid 
bilayer, and binding or conjugating NPs to the liposome surface (Figure 2-1). Tables 
2-1 and 2-2 contains a list of Au and iron oxide LNAs reported in the literature since 
2008. For a given design strategy, the functionality of a LNA is determined by the 
liposome composition, the type of NPs employed, the intermolecular and surface 
interactions between the lipid bilayer and NP, and (as in all cases) the colloidal 
stability. LNAs can be used to concentrate NPs and shield them from the adsorption of 
exogenous molecules. Concentrating the NPs can increase the degree of intracellular 
delivery, which is critical, for example, in imaging and hyperthermia applications.  In 
turn, shielding the NPs from the adsorption of biomolecules can enhance their 
bioavailability and reduce the need for more complex NP surface chemistries.  The 
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caveat here, which is germane to all LNA configurations, is that the liposome itself 
must contain functional lipids or surface coatings for stabilization and, when needed, 
targeting [12]. 
 In addition to serving as a vehicle for NP delivery and being multifunctional, 
LNAs can be used to overcome design challenges of ‘conventional’ liposomes. With 
respect to delivery, the main challenge includes creating an assembly that is stable and 
retains its cargo during both storage and circulation, but is capable of releasing its 
cargo in vivo at a target site (i.e. stable until it needs to become unstable). This 
challenge has been addressed by using lipid mixtures that melt near physiological 
temperature or through chemical mechanisms such as pH-sensitive lipids; which has 
ultimately reduced the number of viable lipid molecules that can be used. In contrast, 
LNAs can utilize physical triggers, predominantly NP heating, to control the onset and 
duration over which a molecule is released. While lipid composition plays an active 
role in determining the release profile from LNAs, the lipids themselves would not 
provide the release trigger. This could greatly expand the range of lipids amenable to 
liposomal release [12]. 
 Finally, LNAs can potentially be used to deliver high concentrations of NPs 
capable of RF or photothermal heating for local hyperthermia. Targeted LNA 
administration can be achieved through known liposomal-based mechanisms (e.g. 
targeting lipids) and may provide a local heat source for both hyperthermia and drug 
release without adversely effecting adjacent tissue.
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 Table 2-1. Reported LNAs based on Au NPs since 2008. 
Lipids (ratio)a Liposome charge 
NP 
Diameter 
(nm) 
Surface Coating Lipid:NPa Association Ref. 
DOPC:DOTAP (8:2) Cationic 80 Citrate n.r.b Encapsulation [91] 
DPPC:DSPC (9:1) Zwitterionic 2.5 Hexanethiol 17.2:1 (w/w) Embedment [95] 
EggPC Zwitterionic 2 Dodecanethiol 100:1-1500:1 Embedment [82] 
DPPC:DSPC  (9:1) Zwitterionic 4 Mercaptosuccinic acid 10:1 (w/w) Encapsulation [95] 
DPPC:DSPC (9:1) Zwitterionic 1.4 DPPE-Nanogold™ n.r. Embedment,Decoration [24] 
DOPC DOPC:DOPC+ (90:10) DOPC:DOPP (9:1) 
ZwitterionicCationic Anionic n.r. Ascorbic acid n.r Decoration [87] 
EYPC EYPC:DDAB (9:1) EYPC:PEG-DSPE (95:5) 
ZwitterionicCationic Zwitterionic 13 Citrate 10:1, 1:1 Decoration [88] 
EggPC:DOTAP  (9:1 w/w) Cationic 4 Mercaptopropionic acid ≥3.6x10-3:1 Decoration [89] 
DPPC:DPTAP:Chol  (6:3:1 w/w) Cationic 20 n.r.  Complexation [13] 
DPPC Zwitterionic 33 PEG 1.8:1 (w/mol) 1:1 (w/mol) 
Encapsulation, Embedment, Decoration
[92] 
 amolar ratios provided unless noted otherwise. 
 bestimated at 4 liposomes per NP.
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 Table 2-2. Reported LNAs based on iron oxide NPs since 2008. 
Lipids (ratio)a Liposome charge 
NP 
diameter 
(nm) 
Surface 
coating Lipid:NPa Association Ref. 
Magnetite (Fe3O4) 
DPPC:Chol (75:25) Zwitterionic 12.5 n.d. 0.8:1 Encapsulation [98] 
[maleimide]PEG-DSPE:FAM-DOPE 
(10:1 w/w)  10-14 
Heptanioc acid, 
acetic acid 1:1.8 (w/w) Encapsulation [99] 
DMPC:Chol:XLb (47.5:47.5:5) 
DPPC:DMPC:XLb (9.5:85.5:5) Zwitterionic 10 Catechol ≥8.3:1 (mol/w) Complexation [90] 
Maghemite (g-Fe2O3) 
DPPC:Chol (67:33) Zwitterionic 10 Glutamic acid n.r. Encapsulation [100]
DPPC:Chol (5:1, 15:3 w/w) 
DPPC:DSPC:Chol (10:5:3 w/w) Zwitterionic 43 Dextran n.r. Encapsulation [93] 
DPPC Zwitterionic 5 Oleic acid 1000:1-10000:1 Embedment [23] 
 amolar ratios provided unless noted otherwise. 
 bcross-linking molecule (adhesive lipid). 
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3.1 Core encapsulation 
 Encapsulating inorganic NPs within the aqueous core of liposomes is one of 
the simplest and earliest developed LNA configurations (e.g. magnetoliposomes or 
MLs [7, 9]). They can be prepared by encapsulating preformed NPs in solution or by 
forming NPs within the liposome core as first shown by Papahadjopoulos in 1983 
[67]. The later approach will not be discussed herein. Encapsualted LNAs (e-LNAs) 
can be prepared by thin film hydration (TFH), double emulsion (DE) [68], or reverse 
phase evaporation (REV) [69]. Prior to removing unencapsulated NPs or diluting, 
post-formation liposome processing such as membrane extrusion or sonication can be 
employed. The obvious design constraints are that the nanoparticles must be colloidal 
stable during LNA formation and that their diameter (d) must be less than that of the 
aqueous liposome core. When dcore = dNP these structures are referred to as supported 
lipid bilayers (SLBs; i.e. NPs containing a lipid bilayer coating). Based on close 
packing of spheres and dcore >> dNP, the maximum theoretical number of encapsulated 
NPs is n ≈ 0.74(Vcore/VNP) where V represents the volume of the core or NP. Wijaya 
and Hamad-Schifferli [70] have shown that it is possible to approach this limit, 
demonstrating high-density encapsulation of Fe3O4 NPs (dNP = 12.5 nm) within DPPC 
liposomes (Figure 2-1, A-1). With this design the available core volume for co-
encapsulating aqueous drug molecules decreases within increasing NP concentration. 
However, the ability for embedding hydrophobic molecules within the bilayer is 
unaffected by NP concentration. 
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 The structure of e-LNAs is dependent on the osmotic pressure differential 
across the lipid bilayer, and the attractive or repulsive forces between the bilayer and 
the NPs. The elasticity of the bilayer determines how the LNA will deform in response 
to these forces. Attractive forces can include van der Waals, hydrophobic, and 
electrostatic interactions; and repulsive forces can include electrostatic, depletion, 
hydration, and steric interactions. As classically described by Lipowsky and 
Döbereiner [71], adhering and non-adhering nanoparticles can lead to changes in 
bilayer curvature, which can impact liposome size, shape, and phase homogeneity. 
This occurs when different particles are present within (i.e. encapsulated NPs) and 
outside (e.g. sugars or proteins) liposomes. For non-adhering encapsulated particles, 
the bilayer can curve towards the larger particles. In contrast, for small adhering 
encapsulated particles (attractive) where dcore >> dNP and dNP < 2lb the bilayer can 
curve away from the particles. For large adhering particles where dNP >> 2lb the 
bilayer can curve around or engulf the particles. Given that NP adhesion to bilayers 
can significantly alter LNA structure and morphology, LNAs with encapsulated NPs 
are generally formed with small non-adhering NPs. The exception to this is LNAs 
formed by coating a single large NP with an adsorbed or supported lipid bilayer (not 
discussed herein). 
 Pradhan et al. [72] compared the encapsulation efficiency of 10 nm Fe3O4 NPs 
coated with lauric acid in LNAs (or more specifically MLs) composed of egg 
PC:cholesterol (1:0 to 1:2, molar ratio) and formed by THF and DE. This represents a 
non-adhesive system. In general higher encapsulation efficiency was achieved by THF 
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compared to DE.  This was attributed to NP aggregation due to lauric acid stripping 
from the nanoparticle surfaces during the DE process. In both cases, the observation 
that an Egg PC:cholesterol ratio of 2:1 yielded the best encapsulation efficiency (70% 
via THF) was attributed to cholesterol inducing a single liquid ordered bilayer phase. 
Changes in liposome size upon encapsulation were not reported. 
 In similar work, Sabate et al. [73] examined the effect of Fe3O4 NP 
concentration coated with tetramethylammonium hydroxide (58 nm hydrodynamic 
dNP) on the encapsulation efficiency of extruded soybean PC MLs. This represents an 
adhesive system. The encapsulation efficiency decreased from 96.6% at 1.22 g 
Fe3O4/mol PC to 18.5% at 119.95 g Fe3O4/mol PC. This was attributed to electrostatic 
interactions (attraction) between the cationic NPs and the PC bilayers. The size of the 
MLs increased from 140 to 197 nm, consistent with lower curvature due to NP 
adhesion at the inner bilayer surface. 
 Gomes et al. [74] prepared polyelectrolyte-coated MLs by encapsulating 8 nm 
anionic γ-Fe2O3 NPs within egg PC liposomes and then coating with alternating 
poly(allylamine hydrochloride) and poly(sodium 4-styrenesulfonate) layers. The final 
coating determined the surface charge (anionic PSS or cationic PAH). The size ranged 
from 200-400 nm and the polyelectrolyte coating stabilized them against detergent-
induced leakage, which is caused by membrane disruption or solubilization.  
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3.2 Bilayer embedment 
 Embedding NPs into the bilayer requires that the NPs be hydrophobic and have 
diameters comparable to or smaller than the thickness of the lipid bilayer (~5 nm; 
Figure 2-1, B). LNAs formed by bilayer embedment (b-LNAs) can be advantageous as 
many nanoparticles are inherently hydrophobic or synthesized in organic solvents (e.g. 
in reverse microemulsions where the surfactant is the initial surface coating) before 
undergoing surface modification for aqueous environments. Similar to the ability of 
cells to accommodate membrane proteins, liposomes can distort to accommodate 
hydrophobic NPs that exceed the thickness of hydrophobic acyl region of the bilayer 
(~3 nm) [23, 75-77].  As with proteins, embedded NPs can affect lipid packing, lipid 
phase behavior, transbilayer permeability, and LNA structure and morphology [23, 28, 
34, 76, 78-82]. A unique aspect of b-LNAs (as well as surface decorated LNAs) is that 
the NPs can provide direct localized heating to the bilayer in the presence of external 
stimuli to trigger release [23, 24]. 
 It is intuitive that the size of a NP (core + surface coating) and its 
concentration, or more specifically the lipid:NP ratio, will influence how the lipid 
bilayer distorts to accommodate it and the resulting LNA structure (Figure 2-3).  
Theoretical studies by Ginzburg and Balijepalli [83] and Wi et al. [84] suggest that the 
maximum size of a NP (dNP) that can be incorporated into a LNA while maintaining a 
lipid bilayer structure is ca. 6.5 nm (Figure 2-3, A and B). Above this size micellar 
structures are more energetically favorable due to high local curvature strain within 
the bilayer [84]. Experimental verification of this critical size and, furthermore, the 
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general size effects of NPs on embedment mechanism and LNA structure are more 
elusive. 
 Clustering of embedded NPs has been observed by Rasch et al. [82] in LNAs 
with dodecanethiol-coated Au (dNP = 1.6-1.8 nm) (Figure 2-1, B-1; Figure 2-3, A).  
They showed that high NP loading with uniform distribution can be achieved in PC 
liposomes via thin film hydration (with sonication and extrusion). Janus particles can 
be prepared with embedded NPs clustered in approximately one half of the liposomes 
via detergent loading followed by dialysis. Clustering occurs as the liposomes 
minimize the energy penalty for bilayer deformation – i.e. for a given concentration of 
embedded NPs the periodic bilayer bending energy needed to accommodate individual 
particles is greater than that needed to accommodate nanoparticle clusters. Park et al. 
[80] and Chen et al. [23] have observed a similar clustering phenomenon with 
stearylamine-coated 3-4 nm Au and oleic acid-coated 5 nm γ-Fe2O3 NPs in DPPC 
liposomes (Figure 2-1, B-2), respectively. This suggests that NP clustering is not 
restricted to dNP < 2 nm [23]. 
 In addition to clustering, embedded NPs with dNP = 2-6.5 nm can reside in 
bilayer ‘pockets’ within individual (Figure 2-3B) or neighboring (Figure 2-3, C) 
LNAs. These cases arise when the lipid:NP ratio is high (~1000:1 or greater). This has 
been observed by Al Jamal et al. [85] for 4 nm hydrophobic CdSe/ZnS core/shell 
quantum dots in DOPC bilayers. 
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Figure 2-3. Change in bilayer embedment as a function of changing nanoparticle 
size. 
Changes in bilayer embedment mechanism with increasing nanoparticle diameter 
(dNP, particle core + surface coating). (A) Small nanoparticles (defined herein as dNP 
< 2 nm) cluster together to minimize bilayer bending energy [82]. (B) Larger 
nanoparticles (defined herein as dNP = 2-6.5 nm) create ‘pockets’ within the bilayer or 
(C) bridge adjoining liposomes [23, 77]. Above dNP ≈ 6.5 nm, micellization is more 
energetically favorable than bilayer embedment [84].  
 
3.3 Surface decoration and complexation 
 Decorated LNAs (d-LNAs) are formed when hydrophilic NPs are absorbed 
onto or coupled to the outer or inner surface of the lipid bilayer (Figure 2-1, C). This is 
achieved through attractive surface interactions, notably long-range electrostatic 
attraction. An advantage of d-LNAs is the ease in which they can be prepared – adding 
NPs to pre-existing liposome dispersions. Similar to bilayer embedment, decorated 
bilayers also provide direct heating to the bilayer in the presence of external stimuli. 
The design constraint for forming d-LNAs is dependent on bilayer NP adhesion and 
curvature. NPs with dNP > ~20 nm lead to the formation of SLBs due to liposome 
adsorption and rupture, followed by the bilayer curving around the particle. The 
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critical NP diameter under which d-LNAs can be formed is dNP < 2(kb/w)1/2, where kb 
is the bilayer bending elasticity, which is dependent on lipid composition and phase 
state, and w is the adhesion energy.  
 The Granick group has shown that stable d-LNA dispersions can be formed 
using zwitterionic liposomes with decorated cationic or anionic NPs (< 20 nm) with a 
NP surface coverage above ~25% [25, 26]. This was achieved by electrostatic 
attraction. Lower surface coverage led to aggregation, which demonstrates the need to 
balance the lipid:NP ratio. It was shown that upon binding the nanoparticles could 
restructure the lipid bilayer, inducing gel phases in fluid liposomes and fluid phases in 
gel liposomes [86]. This observation shows that, even without external stimuli, bound 
NPs can induce changes in lipid phase behavior and, presumably, permeability. 
 Sau et al. [87] have also used electrostatic binding to prepare d-LNAs with Au 
NPs. High NP surface coverage was achieved by using anionic Au NPs with 
physisorbed ascorbic acid and cationic liposomes (9:1 DOPC to ethyl-DOPC; Tm = -
20 oC). This high surface coverage was accompanied by NP aggregation due to the 
high local concentration and (likely) to charge screening via cationic lipids between 
bound particles (similar to Kojima et al. [88]). Binding was also achieved on 
zwitterionic and anionic liposomes with decreasing coverage (and NP aggregation), 
respectively. Pornpattananangkul et al. [89] have taken this one step further and have 
shown that pH can be used to control carboxyl-modified (anionic) Au NP binding to 
cationic liposomes and, in turn, liposome stability. Above the pKa of the carboxyl 
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groups the bound NPs stabilize the d-LNAs and prevent aggregation and fusion, while 
below the pKa the NPs detach and liposome fusion resumes.  
 Last, LNAs can be formed by complexation (c-LNAs) if the liposomes 
surround NP aggregates (Figure 2-1, D1 and D2) or the NPs bind to multiple 
liposomes and act as “bridges” (Figure 2-1, D2). Voldokin et al. [13] have shown that 
either structure can be formed from the same anionic Au NP-cationic liposome by 
manipulating electrostatic interactions using via salt concentration. High NaCl 
concentration (75 mM) enhanced NP aggregation (Figure 2-1, D1-1) and low salt 
concentrations inhibited it (Figure 2-1, D2-1).  In addition to non-specific physical 
interactions (electrostatic), cross-linking can be used to create c-LNAs. Mart et al. [90] 
used Fe3O4 NPs coated with histidine groups to bind to and complex 
zwitterionic/cholesterol liposomes containing Cu(iminodiacetate)-functionalized lipid. 
The objective was to demonstrate a potential method using histidine-Cu(IDA) binding 
to form c-LNAs, thereby concentrating a therapeutic and an imaging agents at a target 
site. The resulting aggregates ranged from 20-100 µm in diameter. 
 
 LNA Controlled Release 
 This section reviews recent work on gold or iron oxide NP-mediated release 
from LNAs. Articles that apply these principles in vitro or in vivo are presented in 
section 4. 
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4.1 Gold nanoparticles and photothermal effects 
 Utilizing the photothermal heating of Au NPs, Paasonen et al. [24] 
demonstrated the ability to control the release of calcein (622.6 MW) from Au LNAs 
composed of DPPC/DSPC at 9:1 (Tm = 44.9 oC) with e-, d-, and b-LNAs (Figure 2-1, 
A-C). Leakage was examined with and without UV light at a wavelength of 250 nm 
over 30 min at 37 oC. Without UV exposure, spontaneous calcein release was 
observed for e-LNAs with encapsulated mercaptosuccinic acid-coated NPs and b-
LNAs with embedded hexanethiol-coated NPs. This was attributed to NP-lipid 
interactions at the bilayer/water interface and within the acyl tail region, respectively, 
which reduced bilayer integrity. With UV exposure, direct contact between NPs and 
the liposomes via bilayer-embedment led to the greatest release (~90% at 30 min). 
Intuitively, direct contact would improve the local heat transfer from the NPs to the 
liposomal bilayers relative to encapsulation. This led to a gel-fluid phase transition 
where calcein release was presumably enhanced by diffusion at the interface between 
coexisting gel and fluid domains. 
 Volodkin et al. [13] demonstrated the release of 5(6)-carboxyfluorescein (CF; 
376.3 MW) from LNAs formed by the complexation of 128 nm cationic liposomes 
(DPPC/DPTAP/chol, Tm ~ 40-45 oC) and 20 nm anionic Au NPs. Low NaCl 
concentration (7.5 mM) yielded LNAs with NP-mediated liposome bridges (Figure 2-
1, D2-1; type I) and high NaCl concentration (75 mM) yielded LNAs with liposome-
coated NP aggregates (Figure 2-1, D1-1; type II). The type II LNAs were ~5 µm. CF 
release from type II LNAs was observed within 5 s after near-IR irradiation. 
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 Anderson et al. [91] utilized the principle of plasmonic nanobubble (PNB) 
formation to control the release of 104 and 240 kDa proteins from cationic LNAs (~1 
µm) containing encapsulated 80 nm anionic Au NPs. Irradiation was achieved using a 
single pump laser at 532 nm over 0.5 ns. Local vapor bubble formation led to 
mechanical disruption, as opposed to thermal, of the LNA bilayer and rapid protein 
release. The advantage of PNB formation is heating is isolated within the LNA 
triggering the immediate release of all encapsulated cargo. 
 Wu et al. [92] used hollow gold nanoshells (HGNs) encapsulated within or 
decorating the surface of DPPC liposomes to trigger CF release by near-IR pulses (800 
nm) via microbubble formation and collapse (Figure 2-1, C-1). LNA release was 
dependent on the proximity of the HGNs to the liposomes (decorated or tethered 
HGNs yielded the greatest response) and the laser power. Their results strongly 
suggest that release was attributed to transient disruption or poration of the lipid 
bilayer via transient bubble cavitation. 
 
4.2 Iron oxide nanoparticles and alternating magnetic field effects 
 Tai et al. [93] examined CF release from thermosensitive zwitterionic 
liposomes containing encapsulated dextran-coated 43 nm γ-Fe2O3 NPs (Resovist™) 
using a high frequency generator (6.4 kW, 750-1150 kHz) operating for 5-25 min. CF 
release from DPPC:Chol (5:1) liposomes without encapsulated NPs was initiated 
between 35 oC and 37 oC. In contrast, the LNA analogs exhibited initial release at 34 
oC and 32 oC with 7 and 14 mg Fe/ml, respectively. This initial release temperature 
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was further tuned by increasing the cholesterol content (DPPC:Chol at 15:3) and 
incorporating a higher melting lipid (DSPC, Tm = 55 oC). Release was attributed to NP 
heating. Using a rat model, they demonstrated that release could also be achieved in 
vivo. 
 Chen et al. [23] have recently examined the release of CF from LNAs formed 
with DPPC and bilayer-embedded oleic acid-coated 5 nm γ-Fe2O3 NPs at lipid:NP 
ratios of 10000:1, 5000:1, and 1000:1 as a function of RF energy (1 kW; 50-250 A, 
281 kHz) (Figure 2-4). Experiments were conducted at non-invasive RF energies near 
or below 4.85105 kA m-1 s-1 for 0-40 min [59]. The greatest release rate was observed 
at 5000:1, indicating an optimal NP loading for triggering release. This optimum 
reflected a balance between NP loading and LNA structure – high loading is needed 
for triggering bilayer release, but can lead to NP aggregation and can compromise 
LNA structure and stability. A unique observation was the fact that increasing NP 
loading reduced or eliminated spontaneous leakage by increasing bilayer stability. CF 
release was attributed to bilayer disruption via local heating and/or LNA rupture, 
which produced transient voids or pores. 
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Figure 2-4. Controlled release from a decorated liposome-nanoparticle assembly 
under the influence of an alternating current electromagnetic field at radio 
frequency. 
Controlled release of carboxyfluorescein (CF), a model encapsulated drug molecule, 
from magnetoliposomes consisting of 5 nm hydrophobic iron oxide NPs embedded 
within the bilayers of DPPC liposomes. (A) Release is shown with (red) and without 
(black) RF heating at 4.85105 kA m-1 s-1 as a function of RF exposure. Images (B) 
and (C) show bare DPPC liposomes and the magnetoliposomes, respectively. The 
initial and total leakage is shown as (D) a function of iron oxide concentration and (E) 
the lipid to NP ratio (L/N), respectively. (F) Total CF leakage after 40 min of RF 
exposure could be varied with line current. Reprinted from [23] with permission. 
 
 
 LNA Performance In vitro and In vivo 
5.1 Cellular uptake and drug delivery 
 Chithrani et al. [94] prepared anionic Au decorated liposomes with 105 nm dh 
by incorporating Au-conjugated DPPE (DPPE-Nanogold; 1.4 nm Au particles) into 
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preformed DPPC/cholesterol liposomes. Incorporation of DPPE-Nanogold was 
confirmed by TEM and EDS. Liposome uptake by HeLa cells in vitro was 
independent of the DPPE-Nanogold concentration (2000:1, 1000:1, and 500:1 Au NPs 
per liposome). This key discovery suggests that the presence of DPPE-Nanogold does 
not influence cell uptake and that high nanoparticle loadings can be achieved in such 
LNAs without compromising internalization. Examining the intracellular fate revealed 
that the Au-liposomes were present in lysosomes and accumulated near the nuclear 
membrane after incubating for 45 min. 
 Paasonen et al. [95] examined uptake and light-induced calcein release of b-
LNAs prepared hexanethiol-coated Au NPs (extension of [24]). The LNAs were 
composed of DSPC:DPPC (9:1 molar ratio) and were multilamellar with sizes ranging 
from 250-370 nm. In vitro studies with human retinal pigment epithelial cell line 
(ARPE-19) showed that the b-LNAs were internalized by endocytosis and localized in 
endosomes. Exposure to UV light at 400 mW/cm2 for 300+ s led to calcien release 
from b-LNAs, but not from liposomes that did not contain embedded nanoparticles. 
 
5.2 Drug delivery and hyperthermia 
Pradhan et al. [20] recently prepared folate (Fol) ligated magnetoliposomes (e-LNAs) 
via thin film hydration that contained co-encapsulated 60 nm iron oxide NPs and 
doxorubicin (DOX) in PBS. A proposed schematic of the e-LNA and the therapeutic 
concept is shown in Figure 2-2. The lipid components included DPPC, Chol, PEG2000-
DSPE, and Fol-PEG2000-DSPE and the liposomes exhibited a melting temperature near 
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41 oC. The liposomes were 361 nm in diameter and polydispersed (0.289), with a 
nanoparticle encapsulation efficiency of 24% (low, presumably attributed to the use of 
the thin film hydration method). The liposomes exhibited temperature-dependent 
DOX release (>2-fold increase from 37 oC to 43 oC). Folate-receptor targeted uptake 
was demonstrated in HeLa and KB cell cultures, and reductions in cell viability were 
attributed to a synergistic effect of DOX and hyperthermia treatment achieved in the 
presence of an AC electromagnetic field. While not mentioned specifically, we 
speculate that liposomal heating by the nanoparticles may have aided DOX release. 
 Babincova et al. [96] prepared DPPC/PEG2000-DSPE LNAs via REV that 
contained both dextran-coated Fe3O4 and C60 fullerene (referred to as 
magnetofullerenosomes) to achieve magnetic targeting and photodynamic therapy 
(PDT), respectively. Bis(di-isobutyloctadecylsiloxy)-2,3-naphthalocyanato silicon 
(isoBO-SiNc), a photosensitizing agent, was also encapsulated. LNA performance for 
treating B16 pigmented melanoma was examined in vivo using a female mouse model. 
Without magnetic targeting, C60-mediated PDT followed by isoBO-SiNc-mediated 
PDT led to a significant reduction in tumor growth over 19 days relative to no 
treatment or isoBO-SiNc-mediated PDT alone. When magnetic targeting was applied 
(0.32 T magnet placed on the tumor surface for 24 h) there was negligible tumor 
growth over the same duration.  
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 Expert Opinion 
 Liposomes or NPs for therapeutic application are well established and have 
been approved by the FDA for clinical use. The combination of these two systems in 
hybrid structures represents a unique opportunity for achieving multiple therapeutic 
objectives. The liposomes can act to concentrate small NPs and shield them from the 
immune system. In turn, the NPs can be used to initiate and control drug release when 
exposed to external stimuli. However, the design and use of LNAs is still in its 
infancy. This is apparent from the literature where, for example, NP loading is 
expressed in multiple ways (e.g. total concentration; lipid:NP molar or mass ratios; 
liposome:NP surface area ratio). Further studies in the design and use of LNAs are 
needed addressing the following questions: 
 How do physical and chemical interactions between NPs and the lipid bilayer 
affect LNA formation, structure, and stability? Encapsulated, decorated, and 
embedded NPs can affect lipid ordering (ordering or disordering are possible) and 
alter bilayer phase behavior. Ordering or phase state affects the permeability and 
stability of LNAs. These effects will be dependent upon the physical and chemical 
properties of the liposome, the NP, and the dispersing phase. Studies are needed 
that demonstrate the relationship between NP loading; liposome morphology, 
structure, and stability; and bilayer permeability for different LNA designs.  
 Is the concept of local or nanoscale heating valid and under what conditions? 
LNAs designed for controlled release usually report a local or nanoscale heating 
mechanism where the NPs transfer heat to the LNA and causes a phase changes 
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within the bilayer that trigger bilayer permeabilization. From this rationale, NPs in 
close proximity to bilayer, such as the case for embedment or decoration, would 
have the greatest effect on controlled release. However, other release mechanisms 
as a result of NP stimulation, working in tandem with bilayer heating, may be 
utilized (Figure 2-5). This statement is based in part on work by Keblinski et al. 
[65], who have shown that the theoretical temperature difference between a 
nanoparticle surface and the bulk phase due to EMF heating (light or RF) is almost 
negligible. This was further verified experimentally by Gupta et al. [97] and 
Bothun and Preiss [98] for Fe3O4 nanoparticles heated by RF. The fact that little 
difference between nanoscale and bulk heating is observed is due to the negligible 
heat transfer resistance in nanoscale films and rapid heat dissipation from the NP 
surface. Hence, NP heating does indeed occur and can trigger LNA release, but the 
heating is not localized to the LNA and no measurable difference can be observed 
with the bulk phase. It is unlikely that a lipid bilayer, even in contact with the 
nanoparticle surface, would exhibit a different temperature than that of the 
surrounding aqueous phase.  
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Figure 2-5. Nanoparticle heating controlled release mechanisms from liposome-
nanoparticle assemblies. 
Controlled release mechanisms of LNAs. (A) Thermally-induced phase transitions due 
to NP heating where release is achieved through high diffusivity at the interface 
between gel and fluid lipid phases. (B) Mechanically-induced release where the 
bilayer is ‘broken’ due to bubble formation/rupture as a result of NP heating. (C) 
Mechanically-induced release where the bilayer is ‘broken’ due to NP rotation or 
oscillation at or within a LNA bilayer. 
 
 What is LNA toxicity and how does the design strategy affect? It is unclear if LNA 
toxicity will stem from the liposomes or the NPs, or if a synergistic effect will 
occur. Toxicity, which is important from a clinical perspective, will depend on the 
LNA design and associated colloidal stability. For example, toxicity could be 
‘low’ if an LNA can retain its NP agent until it reaches a target site. This could be 
the case for bound NPs formed by embedment or encapsulation. However, ‘higher’ 
toxicity could occur if the NPs are released during circulation (i.e. toxicity of 
liposomes + NPs). Release of encapsulated NPs could be attributed to liposome 
fusion or bilayer disintegration, release of embedded NPs may occur due to bilayer 
solubilization by surface-active agents, and release of decorated NPs may occur 
due to charge screening or competitive binding. 
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 What clinical challenges exist to LNA-based therapeutic assemblies? As with 
toxicity, it is unclear if LNAs present unique clinical challenges beyond those 
reported for liposomes or nanoparticles [3, 4, 22]. These challenges include 
achieving biocompatibility, bioavailability, and cellular targeting and uptake. LNA 
structure, function, and stability will clearly impact how these challenges are 
addressed. 
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 Abstract 
 Temperature measurements have been made within magnetite (Fe3O4) 
nanoparticle-liposome dispersions subjected to electromagnetic field at radiofrequency 
(RF) heating based on the fluorescence anisotropy of diphenylhexatriene (DPH) 
embedded within the bilayer.  Incorporating cholesterol within 
dipalmitoylphosphatidylcholine (DPPC) bilayers broadened the anisotropy window 
associated with lipid melting.  Cryogenic transmission electron microscopy showed 
that the dispersions contained magnetoliposomes with nanoparticle aggregates at both 
low and high encapsulation densities.  RF heating results demonstrated the ability to 
measure the temperature of the ML bilayer with on/off RF cycles using DPH 
anisotropy. These measurements reflected the temperature of the bulk aqueous phase, 
which is consistent with previous work showing rapid heat dissipation from a 
nanoparticle surface during RF heating and a negligible difference between surface 
and bulk temperature.  
 
Keywords: Magnetoliposome; Magnetic nanoparticle; Electromagnetic heating; 
Hyperthermia; Lipid bilayer 
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 Introduction 
 Magnetoliposomes (MLs) consist of iron oxide nanoparticles encapsulated 
within lipid bilayer vesicles or liposomes [1-4]. Two common magnetoliposome 
structures formed by encapsulating hydrophilic magnetic nanoparticles are shown in 
Figure 3-1. The lipid bilayer coating provides a biocompatible means of dispersing the 
nanoparticles in aqueous milieu. In addition, the liposome structure provides a means 
of delivering hydrophobic (within the bilayer) or hydrophilic (within the aqueous core) 
molecules co-encapsulated with the nanoparticles. ML delivery to target sites in vivo 
can be achieved physically, by guiding the MLs using magnets placed on a body’s 
exterior [5], as well as chemically using cationic lipids or ligand-conjugated lipids 
with selectivity for specific cellular receptors [5, 6]. Pradhan et al, for example, 
recently showed that the inclusion of a folate-conjugated lipid can be used to target 
MLs to cancer cells via folate receptor (FR) binding and FR-mediated endocytosis [7].  
 A unique property of MLs is the ability to heat the encapsulated magnetic 
nanoparticles, typically iron oxide (maghemite, -Fe2O3 or magnetite, Fe3O4), using 
external alternating current electromagnetic fields (EMFs) operating at 
radiofrequencies (RFs) [6, 8]. With this mode of heating, magnetic losses are 
converted to energy. The magnetic losses are attributed to Neel relaxation, which is 
due to rapidly alternating magnetic dipole moments, and Brownian relaxation, which 
is due to nanoparticle rotation (i.e. friction losses) [9]. ML heating using 
physiologically compatible or benign RF strengths can provide local hyperthermia 
treatment [10] or combined hyperthermia and drug delivery [7]. This is attributed to 
radiofrequencies easily penetrating the body and being non-invasive for up to 1 hour if 
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the product Hf, where H is the field amplitude (current  number of coils per length) 
and f is the frequency, is below 4.85105 kA m-1 s-1 [11]. With respect to drug 
delivery, initiating and controlling drug release from MLs has been attributed to the 
ability to manipulate the phase behavior and diffusivity of the lipid bilayer [7, 12-14]. 
Combining the ability to guide MLs using magnets and trigger release with RFs can 
overcome a major challenge of ‘conventional’ liposomes for drug delivery – obtaining 
high liposome accumulation at a target site and achieving a desired controlled release 
profile [15]. 
 
 
Figure 3-1. Magnetoliposome structures. 
Magnetoliposome structures consisting of (top) a single nanoparticle encapsulated 
within a supported lipid bilayer and (bottom) multiple nanoparticles encapsulated 
within a liposome. 
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 Challenges to ML-based hyperthermia and drug release include measuring 
changes in temperature without the use of invasive probes and at the site of interest – 
i.e. local temperatures in the vicinity of the nanoparticles [8]. With respect to 
hyperthermia, the local temperature in vivo is important in cancer treatment where 
elevated temperatures must be maintained for a period of time to cause cell death (e.g. 
42 oC or a ΔT of 5 oC from physiological temperature for >30 min) [16].  In this case 
questions arise concerning what minimum cellular nanoparticle (or ML) loading is 
needed to achieve sufficient heating, as well as the ability to selectively heat the 
cancer cells or tumor mass and not damage healthy cells or tissues [9].  In turn, for 
drug release applications, the heat delivered to or generated within the MLs may be 
used to control transbilayer release by raising the bilayer to its melting temperature [1, 
12, 17].  However, there is some controversy associated with this statement. Keblinski 
et al. [18] have shown that the theoretical temperature difference between a 
nanoparticle surface and the bulk phase due to EMF heating is almost negligible. This 
was further verified by Gupta et al. [19] for Fe3O4 nanoparticles heated by RFs. In this 
work quantum dots were mixed or covalently anchored to the nanoparticles as 
temperature probes to compare bulk verse local temperature. 
 In this work we describe an in situ spectrofluorometric-based approach to 
determine the effect of RF heating on the temperature of liposomal bilayers in a Fe3O4 
nanoparticle-liposome dispersion containing MLs. The approach is based on the 
anisotropy, <r>, of a lipid bilayer probe molecule, diphenylhexatriene (DPH), and the 
proportionality among anisotropy, bilayer viscosity, and lipid phase state, which 
depend on temperature [20]. Nanoparticle-liposome dispersions were prepared with 
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dipalmitoylphosphatidylcholine (DPPC) and contained 25 mol% cholesterol and 0.2 
mol% DPH. While cholesterol is known to stabilize liposomes, in this work it was 
added specifically to broaden the main phase transition or melting temperature region 
[21, 22]. This provided a large heating window for anisotropy measurements. 
Calculated (via <r>) and measured temperatures were compared to differentiate 
between local and bulk heating relative to MLs as a function of time during on/off RF 
cycles.  
 
 Materials and methods 
3.1 Chemicals  
 Dipalmitoylphosphatidylcholine (DPPC) and cholesterol were purchased from 
Avanti Polar Lipids, and diphenylhexatriene (DPH) from Sigma Chemical Company. 
The aqueous Fe3O4 nanoparticle solution was purchased from Ferrotec GmbH (EMG 
705 ferrofluid, 3.9 vol%). Previous work has shown that in this solution the particles 
are well dispersed with an average diameter of 12.5  3.4 nm [23]. Sterile deionized 
water was obtained from a Millipore Direct-3Q purification system. All materials were 
used as received with the exception of dilution.  
 
3.2 Preparation of Fe3O4 nanoparticle-liposome dispersions  
 Samples were prepared by reverse phase evaporation [24] (Buchi Rotavapor R-
215, Zurich, Switzerland), similar to the procedure by Wijaya and Hamad-Schifferli 
[23]. The following components were added to a 25 ml round bottom flask: 320 µl of 
10 mM DPPC in chloroform, 80 µl of 10 mM cholesterol in chloroform, 40 µl of 0.2 
mM DPH in tetrahydrofuran, and 40 µl of ferrofluid. To this, 4 ml of DI water and 16 
 140 
 
ml of chloroform were added and an emulsion was formed by bath sonication for 5 
min at 50 °C, which is above the DPPC melting temperature (Tm) of 42 oC [25]. The 
sample was cooled at room temperature for 30 min. The solvent phase was then 
removed by rotary evaporation at 25 °C and 100 RPM under 300 mbar for 30 min 
followed by 200 mbar for 2 h. The final dispersions contained 0.8 mM DPPC and 1 
mM Fe3O4, which was equivalent to approximately 0.23 mg ml-1, equivalent to 0.23% 
mass fraction in water and 287.5 g Fe3O4 mol-1 DPPC. 
 Nanoparticle encapsulation efficiency was estimated using a centrifugation 
procedure employed by Pradhan et al. [10]. Briefly, 0.9 wt% NaCl was added to the 
samples (in DI water) at a volume ratio of 1:1. This led to the aggregation of 
unencapsulated nanoparticles via charge screening. The solution was then centrifuged 
at 1000 g for 10 min at 4 oC. The supernatant containing MLs and (if present) empty 
liposomes was removed and the precipitate was resuspended in DI water, digested in 
nitric acid, and analyzed by inductively coupled plasma mass spectrometry (ICP-MS, 
Thermo Electron X Series, Waltham, MA). Encapsulation was calculated based on the 
57Fe isotope. 
 
3.3 Cryogenic transmission electron microscopy (cryo-TEM) 
 The nanoparticle-liposome dispersions were prepared for cryo-TEM at 25 oC 
using a Vitrobot (FEI Company). A quantifoil grid with 2 µm carbon holes on 200 
square mesh copper (Electron Microscopy Sciences, Hatfield, PA) was immersed in 
the sample, blotted to reduce film thickness, and vitrified in liquid ethane. The sample 
was transferred to liquid nitrogen for storage and imaging, which was performed in a 
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cooled stage (Model 915, Gatan Inc., Pleasonton, CA) at 200 kV using a JEOL JEM-
2100F TEM (Peabody, MA). Size analysis was performed using ImageJ software [26].  
The average size reported was based on all liposomes observed in the cryo-TEM 
micrographs. 
 
3.4 RF heating 
RF heating was performed using a 1 kW Hotshot™ (Ameritherm Inc., Scottsville, 
NY) operating from 50 to 250 A and 291 to 287 kHz, respectively.  The specific 
absorption rates (SAR) of the nanoparticles were measured using a 3-turn copper coil 
with a 4.5 cm outer diameter.  To determine SAR values, sample temperatures were 
measured as a function of nanoparticle concentration and electromagnetic field 
strength, Hf, which was varied between 1×105 and 5×105 kA m-1 s-1. SAR (W g-1) 
values were calculated from the initial slope of adiabatic temperature rise of the 
samples, 
  

T /t  SAR mNP /(c p mV ) (Eq. 1), where   

mNP  and   

mV  are the mass of the 
nanoparticles and sample volume, respectively, and 
  

c p  cp, N  (1)cp,F  is the 
average heat capacity based on the nanoparticle volume fraction in the sample, 

 . 
 For in situ fluorescence anisotropy measurements, the 3-turn coil was placed 
around the cuvette holder within the sample compartment of the spectrophotometer. 
The coil was separated slightly to allow for the excitation and emission light paths. 
The sample was diluted 7-fold (0.11 mM DPPC, 0.03 mg Fe3O4 ml-1), placed within a 
quartz cuvette (10 mm path length), and subjected to RF-heating cycles as a function 
of time at 5×105 kA m-1 s-1 (250 A and 281 kHz), which was the maximum field 
strength used for SAR. The bulk solution temperature was measured intermittently 
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using a temperature probe. Steady-state DPH anisotropy within the DPPC bilayer was 
determined with at ex = 350 nm and em = 452 nm using the expression <r> = (IVV - 
IVH)/(IVV + GIVH) (Eq. 2) where I represents the fluorescence emission intensity, V and 
H represent the vertical and horizontal orientation of the excitation and emission 
polarizers, and G = IHV/IHH accounts for the sensitivity of the instrument towards 
vertically and horizontally polarized light. The excitation and emission slit widths 
were set at 10 nm.  
 
 Results and discussion 
4.1 Nanoparticle RF-heating 
 SAR values were determined as a function of RF field strength and 
nanoparticle mass fraction. The SAR increased with increasing field strength and 
decreased slightly with increasing nanoparticle mass fraction (Figure 3-2).  Given that 
SAR values are normalized for nanoparticle concentration, the decrease with 
increasing nanoparticle mass fraction may reflect greater heat loss from the sample 
tubes to the surroundings prior to temperature measurements.  
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Figure 3-2. Specific absorption rate (SAR) of the Fe3O4 nanoparticles as a 
function of RF field strength (Hf, in legend) and nanoparticle mass fraction (in 
water).  
 
4.2 Cryo-TEM and DLS analysis  
 Cryo-TEM micrographs of the nanoparticle-liposome dispersion taken one 
week after preparation are shown in Figure 3-3. Unilamellar liposomes with and 
without smaller encapsulated unilamellar liposomes were observed. The liposomes 
had an average diameter of 317  192 nm and exhibited significant polydispersity 
(based on all structures observed). Polydispersity can be attributed to the fact that no 
post-formation processing was performed, and was not a concern as DPH anisotropy is 
weakly dependent on liposome size (excluding high curvature effects in small 
liposomes). Based on all the liposomal structures shown in Figure 3-3, 30% contained 
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encapsulated nanoparticles (Figure 3-3, arrowed region 2) or nanoparticle aggregates 
(Figure 3-3, arrowed region 1) indicative of MLs. MLs were also observed in ruptured 
or rupturing states with nanoparticle aggregates being released into the bulk aqueous 
phase (Figure 3-3, arrowed region 3).  
 It should be noted that the percentage of liposomes containing nanoparticles or 
nanoparticle aggregates is not equivalent to encapsulation efficiency. An 
encapsulation efficiency of 67% was measured one day after sample preparation based 
on ICP-MS analysis of precipitate and supernatant fractions after centrifugation [10]. 
Comparing cryo-TEM and encapsulation efficiency results suggests that most of the 
nanoparticles were encapsulated as aggregates within a small population of liposomes 
and/or that encapsulated nanoparticles were released due to ML rupture. Nanoparticle 
release from MLs has been observed by Wijaya and Hamad-Schifferli for high-density 
nanoparticle-loaded vesicles (HNLVs) prepared using DPPC and the same ferrofluid 
[23]. In their study the samples were analyzed 30 min after preparation and release 
was attributed to incomplete closure, which reduces encapsulation efficiency. In the 
present work, cryo-TEM was conducted one week after ML formation (stored at 25 
oC) and rupture was still clearly evident.  
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Figure 3-3. Cryo-TEM micrographs of the nanoparticle-liposome dispersion. 
The images depict (1) magnetoliposomes containing encapsulated nanoparticle 
aggregates or (2) single nanoparticles; (3) magnetoliposomes rupturing and 
nanoparticle release; and unencapsulated (4) single nanoparticles and (5) nanoparticle 
aggregates. The scale bar represents 500 nm and is common to both images. 
 
4.3 DPH anisotropy as a function of temperature and RF-heating 
 DPH anisotropy for liposomes (no nanoparticles) and nanoparticle-liposome 
dispersions with MLs (no RF-heating) as a function of temperature is shown in Figure 
3-4. The results indicate a Tm of 43 oC, where the bilayer transitions from an ordered 
gel to disordered fluid phase, and a broad melting region from 31 to 54 oC. These 
results are consistent with the effects of cholesterol on DPPC phase behavior and 
demonstrate that the presence of nanoparticles did not influence lipid melting [21]. A 
least squares regression fit of the liposome-nanoparticle dispersion data provided a 
calibration curve (  

T 5865.0  r 3 4204.9  r 2 1122.8  r 154.4; R² = 0.97) (Eq. 
3) for determining temperature as a function of DPH anisotropy during RF-heating. 
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Figure 3-4. Melting transition determined by DPH anisotropy. 
The reduction in DPH anisotropy with increasing temperature reflects an increase in 
bilayer fluidity, or decrease in microviscosity, as the bilayers transition from a gel to a 
fluid phase. 
 
 DPH anisotropy was measured in situ during RF-heating (5×105 kA m-1 s-1) as 
a function of time. Heating was initiated at time zero and cycled between off and on. 
The T versus <r> calibration curve (Eq. 3) was used to calculate temperature. Prior to 
conducting the experiment, a cuvette containing water was heated by RF for 1 h. The 
temperature rise from this test was from 25 to 26 oC, which demonstrates that heating 
of the cuvette, cuvette holder, and base within the spectrophotometer sample 
compartment was minimal and its contribution to sample heating was negligible. 
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 A rapid increase in the calculated temperature (via <r>) was observed with 
EMF heating up to 1400 s (Fig. 3-5). The temperature changes with on/off EMF 
cycling, between 1400 and 1450 s and 1450 and 2100 s, demonstrate the response and 
reversibility of ML membrane fluidity and its use for remote temperature 
measurements. The correlation between calculated and measured (via probe) 
temperatures suggests that the calculated temperatures reflect that of the bulk as 
opposed to local to the ML bilayer. Hence, bilayer temperature could not be 
differentiated from bulk temperature. This finding was initially counterintuitive 
considering that heat originated within the MLs before being transferred through the 
bilayer into the bulk aqueous phase. To resolve this, a simple heat transfer analysis 
was adopted from Keblinski et al. [18], where they examined nanoscale versus global 
(bulk) EMF heating of nanoparticles. In the expression 
  

Ts Tb  SAR p rp
2 /(3k ), Ts is 
the nanoparticle surface temperature, Tb is the bulk temperature, 
  

 p is the density of 
the encapsulated nanoparticles (Fe3O4, 5.1 g cm-3), 
  

rp  is the radius of the particle, and 
k is the thermal conductivity of water (0.6 W m-1 oC-1). For a single particle with 
  

rp  = 
160 nm, which is near the average radius of the MLs, and using an SAR value of 100 
W g-1 Fe3O4 yields   

Ts  Tb < 10
-5 oC.  This is due to rapid heat dissipation from the 
nanoparticle surface with a timescale proportional to 
  

rp
2 /(k /cp ). Hence, it is unlikely 
that a lipid bilayer, even in contact with the nanoparticle surface, would not exhibit a 
different temperature than that of the bulk aqueous phase. Our results and analysis are 
in close agreement with theoretical work by Keblinski et al. [18]. 
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Figure 3-5. DPH anisotropy and bilayer calculated temperature with RF heating. 
DPH anisotropy (<r>, black squares) was measured at a RF field strength of 5×105 kA 
m-1 s-1. The field was cycled randomly between off and on. Calculated temperature 
(red triangles) was determined from anisotropy using Eq. 1. The results were fitted by 
a fourth order spline fit with an exponential correlation function, and the fitted line is 
intended to guide the eye and depict general trends. Temperature measurements of the 
bulk phase (red squares) are shown for comparison. 
 
 Conclusions 
The fluorescence-based approach provides a means of measuring the lipid bilayer 
temperature in nanoparticle-liposome dispersions subjected to EMF heating. While the 
intent of this work was to provide proof-of-concept using Fe3O4 nanoparticles, the 
technique is applicable to other inorganic nanoparticles provided they do not interfere 
with the spectroscopic measurements. Based on the experimental results and a simple 
heat transfer analysis, the temperature of the bilayer in the MLs employed was equal 
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to that of the bulk aqueous phase. This was due to rapid heat dissipation from the 
nanoparticle surface where the difference between the surface and bulk temperatures 
was negligible. We emphasis that in this work the MLs were not subjected to post-
formation processing, such as sonication, extrusion, or purification. Hence, the MLs 
were heterogeneous and contained unencapsulated iron oxide nanoparticles and 
nanoparticle aggregates. However, based on the heat transfer analysis and inferred by 
previous theoretical work [18], liposomal heating is not dependent on the ratio of 
encapsulated to unencapsulated nanoparticles, but rather on the total nanoparticle 
concentration within the dispersion. This suggests that nanoparticle-lipid interactions. 
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 Abstract 
 Understanding the effect of embedded nanoparticles on the characteristics and 
behavior of lipid bilayers is critical to the development of lipid-nanoparticle 
assemblies (LNAs) for biomedical applications. Decorated LNAs (D-LNAs) were 
formed by embedding 2 nm (GNP2) and 4 nm (GNP4) dodecanethiol-capped gold 
nanoparticles into DPPC liposomes at lipid to nanoparticle ratios (L:N) of 25,000:1, 
10,000:1, and 5,000:1. The effect of nanoparticle size and concentration on D-LNA 
structure was investigated by cryogenic transmission electron microscopy, and lipid 
bilayer permeability and phase behavior were investigated based on the leakage of a 
model drug, carboxyfluorescein, and by differential scanning calorimetry, 
respectively. Studying leakage and phase behavior provides information on the 
interaction of nanoparticles on the temperature-dependent stability and permeability of 
liposomes. The presence of bilayer nanoparticles caused changes in the lipid bilayer 
release and phase behavior compared to pure lipid controls at very low nanoparticle to 
bilayer volume fractions (0.3%-4.6%). Also, the smaller nanoparticles (GNP2) 
affected the bilayer differently than the nanoparticles were closer to the bilayer 
thickness (GNP4). By altering the bilayer phase behavior, embedded gold 
nanoparticles changed the bilayer permeability in a temperature-dependent fashion.  
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 Introduction 
 Liposomes are well-established biocompatible carriers capable of protecting, 
transporting, and delivering hydrophobic cargo (in the bilayer) and/or hydrophilic 
cargo (in the aqueous core) for biomedical applications.1, 2 Liposomal drug delivery 
systems can increase therapeutic effectiveness, increase stability, target diseased sites, 
and control release while reducing overall toxicity and side effects 3. As of 2013, the 
U.S. FDA has approved 13 lipid-based products for clinical use to treat cancers (such 
as breast, ovarian, Kaposi's sarcoma, and acute lymphoblastic leukemia), meningitis, 
and other ailments. They have also been approved as an anesthetic, to treat fungal 
infections, and for menopausal therapy. Clinical trials of lipid-based therapies are 
expanding especially for treatment of cancers, including colorectal, gastric, pancreatic, 
colon, lung, and liver cancers 4, 5.  
 One approach to controlling liposomal delivery and imparting additional 
functionality is through the addition of nanoparticles to form lipid-nanoparticle 
assemblies (LNAs) 1-3. LNAs generally refer to liposome structures with embedded, 
encapsulated or adhered nanoparticles. For more extensive background on the 
formation, applications, and types of LNAs see reviews by Al-Jamal and Kostarelos 3 
and Bothun et al.1, 2 Decorated LNAs (D-LNAs) formed with hydrophobic 
nanoparticles embedded in the acyl tail region of the lipid bilayer represent a unique 
hybrid structure where the nanoparticles add functionality and can be used to control 
liposomal release. Nanoparticles used to form D-LNAs must be similar in size to the 
thickness of the lipid bilayer (4-5 nm) in order to embed. Theoretically, the lipid 
bilayer can distort to accommodate nanoparticles up to 6.5 nm 6, 7. Stable D-LNAs 
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have been formed with iron oxide 8, 9, quantum dots (CdSe and ZnS) 10-14, gold 14-18, 
silver 19, 20, silicon 21, C60 fullerenes 22, 23, and cobalt ferrite24 nanoparticles giving them 
targeting, controlled release, diagnostic, and stimuli-responsive capabilities.  
  Recent D-LNA research has focused on forming and characterizing D-LNA 
structures or developing D-LNAs with new functionalities. Structural D-LNA research 
has mainly focused on increasing nanoparticle concentrations, incorporating larger 
nanostructures and/or nanoparticle aggregates, and nanoparticle localization and 
mobility within the bilayers 8, 15, 16, 25-28. Functional D-LNA research has led to the 
development of stimuli-responsive, targeting, imaging, diagnostic, therapeutic, and/or 
controlled release capabilities for biomedical applications 8-11, 13, 18. However, few 
studies have been conducted to determine the effects of embedded nanoparticles on 
lipid phase behavior, notably the pretransition (Tp) and melting (Tm) temperatures, and 
the associated thermal release behavior. Furthermore, studies that have been reported 
suggest that nanoparticle size and concentration can lead to stabilizing or destabilizing 
effects based on lipid ordering and phase behavior. These properties are important 
when designing D-LNAs for drug delivery applications; and a deeper understanding of 
the relationship between D-LNA structure, phase behavior, and release properties 
could be used to design D-LNAs a priori for specific applications. 
Oh et al. have shown that the membrane fluidity above Tm of 
Dipalmitoylphosphatidylcholine (DPPC) increased with increased loading of 4 nm 
nanoparticles, consistent with liposome destablization17, 19. Similarly, Bothun et al. 
have observed that increasing the concentration of 5.7 nm nanoparticles reduced the 
Tp, Tm, and lipid ordering of DPPC D-LNAs 20. In contrast, liposome stabilization was 
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observed by Chen et. al. where embedded 5 nm nanoparticles suppressed leakage by 
stabilizing the bilayer based on increases in Tm with increasing nanoparticle loading8. 
This behavior was also observed by Von White et al. where 3.9 nm gold nanoparticles 
and excess stabilizing ligand could significantly increase Tm at high nanoparticle 
loadings 15.  
 The aim of this research is to investigate the effect of hydrophobic nanoparticle 
size and concentration on the structure, leakage, and phase behavior of D-LNAs. 
DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) bilayers were loaded with 
dodecanthiol-coated gold nanoparticles (GNPs) of different sizes and lipid-to-
nanoparticle (L:N) ratios. D-LNAs were loaded with 2 nm (GNP2) and 4 nm (GNP4) 
gold nanoparticles. Figure 4-1 depicts the likely D-LNA structures formed from DPPC 
and GNP2 and GNP4, and the structure of DPPC and associated thermal phase 
behavior. Figure 4-1 also depicts nanoparticle clusters in the bilayer of a D-LNA. This 
study was possible by fractionating the AuNPs into discrete size fractions using a 
high-pressure carbon dioxide-based antisolvent process. The interaction between the 
nanoparticles and the lipid bilayer was investigated with cryogenic transmission 
electron microscopy (cryo-TEM), fluorescent leakage of a model drug 
(carboxyfluorescein or CF), and differential scanning calorimetry (DSC). Our results 
show that GNPs influence the phase behavior of DPPC liposomes, which in turn 
modifies the thermal CF release behavior.  
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Figure 4-1. Schematics of D-LNA structures loaded with GNP2 and GNP4.  
(A) GNP2 are assimilated without much bilayer deformation because GNP2 are 
smaller than the thickness of a DPPC lipid bilayer (4-5 nm).6 (B) GNP4 cause the lipid 
bilayer to thicken around the nanoparticle.15 (B) Structure and (C) phase behavior of 
DPPC with associated pretransition (Tp) and main or melting transition (Tm) 
temperatures. 
 
 Methods and Materials 
3.1 Chemicals and Materials.  
Dipalmitoylphosphatidylcholine (DPPC) in chloroform (25 mg/mL) was 
purchased from Avanti Polar Lipids (Alabaster, AL). 5,6-Carboxyfluorescein (CF) and 
Triton X-100 were purchased from Sigma Aldrich (St. Louis, MO). Phosphate 
buffered saline 1X solution (PBS) was purchased from Fisher Scientific (Suwanee, 
GA). Sterile deionized ultrafiltered (DI) water at 18.2 mΩ was used from a Millipore 
Direct-Q3 UV purification system (Billerica, MA). 
 
gel phase (Lβ)
rippled-gel phase (Pβ')
ﬂuid phase (Lα)
Tp ≈ 34 
oC 
Tm ≈ 41 
oC 
DPPC 
(R = C15H29)
A1 B C
A2
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3.2 Gold Nanoparticle Synthesis. 
 Dodecanethiol-stabilized gold nanoparticles (DDT-GNPs) were synthesized 
via an arrested precipitation method previous described for silver29, then modified for 
gold.16 In short, 330 mg of gold chloride trihydrate (Acros Organics, 99%) was 
dissolved in 20 mL of DI water and 6 g of tetraoctylammonium bromide, TOAB, 
(Chem-Impex Int’l Inc, 99.35%) was dissolved in 80 mL of chloroform (Alfa Aesar, 
HPLC grade 99.5%). The two solutions were then combined and stirred vigorously for 
1 hour until the chloroform phase become an orange/red color. The aqueous phase was 
discarded and 600 µL of dodecanethiol, DDT, (Tokyo Chemical Industry, >95%) was 
added to the gold/chloroform solution and stirred for 30 minutes. 20 mL of 0.5 M 
sodium borohydride was then added to the gold/DDT/chloroform mixture and stirred 
for 12 hours. The aqueous phase was then discarded and the nanoparticle solution was 
then washed with methanol (Burdick & Jackson, HPLC grade) to remove any excess 
DDT and TOAB and resuspended in neat toluene (BDH, 99.5%). 
 
3.3 Nanoparticle Fractionation. 
The nanoparticle synthesis process results in a polydisperse sample comprised of 
nanoparticles with diameters ranging from 1-10 nm. For monodisperse nanoparticle 
samples large (diameters of 4 nm) or small (diameters less than 3 nm) nanoparticles, 
nanoparticle fractionation using a solvent/antisolvent centrifugation method (as 
described in Korgel et. al.16) was used to separate the nanoparticles by size. During the 
fractionation process, the largest nanoparticles precipitate out during centrifugation 
with the supernatant comprised of the smaller nanoparticles. Fractionations are 
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performed with different volume percentages of antisolvent (methanol). The first 
fractionation is performed with 40% antisolvent or 40%v/v methanol. The 
nanoparticle solution is mixed with the 40% antisolvent and vortexed. The 
methanol/Au NP mixture is centrifuged at 14500 rpm for 10 minutes. The precipitate 
(with nanoparticles ~4-10 nm in diameter) is resuspended in toluene or chloroform. 
Large and small nanoparticles remain in the supernatant. The supernatant is 
transferred to a new centrifuge tube and the process is repeated for the second 
fractionation at 70% antisolvent. The precipitate, consisting of large nanoparticles (4 
nm nanoparticles), is resuspended in toluene or chloroform. Small nanoparticles 
(nanoparticle diameters less than 3 nm) remain in the supernatant, which is retained 
for the final fractionation with 90%v/v methanol. The solvent/antisolvent mixture is 
removed by rotary evaporation and then is resuspended in toluene or chloroform. 
 
3.4 Nanoparticle Characterization.  
Transmission electron microscopy (TEM) was used to determine the size distribution 
of each nanoparticle fraction. After fractionation and redispersement in neat solvent, a 
drop of the nanoparticle solution was placed on a 400 mesh Formvar/carbon coated 
copper grid (Electron Microscopy Sciences) and dried in air. The TEM measurements 
were conducted on a Hitachi 7600 instrument operating at an acceleration voltage of 
120 kV. The size distributions were analyzed using ImageJ software. For GNP2, size 
was determined by manually measuring 50 random particles. For GNP4, size was 
determined by the automatic measurement of 500–1000 particles.  
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 Dynamic Light Scattering (DLS) was also used to study the size of each 
nanoparticle fraction. Nanoparticle solutions were placed in clear, scratch free 
scintillation vials for DLS measurement with a Wyatt Technologies Dawn Heleos II 
with the QELS option. First, a nanoparticle free solvent, in this case toluene, was 
analyzed to subtract the scattering of the solvent from the scattering pattern of the 
nanoparticles. Each fraction was analyzed separately and the nanoparticle free solvent 
was analyzed again after each fraction to establish a baseline. The sample time for 
each fraction and background measurement was 5 minutes. It is important to note that 
the size obtained by DLS also includes the solvent-ligand saturation layer around the 
nanoparticle and therefore will differ from TEM size results. 
 
3.5 Liposome and DLNA Preparation.  
 10 mM DPPC control liposomes and 10 mM DPPC DLNAs with lipid 
molecule to nanoparticle (L:N) ratios of 25000:1, 10000:1, and 5000:1 were formed 
by thin film hydration. Lipids and GNPs in chloroform were mixed in a 25 mL round 
bottom flask. Chloroform was removed by a BÜCHI Rotavapor R-215 rotoary 
evaporation (Flawil, Switzerland) at 50oC (greater than the melting temperature of 
DPPC) at 300 mbar for 30 min and then 50 mbar for 10 min. To evaporate residual 
chloroform forming a thin film, the flask was placed in a vacuum at greater than 25 in 
Hg overnight. For release studies, the thin film was rehydrated with 1X PBS 
containing 50 mM CF in the flask. The flask was sonicated in a 40 kHz Branson 
Ultrasonics 1510 ultrasonic cleaner (Danbury, CT, USA) a 50oC bath for 60 min. 
while rotating. All liposomes and D-LNA samples had broad diameter ranges typically 
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between 40-125 nm. Overall, the largest and the smallest liposome and D-LNA 
structures observed were 266 nm and 39 nm in diameter, respectively.   
Unencapsulated CF was removed by a modified dry size exclusion 
chromatography [30]. Chromatography columns were prepared by loading 0.5g of 
Sephadex G-50 (medium) mixed in PBS. Columns were centrifuged in a Thermo 
Fisher Scientific Heraeus Megafuge 16R (Waltham, MA, USA) at 1000 XG for 3 min. 
removing the PBS and leaving a chromatography column packed with Sephadex. The 
liposome or DLNA sample with unencapsulated CF is added to the dry Sephadex 
column and centrifuged for 100 XG for 10 min. then 1000 XG for 3 min. removing the 
unencapsulated CF. The sample that flows through the Sephadex column is collected 
(repeated 2 times).   
 
3.6 Fluorescence Leakage Studies.  
CF leakage experiments were conducted within a PerkinElmer LS 55 fluorescence 
spectrometer with a PTP 1 Peltier Temperature Programmer for temperature control 
(Waltham, MA, USA). Fluorescence measurements were taken at excitation and 
emission wavelengths of 492 and 517 nm, respectively, a 5 nm excitation and 
emission slit width, and an integration time of 10 sec. 2 µL of DPPC control or D-
LNA was added to 3 mL of 1X PBS in a quartz cuvette constantly mixing with a 
magnetic stir bar. CF intensity readings of the samples were taken as a function of 
temperature between 25 oC and 46 oC at increments of 1 oC. Each temperature was 
maintained for 5 min. After the temperature readings, 10 µL of 2% Triton X-100 was 
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added to the cuvette and the cuvette was sonicated to lyse the liposomes or DLNAs. 
The percentage of CF leakage was calculated from the following equation: 
𝐶𝐹 𝐿𝑒𝑎𝑘𝑎𝑔𝑒 % = 100 ×
𝐼(𝑇) − 𝐼0
𝐼𝑓 − 𝐼0
 
where I(T) is the CF intensity at temperature T, I0 is the initial CF intensity, and If is 
the CF intensity after lysing. All leakage studies were performed in triplicate.  
CF intensity readings were also taken as a function of time at constant temperature, 25 
°C and 45 °C, corresponding to the DPPC liposomes being in the gel phase and fluid 
phase, respectively. 2 µL of DPPC control or D-LNA was added to 3 mL of 1X PBS 
in a quartz cuvette constantly mixing with a magnetic stir bar. A baseline CF intensity, 
I0, was recorded for 5 min. The temperature was changed and CF intensity was 
integrated and recorded every 10 sec. for 30 min., I(t). After 30 min, 10 µL of 2% 
Triton X-100 was added to the cuvette to lyse the DPPC liposomes or D-LNAs. 
Intensity was recorded for another 15 min to determine the intensity of all the CF in 
the sample, If. Using these terms, percent CF leakage was calculated with the 
following equation:  
𝐶𝐹 𝐿𝑒𝑎𝑘𝑎𝑔𝑒 % = 100 ×
𝐼(𝑡) − 𝐼0
𝐼𝑓 − 𝐼0
 
For all CF quenching experiments, the quenching was not affected by the gold 
nanoparticles because the CF quenching was normalized and they reside in the lipid 
bilayer preventing it from affecting CF quenching. 
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3.7 Differential Scanning Calorimetry. 
Lipid phase behavior was investigated with a TA Instruments Nano DSC (New 
Castle, DE, USA). DPPC and D-LNA samples were diluted in 1xPBS to 0.5 mM lipid. 
Samples and 1xPBS were degassed and loaded into the DSC’s 0.76 mL sample and 
reference capillary cells, respectively. The DSC cell was pressurized to 3 atm and 
equilibrated at 20oC. A heating cycle from 20-50 oC at scan rate of 1oC min-1 with a 5 
min equilibration period at 20 oC and 50 oC were performed. 
 
3.8 Cryogenic Transmission Electron Microscopy (Cryo-TEM). 
 DPPC liposome and D-LNA sizes and structures were determined with cryo-
TEM imaging. ~5 µL of sample is deposited on a Quantifoil grid comprised of 200 
square mesh copper grids suspended with 2 µm carbon hole. (Electron Microscopy 
Sciences, Hatfield, PA, USA). Grids were robotically vitrified in liquid ethane using a 
Vitrobot (FEI Company). Prior to imaging, the vitrified grid is transferred and stored 
in liquid nitrogen. Imaging was performed in a liquid nitrogen cooled stage (Model 
915, Gatan Inc., Pleasonton, CA) at 200 kV using a JEOL JEM-2100F TEM 
(Peabody, MA). DPPC liposome and D-LNA size analysis was performed using 
ImageJ software [31]. The average diameters and standard deviations reported were 
based on 92 randomly selected liposomes or D-LNAs. 
 
 Results and Discussion 
D-LNAs were prepared with two different size fractions of gold nanoparticles; 
fraction GNP2 had an average diameter ± S.D. of 1.99 ± 0.5 nm (Figure 4-2A) and 
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fraction GNP4 had an average diameter ± S.D. of 4.01 ± 0.8 nm (Figure 4-2B). The 
nanoparticles were loaded into the liposomal bilayers at lipid:nanoparticle (L:N) ratios 
of 25,000:1, 10,000:1, and 5,000:1. GNP concentrations and calculated volume 
fractions within the D-LNAs are provided in Table 4-1. 
DPPC liposomes and D-LNAs were characterized by cryo-TEM (Figure 4-3). 
DPPC liposomes were primarily spherical unilamellar structures with an average 
diameter of 101 ± 45 nm (Figure 4-3A) D-LNAs formed with GNP2 and GNP4 had 
average diameters of 56 ± 21 nm (Figure 4-3B, C) and 69 ± 36 nm (Figures 4-3D, E, 
F1, and F2), respectively. In addition to reducing the liposome diameter, GNP loading 
led to less spherical structures with faceted edges and thicker bilayers. GNP4 yielded 
liposomes containing nanoparticle clusters within the bilayers; this likely also 
occurred for GNP2 based on previous work, however, we could not confirm this. It 
should be noted that direct evidence of nanoparticle loading was difficult to obtain at 
the high L:N ratios used. As demonstrated by recent D-LNA studies, nanoparticle 
loading can be more easily observed at significantly lower L:N ratios or higher 
nanoparticle concentrations.9, 10, 16, 22, 25, 26, 28 Furthermore, the structures were 
heterogeneous, with some D-LNAs containing GNP clusters that are clearly visible 
(Figure 4-3D, F1-F2) and others were GNPs were not directly observed. There were 
also ‘darker’ D-LNAs that suggest they were loaded with GNPs, but the individual 
GNPs could not be resolved. We believe that the difficulty in identifying bilayer-
embedded GNPs stems in part from the limitations experienced during cryo-TEM 
imaging. This is depicted in Figure 4-3F1-F2 where a D-LNA with a ‘dark spot’ is 
observed, but only when the TEM is over-focused do we see that this spot is 
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comprised of a GNP cluster. This does not mean that all structures in the D-LNA 
samples contained embedded GNPs – it is likely that there were also ‘empty’ 
liposomes present. Additional TEM work is needed to confirm these assertions. 
 
Figure 4-2. TEM Images of GNPs. 
(A) GNP2 had an average diameter ± S.D. of 1.99 ± 0.5 nm and (B) GNP4 had an 
average diameter ± S.D. of 4.01 ± 0.8 nm. 
 
 
Table 4-1. Concentration and volume fraction of GNPs loaded into D-LNAs. 
GNP fraction L:N 
Concentration GNP Volume Fractiona 
(mg/ml) (mM) Gelb Fluidc 
GNP2 
(1.99 ± 0.5 nm) 
25,000:1 0.02 0.10 0.4 ± 0.1% 0.4 ± 0.1% 
10,000:1 0.05 0.25 1.1 ± 0.3% 1.0 ± 0.3% 
5,000:1 0.10 0.50 2.2 ± 0.6% 2.0 ± 0.6% 
GNP4 
(4.01 ± 0.8 nm) 
25,000:1 0.16 0.8 1.1 ± 0.4% 1.0 ± 0.4% 
10,000:1 0.40 2.0 2.8 ± 1.0% 2.5 ± 0.9% 
5,000:1 0.79 4.0 5.6 ± 2.0% 5.1 ± 1.8% 
aBased on nanoparticle diameter with 1.8 nm (fully extended) DDT ligands32. 
bVolume fraction in the hydrocarbon acyl region of gel phase DPPC bilayers (825 
Å3/lipid)33.  
cVolume fraction in the hydrocarbon acyl region of fluid phase DPPC bilayers (913 
Å3/lipid)33.  
 A                                                        
  
B                                                        
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Figure 4-3. Representative Cryo-TEM micrographs.  
(A) DPPC liposomes, (B-C) D-LNAs prepared with GNP2, and (D-F) D-LNAs 
prepared with GNP4. The L:N ratio is shown on each micrograph. (F1-F2) are 
micrographs of the same region with different focus, which was able to identify the 
individual GNPs that comprised the GNP aggregate contained within the D-LNA 
bilayer. White arrows identify the location of embedded nanoparticles that can be 
viewed directly. 
 
Additional analyses were performed on D-LNAs prepared with GNP4 at a 
higher L:N ratio of 1,000:1 to confirm that GNPs were loaded into the bilayers. CF 
leakage was not examined at this higher L:N ratio. D-LNAs loaded with GNPs were 
easily visible by cryo-TEM analysis (Figure 4-4A1, B1). Magnified images of D-
LNAs with slight over-focusing revealed that the GNPs were disordered within the 
bilayers (Figure 4-4A2, B2). FE-SEM analysis with EDS confirmed that the structures 
were loaded with GNPs (Figure 4-4C1, C2). In this case gold is concentrated where D-
LNAs are observed.  
 166 
 
 
 
Figure 4-4. Representative Cryo-TEM and FE-SEM of GNP4 D-LNAs at 
Lipid:Nanoparticle Ratio of 1000:1. 
Cryo-TEM (A, B) and FE-SEM (C1) micrographs of D-LNAs prepared with GNP4 at 
L:N = 1,000:1. Magnified and over-focused regions from A1 and B1 are shown in A2 
and B2, respectively. (C2) EDS map of gold obtained from image C1. 
 
 Carboxyfluoroscein (CF) leakage from DPPC liposomes and D-LNAs was 
measured in triplicate as a function of temperature from 26 oC to 47 oC. This 
temperature range spanned the pretransition (Tp = 34.4 oC ) and melting temperatures 
(Tm = 41.3 oC ) of DPPC34. DPPC liposomes showed increases in CF leakage between 
32 oC and 36 oC, corresponding to the gel to rippled gel pretransition, (Lβ  Pβ’), and 
between 38 oC and 41 oC, corresponding to the rippled gel to fluid or melting 
transition (Pβ’  Lα) (Figure 4-5). The CF leakage behavior reflects the two bilayer 
phase transitions that occur within the temperature range examined. Comparatively 
little change in CF leakage was observed when the liposomes were in their gel (< 32 
oC) or fluid (> 41 oC) phases, consistent with previous studies.35 
100 nm
20 nm
100 nm
20 nm
A2
A1 B1
B2
1 μm
C1
C2
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CF leakage from D-LNAs prepared with GNP2 exhibited a ‘temperature lag’ 
where leakage shifted to higher temperatures and the total amount of CF leakage at 47 
°C reduced by roughly 50% when compared to DPPC (Figure 4-5A). CF leakage 
increased between 35 oC and 42 oC, after which a modest linear increase in CF leakage 
was observed above 41 oC (< 5%, Figure 4-5A). There was no clear trend between the 
CF leakage and GNP2 loading (L:N).  
D-LNAs prepared with GNP4 exhibited different CF leakage behavior 
compared to GNP2. At the two lower GNP loadings (L:N = 25,000:1 and 10,000:1), 
increases in CF leakage were observed between 34 oC and 36 oC, and between 39 oC 
and 42 oC (Figure 4-5B). The ‘temperature lag’ for CF leakage was reduced with the 
larger GNPs (compared to GNP2) and the leakage behavior reflected the phase 
transitions that were observed for DPPC, though the absolute leakage was not as large. 
At L:N = 5,000:1 there was no ‘temperature lag’ and CF leakage increased linearly 
from 26 oC to 40 oC, with no additional leakage above 43 oC. Based on the CF leakage 
behavior, GNP2 had a greater effect on stabilizing the bilayer and reducing bilayer 
permeability compared to GNP4. This is consistent with the ability of liposome 
bilayers to accommodate smaller nanoparticles. 
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Figure 4-5. Percentage of carboxyfluorecein (CF) leakage as a function of 
temperature. 
DPPC liposomes and D-LNAs prepared with nanoparticle fractions (A) GNP2 and (B) 
GNP4. The symbols and error bars correspond to the average ± S.D. 
 
Results from CF leakage suggest that the leakage behavior is dependent upon 
bilayer phase behavior and the degree to which this changes in the presence of the 
GNPs. To examine this more closely, the derivative of CF leakage as a function of 
temperature was calculated numerically based on ΔCF leakage/ΔT to determine the 
temperatures associated within maximum and minimum changes in CF leakage, and to 
directly compare changes in CF leakage with D-LNA phase behavior determined by 
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DSC. DSC results are summarized in Table 4-2. The The pretransition and melting 
transition appear as peaks in the excess heat capacity (Cp, Figure 4-6).33, 34, 36 
 
Table 4-2. DPPC and D-LNA lipid phase behavior and CF leakage temperatures. 
GNP 
Fraction 
L:N Tp(°C)a Tm, on(°C)b T(°C)a TCF(°C)c ΔT1/2(°C)d 
DPPC  35.8 40.4 41.1 34.5, 39.5 0.9 
GNP2b 
25,000:1 35.9 40.6 41.1 40.5 0.9 
10,000:1 36.0 40.7 41.2 40.5 0.9 
5,000:1 36.3 40.6 41.2 35.5, 38.5 1.0 
GNP4b 
25,000:1 35.6e 39.4 40.8 32.5, 40.5 1.6 
10,000:1 35.6e 39.1 40.6 33.5, 38.5 1.8 
5,000:1 -e 40.2 41.5 31.5, 37.5 1.5 
aTp and Tm correspond to maximum Cp.  
bThe melting onset temperature (Tm, on) is the temperature at which the rippled gel to 
fluid main transition begins.  
cTCF is the temperature corresponding to maxima (peaks) in the ΔCF leakage/ΔT 
results. Dual peaks reflecting Tp and Tm are shown, where applicable, and the greater 
of the 2 peaks are boldfaced. 
dΔT1/2 is the width of the main transition curve at half height of the peak.  
ePretransition peak merged with melting transition peak. For L:N = 5,000:1 the 
pretransition was not observed.  
 
DPPC liposomes exhibited maximum changes in CF leakage at temperatures 
corresponding to the (Lβ  Pβ’) pretransition (exothermic peak at 35.7 oC) and the (Pβ’ 
 Lα) melting transition (exothermic peak at 41.1 oC), (Figure 4-6). There is 
remarkable agreement between the peaks for ΔCF leakage/ΔT and for Cp associated 
with the pretransition and melting transition. When the pretransition peak emerged 
between 30-31 oC, the large ΔCF leakage/ΔT peak also emerged. When this peak 
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plateaued between 37-38 oC the ΔCF leakage/ΔT peak also plateaued. This same trend 
was found for the melting transition. Gel phase lipids are ordered with fully extended 
acyl tails in the trans conformation, whereas fluid phase lipids are disordered in the 
gauche conformation and exhibit a thinner bilayer.33 The rippled gel phase, while not 
completely understood, is defined as a gel phase lipid bilayer with periodic domains of 
fluid phase lipids. The bilayer ripples are caused by the differences in gel and fluid 
phase bilayer thickness and hydration.36, 37 Changes in CF leakage are greatest during 
these transitions because they represent co-existing phase domains within the bilayers 
where transient leakage is high at the interface between the domains. Our results show 
that the change in CF leakage is greatest during the pretransition where Lβ  Pβ’ 
phases coexist.  
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Figure 4-6. Change in CF leakage over change in time and excess heating 
capacity as a function of temperature.  
Change in CF leakage over the change in temperature (ΔCF leakage/ΔT, □) and excess 
heat capacity (Cp, solid line, -) for DPPC (A), GNP2 DLNAs (B1, C1, and D1), and 
GNP4 DLNAs (B2, C2, and D2) at different lipid to nanoparticle ratios (L:N). For 
ΔCF leakage/ΔT, The vertical dashed lines correspond to the pretransition (Tp) and 
melting (Tm) temperatures for DPPC liposomes. For the ΔCF leakage/ΔT graphs, the 
symbols and error bars correspond to the average ± S.D. 
  
0 
10 
20 
30 
40 
50 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
25 30 35 40 45 
C
p
 (
K
J
/m
o
l 
o
C
) 
Δ
C
F
 L
e
a
k
a
g
e
/Δ
T
 
Temperature (oC) 
Large NPs 25,000:1 
0 
10 
20 
30 
40 
50 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
25 30 35 40 45 
C
p
 (
K
J
/m
o
l 
o
C
) 
Δ
C
F
 L
e
a
k
a
g
e
/Δ
T
 
Temperature (oC) 
Large NPs 10,000:1 
0 
10 
20 
30 
40 
50 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
25 30 35 40 45 
C
p
 (
K
J
/m
o
l 
o
C
 )
 
Δ
C
F
 L
e
a
k
a
g
e
/Δ
T
 
Temperature (oC) 
Large NPs 5,000:1 
B2
C2
D2
L:N = 25,000:1
L:N = 10,000:1
L:N = 5,000:1
0 
10 
20 
30 
40 
50 
60 
70 
80 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
25 30 35 40 45 
C
p
 (
K
J
/m
o
l 
o
C
) 
Δ
C
F
 L
e
a
k
a
g
e
/Δ
T
 
Temperature (oC) 
DPPC PP
0 
10 
20 
30 
40 
50 
60 
70 
80 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
25 30 35 40 45 
C
p
 (
K
J
/m
o
l 
o
C
) 
Δ
C
F
 L
e
a
k
a
g
e
/Δ
T
 
Temperature (oC) 
L:N = 25,000:1
0 
10 
20 
30 
40 
50 
60 
70 
80 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
25 30 35 40 45 
C
p
 (
K
J
/m
o
l 
o
C
) 
Δ
C
F
 L
e
a
k
a
g
e
/Δ
T
 
Temperature (oC) 
L:N = 10,000:1
0 
10 
20 
30 
40 
50 
60 
70 
80 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
25 30 35 40 45 
C
p
 (
K
J
/m
o
l 
o
C
) 
Δ
C
F
 L
e
a
k
a
g
e
/Δ
T
 
Temperature (oC) 
Small AuNPs 5,000:1 L:N = 5,000:1
A
B1
C1
D1
 172 
 
 
D-LNAs formed with GNP2 do not exhibit pretransition or melting 
temperatures that are significantly different than that of DPPC based on the position of 
the peaks (Figure 4-6B1, C1, and D1, Table 4-2). However, the changes in CF leakage 
measured for the D-LNAs are considerably different. For DPPC, the greatest change 
in CF leakage occurred during the pretransition. In comparison, the change in CF 
leakage for the D-LNAs corresponding to the pretransition was much smaller, and the 
change in CF leakage corresponding to melting was larger. The effects of GNP 
loading on the bilayer phase transitions and associated CF leakage is more pronounced 
when D-LNAs were prepared with GNP4, though the behavior is different than that 
for GNP2. In this case, changes in CF leakage are observed at temperatures 
corresponding to the pretransition despite the fact that increasing GNP4 loading 
reduced or eliminated this transition (Figure 6B2, C2, and D2). The change in CF 
leakage was shifted to lower temperatures and at the highest GNP4 loading (L:N = 
5,000:1) significant CF leakage occurs between 26 oC and 38 oC. 
GNP4 loading also had a much larger effect on the interaction of bilayer lipids 
during main phase transition based on ΔT1/2 (Table 4-2). ΔT1/2 is the width of the main 
transition curve at half the height of the peak. This parameter relates to the 
cooperativity of neighboring lipids when undergoing the rippled gel to fluid phase 
transition 38. For a first-order lipid phase transition, the peak theoretically should be 
infinitely sharp because all the lipids would undergo the phase transition as a single 
unit. Broadening of the main transition peak is caused by the occurrence of lipids in 
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multiple melting domains and phase states39, 40  For GNP2, only at L:N = 5,000:1 can 
a change in ΔT1/2 be observed. Loading of GNP4 showed a 68-93% change in ΔT1/2.    
Analyzing the CF leakage results in Figures 4-5 and 4-6 suggests that the 
GNPs influence the thermal release behavior (bilayer permeability) by hindering or 
altering the bilayer phase behavior. Cryo-TEM results further show that the GNPs 
alter the D-LNA size and shape, relative to DPPC liposomes, which would also 
influence the release behavior (i.e. CF leakage represents a mass flowrate after time t, 
which is proportional to permeability × surface area). This depicts an exciting yet 
complicated relationship between bilayer permeability and D-LNA structure, where 
GNP size and loading could be used to control the release behavior in a temperature-
dependent way. What is most striking is that the changes in CF leakage and lipid 
phase behavior occurred at such low volume fractions of GNPs within the bilayer 
(Table 4-1). Multiple mechanisms could be at work including (i) changes in lipid 
phase behavior and stabilization or destabilization of lipid phase domains during phase 
transitions (inferred by this and previous work);8, 15, 20, 41, 42 (ii) changes in bilayer 
structure and mechanics such as thickness and elasticity, respectively;9, 15-17, 19; and 
(iii) changes in liposome size and structure, (also inferred by this and previous work) 
and the formation of non-bilayer structures.8 These mechanisms are interrelated and 
likely occur simultaneously, necessitating additional work to determine the how these 
mechanisms contribute to the release behavior. 
Additional insight can be gained by considering molecules that partition into 
lipid bilayers and are known to influence lipid organization, which in turn influences 
inter-lipid interactions that drive phase transitions and the kinetics associated with 
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these transitions. The characteristic time of a pretransition has been reported as 5 ± 2 
min.43 With a DSC scan rate of 1 oC min-1, results for DPPC show that the 
pretransition peak present over a 3 oC temperature range is consistent with this 
characteristic time. In addition to GNPs disrupting lipid organization, either locally or 
globally within the bilayer, the GNPs would also exhibit low translational diffusion 
times within the bilayers that would impact the kinetics associated with lipid re-
organization. This was apparent during the D-LNA pretransitions, where they were 
suppressed or merged with the melting transition at higher temperatures, and the 
greatest for GNP3-4 which occupy more space within the bilayer and are less mobile 
than GNP2. Given that CF leakage is greatest at the interface between phase domains, 
the net effect of inhibiting or delaying a phase transition would be lower CF leakage or 
an apparent temperature lag.  
 
 Conclusions 
 As shown for the GNP D-LNAs, the permeability and phase behavior of 
liposomes can be manipulated by the size and concentration of embedded 
nanoparticles at low volume fractions within the bilayers.  A lipid bilayer is 
approximately 4-5 nm thick, and nanoparticles that were smaller than the bilayer 
thickness (GNP2) affected the bilayer differently than nanoparticles that were closer to 
the bilayer thickness (GNP4). GNP2 caused the pretransition and main transition to 
merge while maintaining similar phase transition temperatures observed for DPPC 
liposomes. Unlike DPPC liposomes, which exhibited the greatest leakage at the 
pretransition temperature, the merger of pretransition and main transition caused by 
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GNP2 corresponded to the merger of the thermal leakage curves associated with these 
transitions. These smaller nanoparticles demonstrated the ability to reduce 
spontaneous leakage at lower temperatures by providing greater bilayer stability. In 
contrast, GNP4 suppressed the pretransition while broadening the main transition, and 
maximum leakage was observed near the pretransition temperature or at lower 
temperatures. These findings demonstrate that liposome leakage and stability can be 
manipulated by the size of embedded nanoparticles even at low loadings. Thus, 
embedded nanoparticles can be used to engineer D-LNAs with desired release 
characteristics for therapeutic applications. The nanoparticles also influence the 
thermal leakage behavior, allowing temperature to be used as a triggered release 
mechanism. Understanding how nanoparticles effect the behavior of lipid bilayers is 
important to the development of new multifunctional drug delivery vehicles from lipid 
nanoparticle assemblies.    
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 Abstract 
 The development of multifunctional bionanotheranostic devices are the 
pinnacle of biomedical research and represent a major step towards the development 
of personalized medicine. Here, lipid coated magnetic nanoparticles (LMNPs) were 
created by coating iron oxide nanoparticles with a PEG (2000 MW) and cationic lipid 
using a dual solvent exchange (DSE) method. LMNPs were created with 0-100 mol% 
PEG and their structure, zeta potential (ζ), MRI r2 relaxivity, binding and release 
siRNA, and heating when subjected to an electromagnetic field (EMF). Based on size 
and ζ, it was confirmed that the DSE method could control the surface composition of 
lipids. PEG surface density and conformation was shown to have an effect on the 
characteristics of LMNPs. MRI r2 relaxivity could be controlled by the surface 
composition of PEG. The greater the PEG surface composition the greater the r2 
relaxivity. LMNPs were also shown to be able to bind siRNA. Release of siRNA 
could be triggered by temperature or when subjected to EMF. The LMNPs developed 
are bionanotheranostic devices combining the enhancement of MRI r2 relaxivities, 
triggered siRNA release, and hyperthermia.  
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Bionanotheranostics (BNT) involves the application of biology and 
nanotechnology to develop platforms with theranostic (dual therapeutic and diagnostic 
functions) capabilities. Superparamagnetic iron oxide nanoparticles (SPIONSs) are 
well established for biomedical applications and provide an attractive platform for 
designing such multifunctional BNTs. The magnetic properties of SPIONs allow them 
to be used as an MRI contrast enhancement agent and for magnetic targeting. Also, 
SPIONs generate heat when subjected to an external alternating magnetic field, which 
can be used for hyperthermia and for triggered release from the surface.1 In addition to 
providing colloidal stability, minimizing clearance in vivo, and achieving cellular 
targeting, the ability to control the surface composition and chemistry can impart the 
SPION with additional capabilities, such as drug and oligonucleotide delivery where 
these molecules can be incorporated within or adsorbed to the coating.1 
Polyethylene glycol (PEG) is a hydrophilic biocompatible polymer commonly 
used to improve the blood circulation half-life, surface hydrophilicity, and reduce 
cytotoxicity of nanoparticles.2-5 PEG is the most heavily studied surface modifying 
polymer for improving the efficiency and effectiveness of therapeutics. PEG has the 
ability to make a particle “stealth”, improving its pharmacokinetics by reducing 
mononuclear phagocyte (immune) system uptake.6 However, there is no consensus as 
to what the optimum PEG coverage-density, conformation, and molecular weight to 
prevent necessary to prevent uptake by the immune system.3, 7, 8 PEG has been used 
for numerous clinical applications, including drug delivery, therapeutic targeting, 
reducing toxicity, preventing uptake by the immune system, and improving circulation 
in the blood by preventing clearance. PEG has also been used to in conjunction with 
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SPIONs for the development BNTs. PEG and SPIONs have been particularly 
interesting in the development of diagnostics, demonstrating the ability to enhance the 
MRI signals. SPION MRI signal is heavily influenced by both the thickness and the 
chemical composition of the SPION surface coating and its effect on the diffusivity of 
water. The SPION magnetic moment influence the magnetic dipole relaxation of water 
held in close proximity to the SPION surface by hydrophilic coatings, such as PEG. 
Relaxivity increases because PEG influences neighboring water molecules by surface 
exclusion, hindering diffusion, and hydrogen bond immobilization.9, 10 Therefore, 
functionalizing with polyethylene glycol (PEG) is an obvious route to achieve the 
hydration shell needed for negative MRI contrast agent. Nanoparticle PEGylation has 
also been shown to inhibit protein adsorption and recognition by the immune system, 
improving the pharmacokinetics and cytotoxicity of nanoparticles.3-5 This work 
provides insight into selecting PEGylation strategies to optimize negative contrast for 
MRI imaging.  
This research extends the concept of surface coating engineering of SPIONs to 
lipid-coated magnetic nanoparticles (LMNPs) with different compositions of cationic 
and PEG-lipids designed for combined MRI contrast enhancement, hyperthermia, and 
delivery of small interfering ribonucleic acid (siRNA). Cationic DOTAP (1,2-
dioleoyl-3-trimethylammonium-propane) lipid electrostatically interacts with the 
negatively charged phosphate backbone of nucleic acids, enabling siRNA to be bound 
to the surface of the LMNPs.5, 11-13 LMNPs were formed with surface lipids 
compositions of methoxy-terminated PEG2000 anchored to a DMPE lipid (1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] 
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(2000 MW)) and the balance of the lipid surface composition comprised of DOTAP. 
Hereinafter, LMNP samples will be identified by the surface lipid mol% of PEG2000. 
We systematically examined the effect of the surface PEG concentration on 
physicochemical properties of LMNPs, the transverse magnetic relaxivity (r2), and the 
siRNA binding capacity. These properties are directly related to PEG-lipid 
concentration and PEG conformation on the LMNP surface. Furthermore, we present 
results demonstrating that PEG conformation also influences the release of siRNA due 
to temperature or in the presence of an alternating electromagnetic field where heat is 
provided by the SPIONs.  
Monodispersed LMNPs were formed using a dual solvent exchange (DSE) 
method to control the lipid surface composition.14 DSE induces the adsorption of 
lipids onto the hydrophobic SPION surface by changing the polarity of the suspending 
solvents rendering water soluble LMNPs. LMNPs were formed by coating 
hydrophobic (oleic acid-coated) SPIONs with cationic DOTAP and/or PEG-DMPE 
(DMPE modified with a PEG-terminated headgroup). DSE involves initially mixing 
SPIONs and lipids at the desired composition in chloroform. In the first solvent 
exchange, chloroform is replaced with dimethyl sulfoxide (DMSO), a solvent miscible 
in both chloroform and water, by rotary evaporation. This exchange induces the 
hydrophobic tail of DOTAP and PEG-DMPE lipids to assemble on the hydrophobic 
SPION surface. The second solvent exchange involves replacing DMSO with water by 
ultracentrifugation, further adhering the lipids to the SPION surface, rendering water 
soluble LMNPs.14  
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Figure 5-1. Schematic of LMNP.  
LMNP consisting of an iron oxide core, a hydrophobic oleic acid coating (red), a lipid 
monolayer (green), and PEG layer (blue). 
 
LMNPs are comprised of 4 layers: (1) iron oxide core, (2) hydrophobic oleic 
acid coating, (3) lipid monolayer, and (4) PEG layer (Figure 5-1). A SPION core is 
coated with oleic acid making it hydrophobic. A lipid monolayer forms on the surface 
by hydrophobic interaction between the lipid tails of DOTAP and PEG-DMPE and 
oleic acid. The hydrophilic DOTAP and PEG-DMPE lipid heads faces away from the 
surface making the LMNPs water soluble. Finally, PEG chains attached to the DMPE 
lipid head extend away from the monolayer forming a water permeable layer.  
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Figure 5-2. (a) LMNP Measured Hydrodynamic Diameter and ζ, (b) Predicted 
PEG Length and Polymer Conformation, (c) Schematic and cryogenic 
transmission electron microscope images of LMNPs.  
(a) Hydrodynamic diameter and ζ versus LMNP surface mol% of PEG2000 (average ± 
S.D.) (b) Theoretical Flory radius, PEG2000 length, and PEG2000 conformation as a 
function LMNP surface mol% of PEG2000. (c) Schematic and cryogenic transmission 
electron microscope (Cryo-TEM) images of LMNPs with 0, 15, and 50 mol% PEG2000 
surface concentration.  
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Table 5-1 Parameters used for calculation of Flory radius, PEG footprint, 
distance between PEG groups, area occupied by PEG, PEG chain length, and 
LMNP diameter. 
Parameter Definition Value Units Ref. 
Flory Radius  
a PEG monomer length 0.35 nm  
N 
Number of repeat monomer 
units for PEG2000 
44  
 
RF Flory radius 3.4 nm  
PEG2000 
FP 
Footprint or projected area of a 
single PEG chain on the LMNP 
surface 
36.1 
nm2 per 
PEG 
 
Iron Oxide Nanoparticles 
DSPION Diameter of SPION 28.3 ± 6.8 nm  
SSPION 
Surface area of iron oxide 
nanoparticle 
2516 nm2 
 
Lipids 
TB,DOTAP DOTAP bilayer thickness 4.2 nm  
TB,DMPE DMPE bilayer thickness 3.6 nm  
ADOTAP  Cross-sectional area of DOTAP 0.53 nm2  
ADMPE Cross-sectional area of DMPE 0.52 nm2  
 
The effect of the surface composition of PEG on the LMNPs was assessed by 
measuring the hydrodynamic diameter, DH, and zeta-potential, ζ, using dynamic light 
scattering (DLS). The DH of the SPION core in chloroform was measured to be 28.3 ± 
6.8 nm. The number-weighted mean DH as a function of mol% PEG are shown in 
Figure 5-2(a). Number-weighted mean size from DLS was recorded because for 
surface-modified PEG nanostructures it is the recommended over z-average. For these 
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structures, values calculated based on number distribution have been shown to be 
more comparable to other sizing techniques, specifically TEM.3 
When PEG lipids are added, the length of PEG (and the LMNP’s size) is 
determined by the structural conformation of the PEG polymer chain on the 
nanoparticle surface. PEG most commonly adopts the mushroom, brush, or dense 
brush conformations on a nanoparticle surface at a liquid/solid interface in a good 
solvent. However, if the PEG chain can interact with the nanoparticle surface, it can 
take on rarer conformations, such as pancake or loop (discussed below).  
PEG’s conformation is determined can be determined by 3 parameters: (1) the 
Flory radius which is the mean radius of the hemispherical volume occupied by an 
unperturbed random coil PEG polymer chain (RF), (2) the distance between PEG 
chains (D), and (3) the PEG chain length (L)2, 3. The parameters used for these 
calculations art in Table 5-1. The Flory radius, RF, is calculated as: 
 
 
 𝑅𝐹 = 𝑎𝑁
3 5⁄ = 3.4 𝑛𝑚 (1) 
 
 
where a is the PEG monomer length and N is the number of repeat monomer units 
(parameters for calculations are in Table 5-1).3 The mean distance between PEG 
groups, D, is calculated with the following equation: 
 
 𝐷 = 2√
𝐴𝑃𝐸𝐺
𝜋
 (2) 
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where APEG is the area that a PEG chain occupies. APEG is calculated with the 
following: 
 𝐴𝑃𝐸𝐺 =
𝑆𝑁𝑃
𝑁𝑃𝐸𝐺
 (3) 
 
 
where SNP is the surface area of the iron oxide nanoparticle (2516 nm2) and NPEG is the 
number of PEG on each nanoparticle. NPEG is calculated based upon the mol% PEG2000 
and the cross-sectional area of the acyl lipid tails, ALIPID, of DOTAP and DMPE (the 
PEG anchor lipid).3  
 PEG takes on the mushroom conformation at low PEG density, D > RF and RF 
≥ L.2, 15 In the mushroom regime, PEG chains have a random coil conformation with 
no interaction with adjacent PEG chains. When D ≈ RF, individual PEG chains begin 
to take on the brush conformation. The brush conformation occurs when PEG chains 
are close enough to have some interaction that disrupting the ability of PEG chains to 
retain their mushroom conformation.15 PEG is in the brush conformation when RF < D 
< 2RF. The dense brush conformation occurs at very high PEG densities when there is 
an increased amount of inter-chain interactions and steric repulsion forcing the PEG 
chains further away from the nanoparticle surface. The dense brush conformation 
occurs when D < RF and L < 2RF.3, 15 PEG2000 should be in the mushroom 
conformation below 9 mol% PEG, in the brush conformation from 9 to 70 mol% PEG, 
and in the dense brush conformation at greater than 70 mol% PEG (Figure 5-2(b)) 
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Table 5-2. Calculated PEG length, PEG footprint, and Calculated and Measured 
DLMNP. 
mol% PEG L (nm) FP (nm2) 
DLMNP (nm) 
Calculated  Measured  
0 0 - 32.5 31.7 ± 12.0 
5 3.4 36.1 38.7 29.9 ± 11.1 
15 4.3 57.6 40.5 36.8 ± 10.8 
25 5.1 81.1 42.1 41.2 ± 12.0 
50 6.4 129.1 44.7 39.2 ± 12.0 
75 7.3 169.7 46.6 37.3 ± 11.0 
100 8.1 206.2 48.1 39.1 ± 10.8 
 
The size of the LMNPs was calculated with the following equation: 
 𝐷𝐿𝑀𝑁𝑃 = 2𝐿 + 𝐷𝑁𝑃 + 𝑇𝐵 (4) 
where L is the length of the PEG chain, DNP is the diameter of the iron oxide 
nanoparticle core (28.3 ± 6.8 nm), and TB is the thickness of the lipid bilayer. TB for 
DOTAP and DMPE (the anchor lipid for PEG) is 4.2 nm16 and 3.6 nm17, respectively. 
The calculated L, FP, and DLMNP and the measured DLMNP are recorded in Table 5-2.    
 At 0 mol% PEG, the LMNPs are completely covered with DOTAP. Therefore, 
L = 0 nm and TB was the thickness of DOTAP. The calculated and measured DLMNP 
were 32.5 nm and 31.7 ± 12 nm, respectively.  
PEG2000 should take on the mushroom conformation below 9 mol% PEG. 
When PEG2000 is in the mushroom conformation, LMushroom = RF = 3.4 nm.3 PEG2000 
should take on the mushroom conformation below 9 mol% PEG. Only the 5 mol% 
PEG LMNP sample should be in the mushroom conformation. The calculated DLMNP = 
38.7 nm. The calculated size does fall within the standard deviation of the measured 
size at DH 29.9 ± 11.1 nm.  
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The measured size may be smaller than expected because the PEG chains are 
methoxy-terminated giving them an anionic charge. When polymer chains are not 
repelled from the nanoparticle surface, a special “pancake” conformation has been 
observed.18 PEG lies along its own length on the nanoparticle surface. The PEG length 
in the pancake conformation, Lpancake, is calculated as: 
 
 
𝐿𝑝𝑎𝑛𝑐𝑎𝑘𝑒 =
1
√𝑁
 
 
(5) 
 
 
where, N is the number of repeat monomer units (44).3, 18, 19 For PEG2000, Lpancake is 0.2 
nm. The PEG2000 lipid anchor is DMPE which has a bilayer thickness of 3.6 nm.17 
Therefore, the calculated size 5 mol% PEG LMNPs is 32.2 nm, which is close to the 
measured DH and well within the standard deviation. However, if the PEG chain is 
lying on the nanoparticle surface, the chain may be forcing other lipids to lie parallel 
to the surface. We do not have a way to account for this but it may be the cause of the 
smaller than calculated LMNPs.  
 PEG can also form a loop conformation when the unattached end of the 
polymer chain can absorb to the surface. The methoxy-terminated PEG lipid used here 
provides an anionic charge at the end of the PEG chain that could potentially attach to 
the cationic DOTAP surface forming a loop conformation. However, little research 
has been done on the behavior and characteristics of this conformation and no 
predictive equations to calculate LPEG were available. Despite, this could account for 
the overestimation of DLMNP. 
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PEG chains in the brush conformation should start to appear on LMNPs with 
greater than 9 mol% PEG. Brush layer thickness, Lbrush, is calculated as:  
 𝐿𝑏𝑟𝑢𝑠ℎ =
𝑁𝑎5 3⁄
𝐷2 3⁄
 (6) 
 
At 15 mol% PEG, Lbrush = 4.3 nm and DH = 40.5 nm. Like 5 mol% PEG, the predicted 
DH is larger than the measured DH = 36.8 ± 10.8 nm, but well within the standard 
deviation. The measured DH then plateaus for all samples ≥ 25 mol% PEG around an 
average of 39.2 nm, through the brush (9-70 mol% PEG) and the dense brush (>70 
mol% PEG) conformations. The size plateau that spans both the brush and dense brush 
conformations is likely due to the structural similarities in the brush and dense brush 
regimes. 
In the predicted brush regime, 25-50 mol% PEG have calculated DH of 42.1 
nm and 44.7 nm, respectively, and measured DH are 41.2 ± 12.0 nm and 39.2 ± 12.0 
nm. In the dense brush regime, 75, and 100 mol% PEG LMNPs have calculated DH of 
46.6 nm, and 48.1 nm, respectively, and the measured DH are 37.3 ± 11.0, and 39.1 ± 
10.8, respectively. The calculated PEG length and LMNP diameter consistently 
overestimated the measured length and LMNP diameter. Despite, the calculated 
parameters were relatively accurate being within the measured standard deviation for 
all samples. 
The size of the LMNP was approximately constant from 25-100 mol% PEG. 
This size plateau is likely due to the anionic methoxy-terminated PEG forcing it 
towards the LMNP surface and restricting the PEG chain from extending away from 
the cationic surface charge. The lack of size change is unlikely to be caused by the 
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LMNP surface being saturated with PEG because the ζ continues to change. The 
changing ζ suggests that the PEG concentration does not remain constant. Also, the 
size changes until the PEG conformation transitions from mushroom-to-brush 
suggesting that this behavior is related to the conformation and/or structure of the 
LMNP surface.  
The overestimation of DH is likely due to the fact that the assumptions under 
which this system relies does not perfectly match with the LMNP system. The system 
used to calculate LMNP size assumes that the PEG chains are fixed to the lipid head 
of the PEG lipid, the lipids form a rigid fixed monolayer, the lipids extend away from 
the nanoparticle surface at full height, and the PEG chain does not interact with the 
nanoparticle surface, the PEG does not interdigitate into the LMNP lipid monolayer, 
and the PEG chains do not interact other than being sterically repelled. The accuracy 
of the above calculations relies most heavily on determining PEG surface coverage, 
which is affected by the above assumptions. PEG surface coverage, whether calculated 
as APEG, measured as the surface chain coverage PEG/nm2 (σ), determined from the 
PEG footprint (FP), or by other means, defines the conformation of surface PEG and 
therein how it occupies the surface. The overestimation of L is likely due to the 
assumption that PEG chains remain fixed and their surface anchor point cannot move 
with the PEG chain. Despite, the calculated sizes were all within the measured 
standard deviation and all the calculations were greater than the measured size. 
Also, the calculation of APEG, and therefore L, are based on the assumption that 
the DSE method coats the LMNPs with the lipid ratio as designed. While the ζ results 
and of other researchers with this method 9, 14, 20, appear to validate this assumption, 
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the DSE method has not been used for coating with lipids having significantly 
different structures. For example, Tong et. al.9 only tested the ability to control the 
surface ratios of DSPE-PEG2000 with different functional groups (NH2, COOH, 
maleimide, and non-functionalized). It remains unclear how effectively the DSE 
method can control the surface composition of significantly different structures, such 
as DOTAP and DMPE-mPEG2000 that have significantly different characteristics 
including critical micelle concentration and the presence of a linked polymer chain. 
The issue is further complicated by the ability of PEG2000 to screen the cationic 
DOTAP lipids in close proximity to the nanoparticle surface potentially skewing the ζ 
results. Despite these issues, the purpose of choosing PEG was to see if it could 
protect siRNA attached to the DOTAP close to the nanoparticle surface, similar to 
PEG’s ability to protect structures from the immune system, and further functionalize 
iron oxide nanoparticles for multifunctional bionanotheranostics. The overestimation 
of LMNP size was likely due to an assumption that caused there to be an error in the 
APEG parameter. 
The ζ is a measure of the surface charge of LMNPs.(Figure 5-2(a)). LMNPs 
coated exclusively with DOTAP displayed the greatest ζ = 58.5 ± 7.8 mV, as 
expected. The ζ drops linearly between 5-25 mol% PEG2000 from 37.0-31.2 mV as 
PEG transitions from the mushroom-to-brush conformation. From 25-75 mol% PEG, 
in the brush regime, the ζ drops steeply from 31.2 to -22.2 mV. This drop is likely due 
to the rise in the anionic/cationic charge ratio and electrostatic screening from the PEG 
chains that extend away from the LMNP surface. The ζ plateaus at about -22 mV in 
the dense brush regime (75-100 mol% PEG) when the anionic PEG completely masks 
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the cationic lipid. The ζ is the electrostatic potential at the interface between the shear 
plane (where oppositely charged ions are bound) and the bulk solution. PEG can 
influence the ζ by displacing counter-ions, shifting the shear plane, and/or providing 
additional charge to the surface.21 The ζ changes with the distance away from the 
nanoparticle surface according to the following equation: 
 
 ln 𝜁(𝐿) = ln 𝐴 − 𝜅L (7) 
 
where L is the position of the shear plans, A is the surface potential, and κ is the 
inverse Debye length.3, 22 Therefore, as the PEG surface density and/or distance away 
from the surface of the charged particle increases, the LMNP ζ decreases.23-26    
Surface charge can be tuned by changing the LMNP lipid surface composition, 
as can be seen in Figure 5-2(a). The recorded ζ confirms that the lipid surface 
composition can be manipulated with the DSE method. Other groups have similarly 
demonstrated that the ζ of a nanoparticle can be manipulated by changing the 
concentration of differently charged surface lipids.27 The ability to control surface 
charge with DSE is important to making LMNPs capable of MRI contrast 
enhancement and siRNA delivery.  
Cryo-TEM images of LMNPs with 0, 15, and 50 mol% PEG-lipid are 
displayed in Figure 5-2(c). No structures can be seen on the surface of the DOTAP (0 
mol% PEG) LMNPs. In contrast, globule-like PEG structures can be seen in the 15 
and 50 mol% images extending from the LMNP surface. The 50 mol% images show a 
higher density of PEG structures than 15 mol%. PEG brush conformations are 
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observed for 50 mol% consistent with previous cryo-TEM observations for PEG 
brushes on block copolymer micelles.28  
The ability to control the surface composition with the DSE method allows the 
benefits of PEGylation to be applied to SPIONs to form multifunctional LMNPs. 
Along with PEG’s ability to improve circulation half-life, biodistribution, efficacy, 
and safety, it also has been shown to improve the r2 relaxivity allowing it to be used as 
a negative MRI contrast agent. Increasing concentrations of surface PEG has been 
show to increase the r2 relaxivitiy by thickening the hydration shell around the 
LMNPs.9, 10 The effect of surface PEG concentration on r2 relaxivity of LMNPs is 
displayed in Figure 5-3(a).  
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Figure 5-3. (a) Concentration of bound siRNA and r2 relaxivity and (b) percent of 
bound siRNA to LMNPs as a function of temperature. 
(a) Concentration of bound siRNA and r2 relaxivity as a function of temperature 
(average ± S.D.). (b) Percent of Bound siRNA to LMNPs as a Function of 
Temperature (average ± S.D.) 
 
The negatively charged phosphate backbone of siRNA electrostatically binds 
to the cationic charge provided by the DOTAP on the LMNP surface. The amount of 
siRNA that is bound to the LMNP surface was measured by a fluorescent quenching 
assay. The siRNA is labeled with a carboxyfluorescein (CF) fluorescent probe that 
self-quenches at concentrations greater than 30 µM.29 siRNA was shown to self-
quench in the presence of LMNPs causing the fluorescent signal to fall. Figure 5-3(a) 
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displays the effect of different siRNA concentrations on LMNPs. The trend in the 
amount of bound siRNA is likely caused by both the LMNPs being more cationic at 
lower mol% PEG and the structural conformation of PEG. At lower PEG 
concentrations, the ζ is more cationic and there are less PEG chains to obstruct siRNA 
from bindng to the LMNP surface. Therefore, more siRNA could attach to the surface 
at lower mol% PEG, but it attachment does not strictly follow ζ. 
The amount of siRNA bound to the LMNP surface was dependent on PEG 
conformation and temperature, as shown in Figure 5-3(b). In the mushroom 
conformation (0-15 mol% PEG), more siRNA was able to bind to the LMNP, due to 
the hightened ζ. PEG becomes more hydrophobic with increasing temperature causing 
the PEG to collapse and potentially interdigitate with the lipid monolayer.30 Therefore, 
in the mushroom conformation, as the temperature rises more cationic charges may be 
available for siRNA to bind to the LMNP due to the change in PEG as temperature 
increases. For the brush conformation (>15 mol% PEG), the percent of bound siRNA 
also decreases with increasing temperature. Under these conditions, the temperature 
causes the PEG to become more hydrophobic, expelling siRNA from the surface. 
These results indicate that LMNPs can be used for the controlled release of siRNA.       
LMNPs also can generate heat when subjected to alternating current 
electromagnetic field operating at radio frequency (RF), allowing them to be used for 
hyperthermia and/or triggered siRNA release. RF heating was performed using a 1 kW 
Hotshot™ set to 300 A (actual output ~227-235A and 362 kHz) for 30 min. The 
change in temperature from the recorded room temperature was recorded and is 
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displayed in Figure 4(a). The heating capacity of nanoparticles in an RF is measured 
by the specific absorption rate (SAR): 
 
 𝑆𝐴𝑅 =
∆𝑇
∆𝑡
𝑐𝑝𝑚𝑉
𝑚𝑆𝑃𝐼𝑂𝑁
 (8) 
 
where cp is the average heat capacity of the sample, in this instance water (C = 4.18 
J/g K), mV is the mass of the sample volume, and mSPION is the mass of the SPIONs. 
∆𝑇
∆𝑡
 
was calculated based on the initial slope of the heating curve. SAR for 15 and 50 
mol% PEG LMNPs were subjected were 52.8 W g-1 and 11.2 W g-1, respectively. This 
ability to heat when subjected to RF  
 The percent of siRNA released from the LMNP surface when subjected to RF 
heating is shown in Figure 5-4(b). The heating generated by the LMNPs caused the 
siRNA to release from the surface. At 50 mol% PEG, the LMNPs release siRNA when 
subjected to RF heating. At 15 mol% PEG, the LMNPs cause more siRNA to bind to 
the surface when subjected to RF heating, causing the percent of siRNA released to be 
negative. However, surprisingly, after ~23 min percent siRNA released begins to 
increase. Currently, it is unclear what mechanism causes this to happen. 
 In conclusion, LMNPs was created capable of being used as an MRI contrast 
agent and a temperature triggered siRNA delivery vehicle. LMNPs were coated with 
different compositions of cationic DOTAP and a methoxy-terminated PEG2000 
anchored to a DMPE lipid. The surface composition of LMNPs were controlled by a 
DSE method. LMNPs were shown to be multifunctional capable of increased MRI 
contrast and siRNA delivery. The MRI r2 relaxivity increased with increasing surface 
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PEG concentration. LMNPs also demonstrated the ability to bind and release siRNA. 
Release of siRNA was shown to be triggered by temperature and RF heating. 
   
 
Figure 5-4. (a) Change in Bulk Sample Temperature over RF Heating Time and 
(b) Percent siRNA Release over RF Heating Time. 
(a) Change in temperature from baseline temperature (~26 °C) over 30 min. when 
subjected to RF heating set to 300 A (actual output ~226.8-235.4 A) and 362 kHz. (b) 
Percent in bound siRNA over 30 min when subjected to RF heating set to 300 A 
(actual output ~226.8-235.4 A) and 362 kHz. 
 
 Supporting Information  
Chemicals and Materials and Experimental Sections.  
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The Experimental Section contains the following sections: Lipid Coated 
Magnetic Nanoparticle (LMNP) Formation, Lipid Coated Magnetic Nanoparticle 
(LMNP) Formation, Dynamic Light Scattering (DLS), Heating with Alternating 
Current Electromagnetic Field (AC EMF) at Radio Frequency (RF), Small Interfering 
RNA (siRNA) Experiments, and Magnetic Resonance Imaging (MRI). 
The Small Interfering RNA (siRNA) Experiments contains the following 
subsections: siRNA Binding, siRNA Release with Temperature, and siRNA RF 
Release. 
The Magnetic Resonance Imaging (MRI) section contains the following 
subsections: MRI Sample Preparation and MRI Methods for r2 Relaxation. 
 
 Chemicals and Materials 
1,2-stearoyl-3-trimethylammonium-propane (DOTAP; 25 mg/mL), 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(DMPE-PEG2000;25 mg/mL), and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-
N-(lissamine rhodamine B sulfonyl) (rhodamine;1 mg/mL) lipids were purchased from 
Avanti Polar Lipids (Alabaster, AL USA). Oleic acid coated 30 nm superparamagnetic 
iron oxide nanoparticles were purc)hased from Ocean NanoTech (San Diego, CA 
USA). DMSO, agarose, 10X Tris-borate-EDTA (TBE) buffer, fetal bovine serum 
(FBS), Opti-MEM Reduced Serum Media, Dulbecco's Modified Eagle Medium 
(DMEM), and Vivaspin 2 100kDa MWCO Sample Concentrators from GE Health 
were purchased from Fisher Scientific (Suwanee, GA USA). FAM-labeled Negative 
Control siRNA (21 base pairs) was purchased from Shanghai GenePharma Co., Ltd. 
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(Shanghai, China). Opti-MEM, DMEM, and FBS were purchased from Sterile 
deionized ultrafiltered (DI) water at 18.2 mΩ was used from a Millipore Direct-Q3 
UV purification system (Billerica, MA USA).  
 
 Experimental Section 
4.1 Lipid Coated Magnetic Nanoparticle (LMNP) Formation 
LMNPs were formed with a weight ratio of 32/1 lipid/Fe with a dual solvent 
exchange method derived from Tong, et. al.14 LMNPs with mole ratios of 100/0, 95/5, 
85/15, 75/25, 50/50, 25/75, and 0/100 DOTAP/PEG and nanoparticles in chloroform 
were mixed together at desired concentrations in a round bottom flask. For rhodamine 
labeled LMNPs, rhodamine lipid was also added at a concentration of 0.6 mol% of 
total lipids. DMSO, equal to 4 times the volume of chloroform, was then added to the 
flask in 50 µL aliquots while sonicating in a 40 kHz Branson Ultrasonics 1510 
ultrasonic cleaner (Danbury, CT USA). The flask was them placed in a New 
Brunswick Scientific Excella E1 Platform Shaker (Enfield, CT USA) at a low-medium 
setting for 30 min. Chloroform was removed by a BÜCHI Rotavapor R-215 rotoary 
evaporation (Flawil, Switzerland) at room temperature and 50 RPM at 200 mbar for 
35 minutes and then 50 mbar for 30 min. 2-3 mL of DI water (at least equal to the 
volume of DMSO) was them added at ~1 mL per 5-6 min. The sample was then 
placed in Vivaspin 2 Sample Concentrator tubes and centrifuged in a Thermo 
Scientific Megafuge 16R (Asheville, NC USA) at 20°C and 7000g for 30 min. 1 mL 
of DI water was then added to each tube using pipette mixing was used to remove any 
LMNPs from the membrane and then centrifuged again. This is repeated 2 more times 
 205 
 
before suspending the LMNPs in the 1-2 mL of DI water. To remove excess lipids and 
micelles, the samples were centrifuged at 18516g for 15 min. at room temperature. 
The supernatant was removed and discarded. The precipitate was resuspended in the 
desired volume of DI Water and redispersed by pipette mixing and vortexing.   
 
4.2 Cryogenic Transmission Electron Microscopy (Cryo-TEM) 
Iron oxide nanoparticles and LMNPs were examined with cryo-TEM imaging. 
~5 µL of sample is deposited on a Quantifoil grid comprised of 200 square mesh 
copper grids suspended with 2 µm carbon hole. (Electron Microscopy Sciences, 
Hatfield, PA, USA). Grids were robotically vitrified in liquid ethane using a Vitrobot 
(FEI Company, Hillsboro, OR USA). Prior to imaging, the vitrified grid is transferred 
and stored in liquid nitrogen. Imaging was performed in a liquid nitrogen cooled stage 
(Model 915, Gatan Inc., Pleasonton, CA USA) at 200 kV using a JEOL JEM-2100F 
TEM (Peabody, MA USA). 
 
4.3 Dynamic Light Scattering (DLS) 
 Hydrodynamic radius and zeta potential was investigated using a Malvern 
Zetasizer Nano ZS (Worcestershire, United Kingdom) equipped with a backscattering 
detector angle of 173° and a 4 mW, 633 nm He–Ne laser. Hydrodynamicdiameters 
(dh) were measured using optical grade polystyrene cuvettes. Zeta potential was 
determined by combined Doppler electrophoretic velocimetry and phase analysis light 
scattering using folded capillary cells. 
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4.4 Heating with Alternating Current Electromagnetic Field (AC EMF) 
Operating at Radio Frequency (RF) 
 RF heating was performed using a 1 kW Hotshot™ (Ameritherm Inc., 
Scottsville, NY) set to 300 A (actual output ~227-235A and 362 kHz) with a 3 turn 
induction heating coil with a 3 cm outer diameter. A 3 mL plastic test tube was 
suspended in the center of the induction heating coils. 1 mL of 1 mg/mL of LMNPs 
were dispersed into the centrifuge tube. Temperature was taken with a LUXTRON 
ONE (LumaSense Technologies, Santa Clara, CA) 200 µm all-silica with PFA Teflon 
jacket (RF immune) fiber optic probe. A hole was made at the center of the test tube 
cap to all the temperature probe to be placed at about the middle of the sample, while 
keeping the sample sealed. Temperature readings were recorded every 0.25 sec. with 
HyperTerminal. Sample temperature recording was then started. The sample was left 
at room temperature for 2 min. to determine a baseline temperature. The sample was 
then subjected to RF heating for 30 min. The specific absorption rates (SAR) of the 
nanoparticles were measured using a 3-turn copper coil with a 3 cm cm outer 
diameter. To determine SAR values, sample temperatures were measured from the 
initial slope of adiabatic temperature rise of the samples: 
 
𝑆𝐴𝑅 =
𝑐?̅?𝑚𝑣
𝑚𝑁𝑃
∆𝑇
∆𝑡
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 Small Interfering RNA (siRNA) Experiments 
5.1 siRNA Binding 
 Fluorescently labeled siRNA enabled LMNP binding to be investigated with a 
fluorescent quenching assay. Fluorescent measurements were taken with a 
PerkinElmer Model LS 55 fluorescence spectrometer (Waltham, MA USA) with an 
excitation and emissions slit width of 10 nm, a 1% attenuation filter, and excitation 
and emission wavelength of 494 nm and 516 nm, respectively. Opti-MEM was added 
to a quartz cuvette and the intensity, IOptiMEM, was recorded. siRNA was then added 
and the intensity, IsiRNA/OptiMEM, was recorded. Finally, LMNPs were added and the 
intensity, I(t), was integrated over 10 sec. intervals and recorded over 15 min. The 
percent of bound siRNA was calculated with the following equation: 
 
𝐵𝑜𝑢𝑛𝑑 𝑠𝑖𝑅𝑁𝐴 % =  
(𝐼𝑠𝑖𝑅𝑁𝐴/𝑂𝑝𝑡𝑖𝑀𝐸𝑀 − 𝐼(𝑡))
(𝐼𝑠𝑖𝑅𝑁𝐴/𝑂𝑝𝑡𝑖𝑀𝐸𝑀 − 𝐼𝑂𝑝𝑡𝑖𝑀𝐸𝑀)
 
 
To ensure that quenching was due to LMNPs only, samples were then transferred to 
centrifuge tubes and centrifuged at 6000g for 15 min. The supernatant was then 
transferred to a quartz cuvette and 3 scans were taken.   
 
5.2 siRNA Release with Temperature 
 Intensity readings were taken similar to above. Opti-MEM was added to a 
quartz cuvette and the intensity, IOptiMEM, was recorded. siRNA was then added and the 
intensity, IsiRNA/OptiMEM, was recording. LMNPs were then added and intensity readings 
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were recorded between 25°-45°C. Temperature was ramped at 2°C and after holding 
the temperature for 5 min. the intensity, I(T), was recorded. The percent of bound 
siRNA was calculated with the following equation: 
 
𝐵𝑜𝑢𝑛𝑑 𝑠𝑖𝑅𝑁𝐴 % =  
(𝐼𝑠𝑖𝑅𝑁𝐴/𝑂𝑝𝑡𝑖𝑀𝐸𝑀 − 𝐼(𝑇))
(𝐼𝑠𝑖𝑅𝑁𝐴/𝑂𝑝𝑡𝑖𝑀𝐸𝑀 − 𝐼𝑂𝑝𝑡𝑖𝑀𝐸𝑀)
 
 
5.3 siRNA RF Release 
 siRNA RF release experiments were conducted with a copper heating coil (3 
turns at 4.5 cm mean diameter) around a custom-designed polycarbonate cuvette 
holder and base of the fluorescent spectrometer. The amount of bound siRNA before 
RF heating was calculated with the following equation: 
 
𝐵𝑜𝑢𝑛𝑑 𝑠𝑖𝑅𝑁𝐴 % =  
(𝐼𝑠𝑖𝑅𝑁𝐴/𝑂𝑝𝑡𝑖𝑀𝐸𝑀 − 𝐼𝐿𝑀𝑁𝑃/𝑠𝑖𝑅𝑁𝐴/𝑂𝑝𝑡𝑖𝑀𝐸𝑀)
(𝐼𝑠𝑖𝑅𝑁𝐴/𝑂𝑝𝑡𝑖𝑀𝐸𝑀 − 𝐼𝑂𝑝𝑡𝑖𝑀𝐸𝑀)
 
 
Opti-MEM was added to a quartz microcuvette and the intensity was taken for 2 min. 
The intensity, IOptiMEM, was the average of the last 30 secs. Then, 2.0 µL of siRNA 
(16.67 µM) was added and the intensity taken for 2 min. The intensity, IsiRNA/OptiMEM, 
was the average of the last 30 sec. Lastly, 41.2 µL of LMNP (1.25x1012 LMNP/mL) 
was added and the intensity taken for 2 min. The intensity, ILMNP/siRNA/OptiMEM, was the 
average of the last 30 sec. The microcuvette was subjected to RF heating for 10 min. 
RF heating was conducted within a 1 kW Hotshot (Ameritherm Inc., Scottsville, NY 
USA) operating at a setting of 300 A and 270-281 kHz.    
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 Magnetic Resonance Imaging (MRI) 
6.1 MRI Sample Preparation 
 LMNPs were suspended in 1% agarose at concentrations of 1, 10, and 20 
µg/mL Fe3O4 in 4 mL plastic sample tubes. 1% agarose gels were prepared by mixing 
agarose with 10X TBE buffer (diluted to 1X) in a flask on a hot plate set to keep the 
gel at 80°C until the agarose is completely dissolved. The gel and LMNP sample was 
then pipetted into a sample holder, vortexed, and stored at 4°-8°C until imaged.  
 
6.2 MRI Methods for r2 Relaxation 
 Samples were imaged using a Siemens Prisma 3T scanner. The sample holder 
was placed in a 64 channel head receive array. LMNP samples in 4ml vials were 
scanned using spin echo (r2). Cross section images of the vials were obtained with 
voxel size of 0.78mm and slice thickness of 4mm. Repetition time was 2400ms for all 
sequences. For the spin echo acquisition 24 echoes were collected over the range of 9 
– 216ms (9ms step). The inversion recovery data were taken with inversion times of 
100, 200, 300, 400, 600, 1000, and 1500ms. Relaxation time constants were 
determined using a nonlinear least squares fit for pixel intensity vs echo time for r2. 
Three-parameter nonlinear least squares fitting routines (M0, T1,2. DC offset) were 
used for r2 to take into account through-slice dephasing effects31. Relaxivity was 
calculated as a linear fit of relaxation rates to iron concentration. 
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